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Interferon-alpha (IFN-α) therapy for chronic hepatitis C virus (HCV) infection is 
associated with the development of depression and other neuropsychiatric 
adverse effects. However, well-defined predictors of this depression are still 
lacking. Several interlinked biological systems as well as cognitive and 
psychosocial factors may predispose individuals to the development of IFN-α-
induced depression. The aim of this study was to identify such predictive factors 
as well as prospectively monitor the impact of IFN-α on a variety of clinical and 
biological outcomes.  
 
Forty-eight patients with chronic HCV infection were recruited and assessed at 
baseline and after 4, 8, 12, 16, 20 and 24 weeks of IFN-α treatment. At each 
assessment, patients were evaluated with a number of questionnaires as well 
as the structured Mini International Neuropsychiatric Interview (MINI) for a 
diagnosis of major depressive disorder. Blood samples were also collected at all 
time points as well as salivary cortisol at baseline and end of treatment.  
 
IFN-α-induced depression developed in 40% of the patients. Patients who 
developed IFN-α-induced depression had more negative illness perceptions, 
lower baseline levels of cortisol during the day, and lower baseline levels of 
kynurenic acid. Patients who developed IFN-α-induced depression also had 
altered gene expression in a number of pathways relevant for depression such 
as inflammation and neuroplasticity. Finally, detection and management of 
depression in this population is shown to be a complex process, reliant on the 
availability of clinical experts and good communication within a multidisciplinary 
team. 
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In conclusion, the findings of this study provide evidence for a number of 
cognitive, psychosocial and biological predictors of IFN-α-induced depression. 
These findings provide a rationale to test the effect of preventative cognitive 
interventions in these patients. However, future studies are needed to confirm 
some of these novel clinical and biological predictors, as well as to look at the 
interplay between these factors. 
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1.1 What is depression?  
Major depressive disorder (MDD) is a highly prevalent neuropsychiatric 
condition characterised by a broad range of symptoms. The last edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), states five 
or more of a range of symptoms must be present, during a 2 week period for a 
diagnosis of MDD (APA, 2000). Furthermore, these symptoms must cause 
significant distress or impairment of normal functioning, and should not be 
attributable to a recent loss or be associated with a general medical condition or 
with substance abuse (APA, 2000). The symptoms for depression diagnoses 
are listed as:  
 
- Depressed mood most of the day, nearly every day 
- Diminished interest or pleasure in activities most of the day, nearly every day 
- Significant weight loss or change in appetite nearly every day 
- Insomnia or hypersomnia nearly every day 
- Psychomotor agitation or retardation nearly every day 
- Fatigue or loss of energy nearly every day  
- Worthlessness, or excessive or inappropriate guilt nearly every day 
- Diminished ability to think or concentrate, or indecision, nearly every day 
- Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, 
or a suicide attempt or a specific plan for committing suicide.  
 
MDD may manifest as a single episode or as recurrent episodes with a course 
of up to 2 years or longer in those with the single-episode form (Akiskal, 2009). 
The prognosis for recovery from an acute episode of MDD is good for most 
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patients, however, three out of four patients experience recurrences throughout 
life with varying degrees of residual symptoms between episodes (Akiskal, 
2009). Lifetime prevalence of MDD varies widely across different populations 
with the majority being in the range of 8-12% (Andrade et al., 2003). The 
incidence of MDD has and continues to steadily increase, and the mean age of 
onset has been reported to have decreased to around 27 years old (Kessler, 
2002). One of the most consistent socio-demographic correlates of MDD across 
populations is being female (Andrade et al., 2003, Eaton et al., 1997, Kendler et 
al., 1993). MDD has a multifactorial aetiology originating from the interaction 
between environmental and genetic factors, and presents frequent comorbidity 
(Zunszain et al., 2012b). 
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1.2 Inflammation and Depression 
1.2.1 Introduction 
Since MDD is a complex disorder, it is likely that alterations in several 
interacting systems underlie its pathogenesis. As such, numerous hypotheses 
have been proposed to elucidate its origins. One of these is the inflammatory 
hypothesis, initially suggested as the macrophage theory of depression (Smith, 
1991), and now also known as the malaise or cytokine theory of depression 
(Maes et al., 2009, Miller et al., 2009). This particular hypothesis emphasises 
the role of psycho-neuroimmunological dysfunctions where there is an 
activation of the immune system. Subsets of MDD patients, who are otherwise 
medically healthy, have been repeatedly shown to have an altered peripheral 
immune system. This includes impaired cellular immunity, increased levels of 
pro-inflammatory cytokines, increased levels of acute phase proteins, and 
increased expression of chemokines and adhesion molecules (Bouhuys et al., 
2004, Maes, 1995, Miller et al., 2002, Musselman et al., 2001b). Studies have 
indicated that innate immune cytokines can influence pathophysiological 
domains, such as neurotransmitter metabolism, neuroendocrine function and 
regional brain activity, all of which are relevant to MDD (Dantzer et al., 2008, 
Schiepers et al., 2005). Indeed, administration of high levels of pro-inflammatory 
cytokines has been shown to cause changes in behaviour, such as low mood, 
fatigue, anxiety, sleep disturbances, anhedonia and cognitive dysfunction, all of 
which closely resemble symptoms observed in MDD (Capuron and Miller, 2004, 
Pollak and Yirmiya, 2002), and which constitute the main focus of my PhD. 
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1.2.2 Cytokine abnormalities in depression 
Several biomarkers of inflammation have been measured in MDD and some of 
the most frequently reported are cytokines including interleukin-1 (IL-1), 
interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α). Also of 
importance is C-reactive protein (CRP) which is produced by hepatocytes in 
response to IL-6. Recent meta-analyses have reported positive associations of 
all of these immune molecules with MDD, in both serum and plasma (Dowlati et 
al., 2010, Howren et al., 2009). Moreover, some studies have demonstrated 
these elevations occur not only in peripheral blood, but also in the central 
nervous system, in particular in cerebrospinal fluid (CSF) (Levine et al., 1999). 
Additionally, some of these increases have also been measured in the brain, 
with post-mortem gene expression analyses showing an up-regulation of a 
variety of pro- and anti-inflammatory cytokines in the prefrontal cortex of MDD 
patients (Shelton et al., 2011). Similarly, mRNA and protein expression levels of 
IL-1β, IL-6, and TNF-α have been shown to be significantly increased in the 
brains of teenage suicide victims when compared with normal control subjects 
(Pandey et al., 2011). Depressed patients have also been shown to have higher 
levels of other acute phase proteins, chemokines and cellular adhesion 
molecules including a-1-acid glycoprotein, a-1-antichymotrypsin, haptoglobin, 
human macrophage chemoattractant protein-1 (MCP-1), soluble intracellular 
adhesion molecule-1 (sICAM-1) and E-selectin (Raison et al., 2006).  
 
It is still unclear whether or not these changes occur before and therefore lead 
to the development of MDD, or are instead a consequence of the illness. That 
is, is an altered immune system an ‘‘at-risk’’ or a ‘‘state’’ condition? For a long 
time the brain was considered, from an immunological point of view, to be a 
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privileged organ. It is now known that pro-inflammatory cytokines are produced 
in response to insults not only by immune cells but also by neurons and neural 
stem cells (Tsakiri et al., 2008, Zunszain et al., 2012a). Cytokines can act 
directly on the brain causing changes known as ‘‘sickness behaviour’’, a co-
ordinated set of subjective, behavioural and physiological changes that develop 
in sick individuals during the course of an infection (Dantzer, 2004). If there is a 
prolonged activation of the peripheral immune system, the immune signalling to 
the brain can lead to an exacerbation of sickness behaviour and to the 
development of depressive symptoms in vulnerable individuals (Dantzer et al., 
2008). The administration of cytokines and several animal models, discussed 
below, support this view. Further support for an aetiological role of cytokines in 
MDD comes from longitudinal studies. For example, a decade-long study found 
that serum levels of high sensitivity CRP in women is an independent risk 
marker for de novo MDD (Pasco et al., 2010). Similarly, in a 12-year follow-up 
study, levels of CRP and IL-6 have been shown to predict the subsequent 
development of MDD (Gimeno et al., 2009). 
 
1.2.3 Immune stimulation and “sickness behaviour” 
As mentioned above, pro-inflammatory cytokines can induce behavioural 
symptoms referred to as sickness behaviour (Dantzer, 2001b). Acute immune 
stimulation via the administration of pro-inflammatory cytokines or by treatment 
with cytokine-inducers has been shown to lead to emotional symptoms 
indicative of sickness behaviour and depression. For example, a single 
exposure to Salmonella typhi vaccine has been shown to increase negative 
mood in conjunction with increases in IL-6 (Wright et al., 2005). In addition to a 
robust inflammatory response as indicated by increased levels of IL-6, 
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Salmonella typhi vaccine has been demonstrated to cause increases in 
subjective ratings of fatigue and confusion, as well as evoke neural activity 
within the substantia nigra during a cognitive task (Brydon et al., 2008). In two 
further studies it was shown that Salmonella typhi but not placebo, causes 
inflammation-related mood reduction, accompanied by enhanced activity in 
several brain regions including: subgenual anterior cingulate cortex (sACC), 
thalamus, amygdale, cingulate and anterior insula (Harrison et al., 2009a, 
Harrison et al., 2009b). Using Salmonella abortus equi endotoxin, increases in 
levels of anxiety and depressed mood, together with a decrease in verbal and 
non-verbal memory functions has also been shown (Reichenberg et al., 2001). 
Furthermore, these changes correlated with increased circulating levels of TNF-
α, soluble TNF receptors, IL-6, IL-1 receptor antagonist and cortisol. Feelings of 
social disconnection and depressed mood, together with significant increases in 
IL-6 and TNF-α have also been observed after a single exposure to Escherichia 
coli endotoxin (Eisenberger et al., 2010b). Moreover, short-term exposure to 
low-dose Escherichia coli endotoxin has been shown to be associated with 
increased depressed mood over time in healthy individuals, by altering reward-
related neural responses (Eisenberger et al., 2010a). 
 
Animal studies have also provided useful evidence for a putative role of 
cytokines in the context of MDD. Administration of different pro-inflammatory 
cytokines in rodents has been shown to result in sickness symptoms including: 
decreased interest in exploration, depressed motor activity, withdrawal from 
social activities, reduced food and water intake, deficient cognition, 
hyperalgesia and hypersomnia (Dantzer, 2001a, Yirmiya et al., 2002). In a more 
indirect way, mice subjected to chronic mild stress show increased IL-1β levels 
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in the hippocampus and in parallel, changes in behaviour resembling 
depressive symptoms, such as decreased sucrose preference and reduced 
social exploration. In contrast, mice with a deletion of the IL-1 receptor do not 
display such behavioural changes (Goshen et al., 2008). In another indirect 
study, constant darkness produced depression-like behaviour in mice with 
concomitant elevated levels of IL-6 in plasma as well as in the hippocampus 
(Monje et al., 2011). Furthermore, exposure to TNF-α has also been shown to 
produce depressive-like states in mice, an effect which can then be blocked by 
co-administration of an anti-TNF-α antibody (Kaster et al., 2012). Administration 
of cytokine antagonists, such as IL-1 receptor antagonist, or anti-inflammatory 
cytokines such as IL-10, can block the behavioural effects of treatment with 
cytokines and/or endotoxins in animals (Bluthe et al., 1995, Dantzer et al., 2008, 
Kent et al., 1992). Interestingly, treatment of animals with antidepressants can 
also relieve some of the symptoms of cytokine-induced sickness behaviour 
(Pollak and Yirmiya, 2002). 
 
1.2.4 Other evidence supporting a role for inflammation in depression 
Two further series of evidence support a role for inflammation in depression. 
Firstly, it is well documented that depression occurs 5 to 10 times more often in 
the medically ill than in the general population and has a significant impact on 
quality of life, treatment adherence, morbidity, and mortality (Evans et al., 
1999). Furthermore, MDD is particularly common in conditions with an 
inflammatory component, such as cardiovascular disease and rheumatoid 
arthritis, as well as in autoimmune and neurodegenerative disorders (Evans et 
al., 2005, Pollak and Yirmiya, 2002, Wise and Taylor, 1990). 
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Secondly, the contribution of psychosocial stress to the development of MDD is 
also well-documented (Mundt et al., 2000) and this may be mediated by an 
activation of inflammatory processes. Both acute and chronic psychosocial 
stress have been shown to activate innate immune signalling pathways as well 
as innate immune cytokines such as IL-6 (Bierhaus et al., 2003). For example, 
chronic stress including difficult caregiving and hostile marital relationships, has 
been associated with increased levels of CRP (Miller, 2008). Early life stress 
may be especially relevant as it appears to produce neuroendocrine and 
immunological abnormalities that are thought to mediate the development of a 
pro-inflammatory phenotype in adulthood (Chida et al., 2007, Elenkov, 2008, 
Hepgul et al., 2012). Several studies have demonstrated that childhood trauma 
predisposes to increased inflammation in adulthood, as shown by higher levels 
of CRP and fibrinogen, as well as by increased reactivity of the hypothalamic-
pituitary-adrenal (HPA) axis (Danese et al., 2008, Heim et al., 2008). In healthy 
individuals, childhood maltreatment has been associated with increased levels 
of CRP in adulthood, independent of other co-occurring early-life risks, current 
stress or health problems (Danese et al., 2009, Danese et al., 2007). Similarly, 
exposure to an acute stressor, in men with MDD and a history of early life 
stress, has been shown to cause an exaggerated IL-6 response, together with 
increased DNA binding of the key pro-inflammatory transcription factor, nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) in peripheral 
blood mononuclear cells (Pace et al., 2006). Additionally, greater acute IL-6 
release and higher IL-6 concentrations over time have been observed in 




1.3 Interferon-alpha for Hepatitis C infection: a clinical model of 
cytokine-induced depression 
1.3.1 Introduction 
In order to investigate the pathways through which inflammation and cytokines 
can induce depression, it is essential to have relevant model systems. One 
such model system involves patients undergoing treatment with the pro-
inflammatory cytokine interferon-alpha (IFN-α). This is an important and widely 
used model as it is an existing clinical observation that a high percentage of 
patients who are administered IFN-α develop a behavioural syndrome that is 
strikingly similar to major depression. As such, this model can be readily utilised 
for observational studies without the need for any interventional measures. 
 
1.3.2 Hepatitis C infection 
Since the isolation of its pathogenic agent, the Hepatitis C Virus (HCV), in 1989, 
hepatitis C has grown as a public health concern. HCV infection affects around 
200 thousand people in England, and approximately 170 million worldwide (See 
Figure 1.1) (Harris et al., 2011, Lavanchy, 2009). There are various routes of 
transmission of HCV and up until the 1980s, one of the most common was 
exposure to contaminated blood or blood products. However, since the 
introduction of routine testing of donated bloods, transmission via blood 
transfusion has been virtually eliminated (Donahue et al., 1992). Today, the use 
of injectable drugs is the main source of HCV infection in most developed 
countries and is also an increasing source of infection in developing countries 
(Palmateer et al., 2012, Sweeting et al., 2009, Wasley and Alter, 2000). 
Furthermore, in developing countries, the re-use of contaminated or 
inadequately sterilized equipment in medical and dental procedures is another 
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major source of transmission (Hutin and Chen, 1999, Ver Hoeve et al., 2012). 
Generally, acute HCV infection is relatively asymptomatic because it replicates 
slowly and so the infection may take decades to progress. However, it is 
estimated that up to 85% of patients with acute HCV will develop chronic HCV 
infection, and nearly 20% will develop liver cirrhosis (Fattovich et al., 1997, 
GBD, 2004, Sockalingam and Abbey, 2009). In fact, HCV infection is the 
leading cause of cirrhosis and the main indication for liver transplantation 
worldwide (Schiff, 2011). As a result of cirrhosis, 1-5% of patients may also go 
on to develop hepatocellular carcinoma (GBD, 2004). Complicating the picture 
further, HCV exists in at least six genotypes and treatment success varies by 




Figure 1.1 The global prevalence of Hepatitis C 
The estimated global prevalence rates of Hepatitis C infection in the year 2004. Figure from 
(Lavanchy, 2009): The Global burden of hepatitis C. Liver International, 29, 78-81. 
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1.3.3 Interferon-alpha for Hepatitis C infection 
Standard treatment for HCV infection involves a combination of once-weekly 
subcutaneous pegylated-interferon-alpha (peg-IFN-α) and twice-daily oral 
ribavirin; an antiviral agent. This treatment is usually given for 24 weeks (for 
genotypes 2 and 3) or for 48 weeks (for genotypes 1, 4 and 5) (Sockalingam 
and Abbey, 2009). IFN-α is a cytokine released by the innate immune system 
and has an important function in the innate antiviral response (Feld and 
Hoofnagle, 2005). IFN-α can attach to cell-surface receptors that signal through 
Janus-activated kinase (JAK) and signal transducers and activators of 
transcription, leading to induction of multiple IFN-stimulated genes (Hoofnagle 
and Seeff, 2006). These genes include double-stranded RNases, viral protein 
translation inhibitors, and proteins which destabilize viral messenger RNA. IFN-
α also induces the expression of genes involved in the innate immune response 
and acutely induces the production and release of other innate immune 
cytokines such as IL-6 and TNF-α (Raison et al., 2008). As well as this, IFN-α is 
also thought to facilitate the recognition of virus-infected or tumour cells by 
cytolytic T-lymphocytes (Wichers and Maes, 2002). As such, IFN-α possesses 
marked anti-viral, anti-cancer, and immunomodulatory properties, and is also 
approved for the treatment of a number of other disorders including: multiple 
sclerosis, malignant melanoma and chronic myelogenous leukaemia (Piper et 
al., 2001).  
 
For HCV infection, response to IFN-α treatment is measured by Sustained 
Virological Response (SVR) rates, defined as undetectable HCV levels 6 
months post treatment. The overall rate of SVR was generally low with IFN-α 
monotherapy and the subsequent addition of ribavirin led to improvements in 
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SVR rates. Ribavirin is a nucleoside analogue with broad activity against viral 
pathogens (Feld and Hoofnagle, 2005). The mechanisms of action of ribavirin 
against HCV are not completely clear, however, it appears to have 
immunomodulatory effects as well as modulating the expression of IFN-
stimulated genes and inducing viral mutagenesis (Paeshuyse et al., 2011). With 
this combination therapy, SVR rates approach 50% for genotype 1 and about 
80% for genotypes 2 and 3 (Agarwal et al., 2007).  
 
Two new antiviral products have recently been licensed for the treatment of 
HCV infection in combination with IFN-α and ribavirin. Bocepravir and telaprevir 
are both protease inhibitors which have been approved for use in treatment of 
HCV genotype 1 (Ghany et al., 2011). Phase III trials have shown that in 
combination with the standard treatment, both boceprevir and telaprevir 
increase SVR rates for genotype 1 from less than 50% to 70%, while also 
cutting treatment time in half for some individuals (Gravitz, 2011). However, as 
these drugs will supplement and not replace the standard IFN-α plus ribavirin 
therapy, they will not eliminate the difficult side effects associated with HCV 
treatment. Despite its efficacy on improving SVR rates, unfortunately IFN-α 
induces a number of neurotoxic effects such as depression, anxiety, mania and 
fatigue (Sockalingam and Abbey, 2009). 
 
1.3.4 IFN-α-induced neuropsychiatric effects 
After the initial injection of IFN-α, almost all patients experience an acute 
cytokine-induced sickness behaviour, including malaise, myalgia, anorexia, 
fatigue, apathy, poor concentration and attention, non-specific pain and several 
other flu-like symptoms (Capuron and Miller, 2004, Dieperink et al., 2000, 
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Raison et al., 2005b). Flu-like symptoms such as fever, cough, dyspnea, 
pharyngitis, rhinorrhea and rash generally subside in 1-2 weeks, however, 
fatigue, malaise, apathy and cognitive and behavioral changes usually persist 
for several weeks throughout the treatment period. This sickness behaviour 
induced by IFN-α is consistent with the effects seen with cytokine administration 
in animals as mentioned earlier (Dantzer, 2004, Konsman et al., 2002, Raison 
et al., 2006, Yirmiya et al., 2002). 
 
1.3.5 Clinical features of Interferon-alpha-induced depression 
The symptoms caused by IFN-α are similar to that of somatic or vegetative 
symptoms seen in MDD (Raison and Miller, 2003). Table 1.1 demonstrates the 
symptoms of acute sickness behaviour induced by IFN-α therapy, which overlap 
with and are commonly manifested symptoms seen in MDD patients. The 
development of MDD during IFN-α therapy in patients with HCV infection is 
common with an incidence of up to 45% (Asnis and De La Garza, 2006, 



































Loss of interest 
Anhedonia 





Adapted from (Smith et al., 2011b): Risk factors for the development of depression in patients 
with hepatitis C taking interferon-α. Neuropsychiatric Disease and Treatment, 7, 275-92. 
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The onset of depressive symptoms usually occurs within the first 3 months of 
IFN-α therapy (Capuron et al., 2002b). Interestingly, dimensional analyses of 
IFN-α-induced symptoms have shown evidence for the development of two 
behavioural syndromes; a neurovegetative versus a mood and cognitive 
syndrome (See Figure 1.2) (Capuron et al., 2002a, Capuron and Miller, 2011). 
The neurovegetative syndrome develops rapidly in almost all patients and 
persists for the duration of IFN-α treatment. This consists of symptoms of 
fatigue, psychomotor slowing, pain, loss of appetite and sleep disturbances. On 
the other hand, the mood and cognitive syndrome, characterized by low mood, 
anxiety, as well as memory and attention deficits, usually appears later on in 
treatment (Capuron et al., 2002a, Capuron and Miller, 2004). Furthermore, the 
mood and cognitive symptoms appear to respond to treatment with 
antidepressants whereas the neurovegetative symptoms do not (Capuron and 
Miller, 2004, Capuron and Miller, 2011). These two distinct syndromes may 
have different underlying pathophysiology and as such require different 




Figure 1.2 The development of two behavioural syndromes; a neurovegetative 
versus a mood and cognitive, over the course of IFN-α treatment 
 
IFN-α treatment induces two types of behavioural symptoms both with a different time course 
and antidepressant response. Neurovegetative symptoms develop rapidly, whereas mood and 
cognitive symptoms develop at a later stage. Figure from (Capuron and Miller, 2011): Immune 
system to brain signaling: Neuropsychopharmacological implications. Pharmacology & 
Therapeutics, 130, 226-38.  
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Furthermore, the experience of depressive symptoms during the course of 
antiviral treatment has important negative consequences, such as impairing 
quality of life, reducing compliance as well as leading to dose reduction or 
discontinuation of treatment, all of which compromise the therapeutic response 
to the treatment (Asnis and De La Garza, 2006). In some rare cases IFN-α-
induced depression can be so severe that patients experience suicidal ideation 
(Ademmer et al., 2001, Dieperink et al., 2004), and a few reports describe 
patients who have attempted or committed suicide (Fukunishi et al., 1998, 
Janssen et al., 1994, Sockalingam et al., 2011). As such, effective and timely 
detection of IFN-α-induced depression is important to ensure that appropriate 
treatment and support can be provided.  
 
1.3.6 Clinical predictors of IFN-α-induced depression 
1.3.6.1 Previous history and baseline levels of depression 
There is conflicting evidence about what factors are predictive of depressive 
symptoms during IFN-α treatment. One clinical predictor most often associated 
with subsequent development of depression during treatment is the presence of 
mood or anxiety symptoms prior to treatment. Studies have suggested that a 
previous history of psychiatric illness, especially MDD, increases vulnerability to 
the development of depression on treatment (Castera et al., 2006, Raison et al., 
2005a). Furthermore, higher baseline depression scores have been consistently 
demonstrated to predict later scores and subsequent development of MDD 
during treatment (Castellvi et al., 2009, Dieperink et al., 2003, Evon et al., 2009, 
Lotrich et al., 2007).  
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It has also been reported that the development of depressive and 
neuropsychiatric symptoms in the early stages of therapy can predict the later 
development of MDD (Capuron et al., 2002b). Family history of a mood disorder 
or the presence of a sleep disorder has also been suggested to predict the 
occurrence of IFN-α-induced neuropsychiatric symptoms (Raison et al., 2005b, 
Sockalingam and Abbey, 2009). It could, however be argued that pre-existing 
vulnerability as a risk factor has such support as it has been the most 
extensively investigated, and in fact a history of a psychiatric disorder before 
starting IFN-α therapy does not unequivocally predict the occurrence of such 
symptoms (Pariante et al., 1999). In fact, it has been previously demonstrated 
that after adjusting for baseline scores, patients with a pre-existing psychiatric 
diagnosis and patients with no psychiatric history had no difference in maximal 
depression or anxiety scores (Pariante et al., 2002). Furthermore, the same 
study found no significant difference between groups in the incidence of 
adverse psychiatric effects severe enough to require psychopharmacological 
treatment. This is an important issue as in some cases a previous history of 
psychopathology has been considered as a significant cause for treatment 
withdrawal, due to the theoretical risk of worsening of psychiatric 
symptomatology induced by IFN-α treatment. Withholding IFN-α in this way, 
especially from members of a stigmatized class, raises questions about fairness 
and discrimination (Spennati and Pariante, 2012). In my PhD, I will assess the 
difference between using absolute values versus change from baseline scores 




1.3.6.2 Other predictors 
Some studies have investigated demographic and social risk factors; however, 
there appears to be no consensus on whether or not these impact on the 
development of depression (Raison et al., 2005a, Smith et al., 2011b). One risk 
factor which appears to be related to depressive outcomes is that of social 
support. Indeed, lower levels of social support have been shown to significantly 
increase the risk of developing depression during IFN-α therapy (Evon et al., 
2011, Evon et al., 2009). It is interesting to note the absence, among the clinical 
predictors that have been investigated, of a “usual suspect” risk factor for the 
development of depression, especially in relationship with stress and 
inflammation - a history of childhood trauma. As mentioned previously there is 
clear evidence, across different populations, that childhood trauma predisposes 
to inflammation in adulthood as well as depression (Archer et al., 2012, Caspi et 
al., 2003, Danese and McEwen, 2012, Danese et al., 2009, Danese et al., 
2008). 
 
Few studies have evaluated the link between depression and patients’ health 
related quality of life during therapy, which can be influenced not only by the 
biological and symptomatic aspects of the therapy but also by a person’s 
perceptions of their health status (Hunt et al., 1997). Illness perceptions are a 
patient’s own implicit common sense beliefs about their illness, and the manner 
in which patients perceive their illness and subsequent therapy is likely to 
influence many aspects of their experience including side-effects (such as 
developing depression) and other health outcomes. Across disease groups, and 
particularly in chronic disorders, illness perceptions have been found to be 
associated with several emotional well-being and quality of life outcomes 
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(Endermann and Zimmermann, 2009) however, they have not previously been 
investigated in patients receiving IFN-α therapy for HCV infection. 
 
1.3.7 Importance of identifying predictive factors  
It is important to identify predictors of IFN-α-induced depression in order to 
understand which individuals may require an intervention, particularly treatment 
with antidepressants. Prophylactic treatment with antidepressants in the form of 
selective serotonin reuptake inhibitors (SSRIs) has been shown to be effective 
in preventing IFN-α-induced depression in patients with malignant melanoma 
(Musselman et al., 2001b). However, attempts of using antidepressants 
prophylactically in patients with chronic HCV infection have shown less 
promising results. Only eight randomised placebo-controlled trials of 
prophylactic antidepressant treatment exist, and the majority of these studies 
suggest it is not always effective without any major differences seen between 
placebo and antidepressants (Diez-Quevedo et al., 2010, Morasco et al., 2010, 
Morasco et al., 2007, Musselman et al., 2001a, Raison et al., 2007).  
 
Moreover, some studies suggest extreme caution in the use of SSRIs in this 
condition as SSRIs have antithrombotic action that further increases the risk of 
haemorrhages in these patients, in the presence of IFN-α-induced 
thrombocytopenia and oesophageal varices (Weinrieb et al., 2003). As well as 
this, patients receiving IFN-α are at risk of developing mania (Onyike et al., 
2004, Quelhas and Lopes, 2009), a risk which is notably increased by 
antidepressants (Beckwith, 2008, Wu et al., 2007). Furthermore, the altered 
liver function found in these patients could change the metabolism of 
antidepressants, with additional toxicity risks associated with potentially higher 
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plasma concentrations of these drugs. Finally, many patients are reluctant to 
take psychoactive medication, particularly given an often prolonged history of 
drug abuse. Other treatment options include psychiatric interventions which 
have been suggested to reduce depressive symptoms (Farber et al., 2005, Neri 
et al., 2010) and cognitive behavioural therapy which has been successfully 
used to prevent the development of depression during treatment (Ramsey et al., 
2011). Given that prophylactic treatment “for all” is not a feasible option; it is 
highly important to better understand the underlying mechanisms by which IFN-
α-induced depression develops.  
 
1.3.8 Mechanisms of IFN-α-induced depression 
Identifying biological predictors of IFN-α-induced depression is not only clinically 
useful but can also help in defining the molecular mechanisms of cytokine-
induced depression. Previous works by my supervisors and others have 
identified genetic markers on the serotonin transporter and IL-6 genes (Bull et 
al., 2009, Kraus et al., 2007), as well as in genes involved in the metabolism of 
polyunsaturated fatty acids (Su et al., 2010), which seem to predict the 
development of IFN-α-induced depression. As discussed below, other studies 
have examined changes in biomarkers such as cortisol (Capuron et al., 2003b), 
serum tryptophan concentrations (Capuron et al., 2003a) and even brain 
functions (Capuron et al., 2005, Taylor et al., 2013) during IFN-α treatment.  
 
1.3.8.1 HPA axis 
A disturbance in HPA axis functionality is a well-established and consistent 
finding in MDD (Miller et al., 2009, Pariante, 2003, Pariante, 2006, Stetler and 
Miller, 2011). Regulation of the HPA axis starts by release of corticotropin-
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releasing hormone (CRH) from the paraventricular nucleus of the 
hypothalamus. CRH leads to the release of adrenocorticotropic hormone 
(ACTH) in the pituitary, inducing discharge of cortisol from the adrenal cortex. In 
healthy individuals, cortisol exerts a negative feedback mechanism that controls 






Figure 1.3 The hypothalamus-pituitary-adrenal (HPA) axis 
 
The hypothalamus-pituitary-adrenal (HPA axis) activity is mediated by the secretion of 
corticotrophin releasing factor (CRH) from the hypothalamus, which in turn activates the 
secretion of adrenocorticotropin hormone (ACTH) from the pituitary, which finally stimulates the 
secretion of cortisol from the adrenal cortex. Cortisol interacts with its receptors in multiple 
target tissues including the HPA axis, where it is responsible for feedback inhibition of ACTH 




Interferons are known to activate the HPA axis (Dafny and Yang, 2005) and so 
this pathway may also be involved in the development of IFN-α-induced 
depression. Indeed, administration of cytokines has been shown to stimulate 
the expression and release of CRH, ACTH and cortisol, all of which have been 
found to be elevated in MDD (Pace et al., 2007, Pariante and Miller, 2001). Few 
studies have assessed the relationship between IFN-α and HPA axis activity, 
and these have produced mixed results.  
 
Acute activation of the HPA axis after administration of IFN-α has been shown 
to be associated with subsequent development of depressive symptoms, with 
an exaggerated cortisol response to the first injection of IFN-α predicting the 
future occurrence of depression (Capuron and Miller, 2004). As shown in Figure 
1.4, both ACTH and cortisol levels are higher in patients who later go on to 
develop IFN-α-induced depression and these effects are evident within 2 hours 
of IFN-α administration. This suggests that a “hyper-reactive” HPA axis is a risk 
factor for developing IFN-α-induced depression. Interestingly, the same study 
showed that these initial ACTH and cortisol responses correlated with 
depressive, anxiety and cognitive symptoms, but not with neurovegetative or 
somatic symptoms. This supports the notion that distinct symptom dimensions 
induced by IFN-α, may have different underlying mechanisms (Capuron and 





Figure 1.4 ACTH and cortisol response to the first injection of IFN-α, and the 
association with the future occurrence of depression 
 
Adrenocorticotropic hormone (ACTH) (A) and cortisol (B) responses to the first injection of IFN-
α are higher in patients who subsequently develop IFN-α-induced depression, and correlate with 
mood and cognitive symptoms but not neurovegetative or somatic symptoms (C). Figure from 
(Capuron and Miller, 2004): Cytokines and Psychopathology: Lessons from Interferon-α. 
Biological Psychiatry, 56, 819-24. 
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However, data from studies looking at chronic administration have been less 
reliable. In one study, IFN-α has been shown to induce a progressive increase 
in cortisol output during the day, accompanied by a reduction in the cortisol 
awakening response, both becoming significant after 8 weeks of treatment 
(Wichers et al., 2007). A second study also found IFN-α-induced depression to 
be associated with increased evening cortisol levels, and a consequent 
flattening of the cortisol rhythm (that is, a smaller difference between the 
morning peak and the evening through), an abnormality also described in MDD 
(Raison et al., 2008). On the other hand, some studies have found that IFN-α 
does not induce changes in plasma cortisol levels and cannot be correlated with 
depression scores (Fontana et al., 2008). Wichers et al. reported no association 
between daily average salivary cortisol concentrations or the cortisol awakening 
response and depressive symptoms in HCV patients undergoing IFN-α 
treatment (Wichers et al., 2007).  
 
One pathway by which cytokines may influence HPA axis function is through 
their effects on negative feedback regulation which itself is thought to be 
mediated, at least in part, by alterations in the glucocorticoid receptor (GR) 
(Miller et al., 2009). Cytokine activation of signalling pathways, such as p38 
mitogen-activated protein kinase (MAPK), and NF-κB have been shown to 
inhibit GR function and decrease GR expression (Dantzer et al., 2008, Pace et 
al., 2007). Indeed, it was recently demonstrated that following the initial injection 
of IFN-α, an activation of p38 MAPK in peripheral blood lymphocytes, was 
associated with subsequent depression and fatigue. This suggests that 
increased sensitivity of p38 MAPK signalling pathways may represent a 
vulnerability to IFN-α-induced depression (Felger et al., 2011). In my PhD, I will 
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assess the relationship between inflammation and HPA axis activity by 
measuring salivary cortisol. I will investigate whether HPA axis alterations are 
evident at baseline, and if these are associated with subsequent development 
of IFN-α-induced depression. I will also examine the effect of IFN-α on salivary 
cortisol levels over the course of the treatment period. 
 
1.3.8.2 Serotonin system 
There is a wealth of evidence to suggest that the neurotransmitter serotonin 
plays a role in MDD (Owens and Nemeroff, 1994) and it is suggested that IFN-α 
also has effects on the function of the serotonin system (Schaefer et al., 2003). 
Indeed, polymorphisms in the serotonin transporter linked polymorphic region 
(5-HTTLPR) have been shown to influence the development of IFN-α-induced 
depression. Specifically, two studies have found evidence for an “at risk” effect 
of S/S genotype and a “protective” effect of L/L genotype in the development of 
IFN-α-induced depression (Bull et al., 2009, Lotrich et al., 2009). More recently, 
a third study also investigated the same polymorphic region and found no 
statistically significant differences between S/S and L/L genotypes in either 
depression or anxiety levels, however subjects with L/L genotype did present 
lower changes from baseline for depressive symptoms (Udina et al., 2013). The 
involvement of the serotonin system in the development of IFN-α-induced 
depression is further supported by the ability of SSRIs to successfully 
ameliorate depressive symptoms (Gupta et al., 2006, Kraus et al., 2002). In 
fact, a recent literature review, demonstrated that most studies report SSRIs to 
have a very high success rate in treating IFN-α-induced depression – up to 85% 
(Baraldi et al., 2012). Furthermore, this is well beyond the treatment outcomes 
observed in randomized controlled clinical trials in major depression outside of 
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the context of IFN-α therapy, where the overall efficacy for most old and new 
antidepressant treatments is never higher than 50% (Khan et al., 2005, Parker, 
2005). 
 
Many investigations of the serotonergic system have focused specifically on the 
role of the enzyme indoleamine 2,3- dioxygenase (IDO) which can be induced 
by several pro-inflammatory cytokines (Wirleitner et al., 2003). When activated, 
IDO breaks down the essential amino acid tryptophan, the primary precursor of 
serotonin, into kynurenine (KYN) (Schwarcz and Pellicciari, 2002) (See Figure 
1.5). KYN is a precursor of the bioactive metabolites quinolinic acid (QUIN) and 
kynurenic acid (KYNA). QUIN is an N-methyl-D-aspartate (NMDA) receptor 
agonist, and thus considered to be potentially neurotoxic and contributing to the 
development of MDD (Muller and Schwarz, 2007). Conversely, KYNA is an 
NMDA receptor antagonist and is generally considered neuroprotective (Muller 
and Schwarz, 2007, Myint et al., 2007). IFN-α administration has been 
associated with an up-regulation of IDO, leading to reduced levels of serum 
tryptophan and serotonin (Bonaccorso et al., 2002a, Wichers et al., 2005). A 
recent genetic study has also shown that a polymorphism in the promoter 
region of the gene encoding IDO is associated with depressive symptoms 
during IFN-α therapy (Smith et al., 2011a). Interestingly, Capuron et al. reported 
that IFN-α-induced decreases in tryptophan, correlated with depressive, anxiety 
and cognitive symptoms but not the neurovegetative symptoms induced by IFN-
α (Capuron et al., 2003a). This is similar to the results reported above for CRH 
and suggest that serotonin and CRH pathways may interact in mediating the 
development of mood and cognitive symptoms during IFN-α treatment (Capuron 








Figure 1.5 The metabolism of tryptophan  
 
Tryptophan is synthesised into serotonin by tryptophan hydroxylase (TPH) or broken down in to 
kynurenine by the enzymes indoleamine 2,3- dioxygenase (IDO) and tryptophan 2,3-
dioxygenase (TDO). Kynurenine is further metabolised by either kynurenine aminotransferases 
(KATs) resulting in kynurenic acid, or by kynurenine 3-monooxygenase (KMO) resulting in 3-
hydroxykynurenine. 3-hydroxykynurenine is further metabolised by kynureninase (KYN) and 
subsequently synthesised into quinolinic acid (QUIN) via the activation of 3-hydroxyanthranilate 
3,4-dioxygenase (HAAO). Figure adapted from (Zunszain et al., 2012b): Inflammation and 
Depression. Current topics in behavioural neurosciences. [Epub ahead of print]. 
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As shown in Figure 1.6, as well as the reductions in tryptophan levels, it has 
also been demonstrated that upon IFN-α administration, there is an increase in 
KYN and QUIN which in turn correlate with depression scores (Raison et al., 
2010b). Furthermore, CSF levels of the serotonin metabolite 5-
hyroxyindoleacetic acid have also been shown to significantly predict 
development of depressive symptoms (Raison et al., 2010b). Both the reduced 
peripheral availability of tryptophan (putatively leading to reduced serotonin 
synthesis in the brain) and the production of neurotoxic tryptophan metabolites 
are considered essential steps in the pathophysiological processes leading to 
IFN-α-induced depression (Capuron and Miller, 2004). In my PhD, I will 
investigate the relationship between levels of kynurenine and tryptophan 
pathway metabolites and the development of IFN-α-induced depression, as well 
as monitor the change in levels over the treatment course. 
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Figure 1.6 CSF levels of tryptophan and kynurenine pathway metabolites in 
HCV infected patients receiving IFN-α versus control patients 
 
Cerebrospinal fluid (CSF) concentrations of kynurenine (KYN), quinolinic acid (QUIN) and 
kynurenic acid (KA) were significantly elevated in HCV infected subjects treated with IFN-α for 
12 weeks when compared to untreated control patients. No differences were found between the 
groups in CSF concentrations of tryptophan (TRP). Figure from (Raison et al., 2010b): CSF 
concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: 
relationship to CNS immune responses and depression. Molecular Psychiatry, 15, 393-403. 
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1.3.8.3 Polyunsaturated fatty acids (PUFAs) 
Polyunsaturated fatty acids (PUFAs) play an important role in MDD (Freeman et 
al., 2006) as well as in cytokine-induced sickness behaviour (Kozak et al., 
1997). Specifically, societies with a high consumption of omega-3 PUFA rich 
foods such as fish, appear to have a lower prevalence of MDD (Tanskanen et 
al., 2001). Furthermore, there is evidence for lowered levels of omega-3 PUFAs 
including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the 
serum, fat tissues and brains of MDD patients (Lin et al., 2010, Maes et al., 
1999). Studies have also shown evidence for a higher ratio of omega-6 PUFAs; 
such as arachidonic acid (AA), to omega-3 PUFAs to be associated with MDD 
(Frasure-Smith et al., 2004, Tiemeier et al., 2003). 
 
 Administration of omega-3 PUFAs have been shown to significantly improve 
depressive symptoms in MDD patients (Lesperance et al., 2011). A meta-
analysis of the placebo controlled double-blind trials of omega-3 PUFAs in MDD 
showed that EPA has significant antidepressant activity although this is 
dependent on severity of depression (Lin et al., 2012, Lin and Su, 2007). One 
possible explanation for the association between depletions in omega-3 PUFAs 
and MDD, and the clinical efficacy of omega-3 PUFAs administration, is the fact 
that omega-3 and omega-6 PUFAs modulate immune functions (Leonard and 
Maes, 2012). Omega-3 PUFAs, attenuate prostaglandin E2 (PGE2) synthesis 
(See Figure 1.7) and the production of monocytic and T cell cytokines, including 
IL-1, IL-6, TNF-α and interferon-gamma (IFN-γ) (Maes et al., 1999, Su, 2009). 
The depletion of omega-3 PUFAs and the relatively higher omega-6 contents 
seen in MDD may cause an increase in the production of pro-inflammatory 
cytokines and T cell cytokines, and therefore take part in the immune 
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pathophysiology of MDD (Leonard and Maes, 2012). Another possible 
explanation is the regulation of neurotransmitters and signal transduction by 
PUFAs. DHA has been shown to be associated with increased neuronal 
membrane stability and functions of serotonin and dopamine transmission 
which could have implications for the development of MDD (Chalon, 2006). 
Omega-3 PUFAs can also have an effect on brain-derived neurotrophic factor 
(BDNF) which is known to be involved in synaptic plasticity as well as providing 
neuroprotection, and enhancing neurotransmission (Ikemoto et al., 2000) all of 






Figure 1.7 The metabolism of polyunsaturated fatty acids (PUFAs) 
 




Only a few studies have investigated the role of PUFAs in the development of 
IFN-α-induced depression. As shown in Figure 1.8, a recent study found that 
lower baseline DHA levels and higher omega-6/omega-3 ratio predicted 
depression incidence (Lotrich et al., 2012). Furthermore, there is also evidence 
for the involvement of genetic polymorphisms in two key enzymes of PUFA 
metabolism and PGE2 synthesis; phospholipase A2 (PLA2) and 
cyclooxygenase-2 (COX2) (Su et al., 2010). Patients who developed IFN-α-
induced depression had a higher frequency of the PLA2 BanI G/G or COX2 
rs4648308 A/G genotypes. Interestingly, these “at risk” genotypes were also 
associated with lower levels of DHA and EPA, at baseline and during IFN-α 
treatment, suggesting that increased reactivity of inflammatory processes is 
fundamental in the development of depressive symptoms. In my PhD, I will 
investigate whether baseline levels of omega-3 and omega-6 fatty acids are 
associated with later development of IFN-α-induced depression. Moreover, I will 




Figure 1.8 The ratio of AA/DHA+EPA at baseline in patients with and without 
IFN-α-induced depression 
 
The ratio of the omega-6 fatty acid arachidonic acid (AA) to the combined levels of the omega-3 
fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at baseline is 
associated with subsequent major depression (MDD) development during IFN-α treatment. 
Figure from (Lotrich et al., 2012): Elevated ratio of arachidonic acid to long-chain omega-3 fatty 
acids predicts depression development following interferon-alpha treatment: Relationship with 
interleukin-6. Brain, Behaviour and Immunity, 31, 48-53. 
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1.3.8.4 Gene expression 
Finally, an emerging and useful method to investigate the pathogenesis of MDD 
is the use of peripheral blood to measure the expression levels of genes. This is 
a useful approach in biomarker identification, with opportunities for both 
hypothesis-driven biomarker search and for hypothesis-free “transcriptomics”-
based discovery (Sunde, 2010). “Blood gene expression” usually refers to 
“intracellular RNA from blood”, and it is technically associated, in most cases, 
with two approaches: the use of tubes for blood collection that stabilize mRNA 
from all cells in the blood; and the extraction of mRNA from separate distinct 
blood cell populations. What is really of importance for researchers is whether 
blood mRNA can be used as a proxy for mRNA expression in other tissues that 
are more relevant to the pathogenic processes of interest – in psychiatry and 
neuroscience, the brain. In this regard, peripheral blood gene expression is very 
promising, as several studies have shown that blood cells share more than 80% 
of the transcriptome with other body tissues, including the brain (Liew et al., 
2006). For example, Sullivan and colleagues compared the transcriptional 
profiling of 79 human tissues, including that of whole blood and of several brain 
areas. They, demonstrated that whole blood shares significant gene expression 
similarities with multiple brain tissues, in particular for genes encoding for 
neurotransmitter receptors and transporters, stress mediators, cytokines, 
hormones, and growth factors, all of which are relevant to MDD (Sullivan et al., 
2006). As such, investigating peripheral blood gene expression appears to be a 
useful tool for assessing and understanding MDD.  
 
Only a few studies have employed this technique in IFN-α-induced depression. 
In mRNA from peripheral blood mononuclear cells (PBMCs), levels of TNF-α 
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were found to remain stable between baseline and treatment week 4 in patients 
who developed IFN-α-induced depression, whereas in patients who did not 
develop depression levels were seen to decrease. Concomitantly, IL-10 levels 
decreased in depressed patients and increased in non-depressed patients 
(Krueger et al., 2011). Again using mRNA from PBMCs, depression as well as 
fatigue during IFN-α treatment were found to be associated with an increase in 
the expression of 2’-5’-oligoadenylate synthetase 2 (OAS2), a gene involved in 
the innate immune response to viral infection (Felger et al., 2012). Finally, a 
recent study analysing mRNA extracted from whole blood using PAXgene 
Blood RNA Tubes (PreAnalytiX, Switzerland), found that pre-treatment up-
regulation of TNF receptor associated factor-6 (TRAF6) and down-regulation of 
transforming growth factor beta-1 (TGF-β1), predicted the development of 
depression during IFN-α treatment (Birerdinc et al., 2012). In my PhD, I will 
conduct microarray analysis in order to identify genes which are differentially 
expressed at baseline in patients who later develop IFN-α-induced depression 
when compared to those who do not. In this way, I will be able to identify 
potential predictors of IFN-α-induced depression using a hypothesis-free 
approach. Furthermore, I will also investigate differences in candidate genes, 




1.4 Current clinical practice and management 
Understanding the underlying mechanisms of IFN-α-induced depression is 
essential in order to increase the accuracy with which vulnerable patients are 
identified. However, judgements of clinical experts are likely to remain 
indispensable in identifying vulnerable patients and providing care. New 
biomarker tools and methods will have to be integrated with current clinical 
practices, and so it is important to understand how clinical experts make 
decisions. Different theoretical perspectives have been used to study health 
care practitioners’ decision making. Many approaches focus on the factors that 
determine how the most accurate decisions are made. However, emerging 
studies of how experts make decisions in naturalistic contexts has challenged 
these notions and provided evidence that decisions made outside the laboratory 
do not involve experts generating and weighting lists of action options. 
Researchers working in the naturalistic decision making (NDM) tradition have 
found that experts make decisions by recognising patterns and matching these 
to known courses of action (Hoffman and Millitello, 2009). Based on this, one 
stream of my PhD will assess the decision making processes that take place in 
the identification and monitoring of IFN-α-induced depression.  
 
1.4.1 The Naturalistic Decision Making (NDM) framework 
The focus of NDM studies of decision making is how experts make decisions in 
the real world. This perspective assumes that decisions in the real world involve 
ill-structured problems, uncertainty, time constraints, high stakes, multiple 
actors, organizational goals and action/feedback loops (Zsambok, 1997), and 
medical decision making shares many of these features. NDM approaches also 
emphasise the importance of the context in shaping decisions, and focus on the 
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information that is sought and attended to in the assessment of the situation 
(Hedberg and Satterlund Larsson, 2003). Using these insights, depression risk 
assessment in HCV patients can be viewed as a complex cognitive task which 
involves on-going decision making about patients’ risk factors and their 
responses to treatment. Moreover, scientific knowledge about how to predict 
which patients will develop IFN-α-induced depression and which will not, is 
incomplete, and patients are not completely known to clinicians, so clinicians 
work with ill-defined and incomplete information. In my PhD, I will use the NDM 
approach as a framing perspective, to improve our understanding of staff 




1.5 Aims and hypotheses of the study 
1.5.1 Clinical and biological effects of IFN-α 
IFN-α induces a broad range of neuropsychiatric side-effects (Raison et al., 
2005b, Udina et al., 2012) and has effects on a variety of biological systems 
(Capuron and Miller, 2011, Raison et al., 2008). As such, a primary aim of this 
thesis is to monitor the impact of IFN-α treatment on a number of clinical and 
biological parameters. Specifically, I predict that: 
 
- IFN-α will lead to an increase in depression, fatigue, stress and anxiety 
scores. 
- IFN-α will lead to a decrease in health status and well-being measures. 
- IFN-α will lead to a decrease in tryptophan levels, with a subsequent 
increase in kynurenine and its neurotoxic metabolites, and a decrease in 
the levels of the neuroprotective metabolite; kynurenic acid. 
- IFN-α will lead to a decrease in the level of omega-3 PUFAs and an 
increase in omega-6 contents. 
- IFN-α will lead to a number of gene expression changes particularly 
increased expression of genes involved in: tryptophan metabolism, PUFA 
metabolism and inflammation, and reduced expression of genes involved 
in GR functionality and neuroplasticity. 
 
1.5.2 Clinical predictors of IFN-α-induced depression 
Previous studies have found few clinical predictors of IFN-α-induced depression 
with the most widely investigated being a previous history of depression (Raison 
et al., 2005a, Smith et al., 2011b). However, known risk factors for MDD outside 
of the context of IFN-α treatment, such as a history of childhood trauma have 
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not yet been investigated in patients undergoing IFN-α therapy. As such, the 
second primary aim of this thesis is to identify novel clinical predictors of IFN-α-
induced depression such as childhood trauma and illness perceptions. I will 
assess the contribution of a number of clinical and lifestyle factors on the 
subsequent development of IFN-α-induced depression. Specifically, I predict 
that: 
 
- A previous history of depression, a family history of psychiatric illness and 
baseline psychopathology will be associated with the development of IFN-
α-induced depression.  
- Exposure to recent stressful life events as well as childhood trauma 
(physical and sexual abuse, parental loss or parental separation) will be 
associated with the development of IFN-α-induced depression.  
- Negative illness perceptions will be associated with IFN-α-induced 
depression.  
 
1.5.3 Biological predictors of IFN-α-induced depression 
Several studies have shown IFN-α induces changes in the function of a number 
of biological systems including the immune and neuroendocrine systems, and 
these changes are related to depressive outcomes (Capuron et al., 2003b, 
Raison et al., 2009, Wichers et al., 2007). However, most of these have studied 
changes in these biological systems as a result of IFN-α, rather than assess 
baseline predictors. The third primary aim of this thesis is to investigate the 
baseline levels of a number of biological variables on the development of IFN-α-
induced depression. I will investigate a number of biological systems and 
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furthermore, identify novel contributors through the use of microarray which 
offers a hypothesis-free approach. Specifically, I predict that: 
 
- Increased cortisol awakening response as well as increased cortisol 
during the day will be associated with IFN-α-induced depression.  
- Lower levels of tryptophan and higher kynurenine metabolite contents will 
be associated with the development of IFN-α-induced depression. 
- Lower omega-3 PUFAs and higher omega-6 PUFAs will be associated 
with the development of IFN-α-induced depression.  
- Increased expression of genes involved in tryptophan metabolism, PUFA 
metabolism and inflammation accompanied by reduced expression of 
genes involved in GR functionality and neuroplasticity will be associated 
with associated with IFN-α-induced depression. 
 
1.5.4 Qualitative assessment of current clinical practice 
Despite the potential to identify clinical and biological predictors of IFN-α-
induced depression, the judgements and decisions of clinical experts will still be 
vital in identifying vulnerable patients and providing care, at least in the short 
term. As such, it is important to understand how clinical experts make decisions 
and how clinical teams co-ordinate their activities to care for patients. The final 
aim of this thesis is to gain an in-depth understanding of staff experiences of, 
and attitudes towards the identification and monitoring of IFN-α-induced-
depression, and their decision-making processes. Specifically, I will investigate 
the following questions: 
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- What factors do clinical nurse specialists see as important in determining 
risk of developing depression, at initial consultation and in on-going 
monitoring? 
- What actions do clinical nurse specialists take? 
- What are the sources of uncertainty for clinical nurse specialists and 





2.1 Study on patients undergoing IFN-α therapy 
2.1.1 Study Design 
A prospective cohort design was used to investigate the effects of IFN-α 
therapy. Patients were evaluated at baseline (week 0) and after 4, 8, 12, 16, 20 
and 24 weeks of IFN-α treatment. 
 
2.1.2 Participant Selection 
Patients were recruited from the outpatient liver departments of three London 
hospitals: King’s College Hospital, Guy’s and St. Thomas’ Hospital and St. 
George’s Hospital. Eligible patients were adult patients with chronic hepatitis C 
virus (HCV) infection who were due to commence combination antiviral therapy 
with IFN-α and ribavirin. All patients received combination therapy for at least 24 
weeks. This comprised of weekly subcutaneous IFN-α injections (1.5 µg per kg 
of body weight) and daily ribavirin tablets (800 to 1400 mg orally per day in 2 
divided doses). Exclusion criteria included age below 18 years, any 
autoimmune disorder, any cause for liver disease other than HCV, current use 
of antidepressants, lack of English language and co-infection with HIV or 
hepatitis B. Written informed consent was obtained from all participants after a 
complete explanation of the study, a presentation of a participant information 
sheet and an opportunity to ask questions. The study was approved by the 
King’s College Hospital Research Ethics Committee (Ref: 10/H0808/30). All 
patients were recruited from September 2010 to May 2012 with data from the 
last treatment week 24 assessment collected by November 2012. A total of 58 
participants were recruited however, 10 participants only completed the 
baseline assessments as they either withdrew their participation in the study or 
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their treatment was stopped within the first 4 weeks due to extreme adverse 
effects. Their data were not included in this PhD; therefore, the final sample of 
this study comprises 48 patients (see Results). 
 
2.1.3 Clinical data collection at baseline 
Several assessments were conducted at the baseline, immediately before IFN-α 
therapy, in order to identify potential risk/predictive factors for the development 
of IFN-α-induced depression. Copies of all psychometric scales can be found in 
the Appendix. 
 
2.1.3.1 Socio-demographic Data 
Socio-demographic data (age; gender; self-rated ethnicity; level of education 
achieved; current relationship status and current employment status) were 
collected at baseline using a modified version of the MRC Socio-demographic 
Schedule (Mallett et al., 2002). As some variables were characterised by small 
cell sizes it was necessary to collapse categories. As such, I created 
dichotomised variables to consolidate multiple classes of data: for ethnicity, 
looking at White British individuals versus all other ethnicities; for level of 
education, looking at university degree versus all others; for current relationship 
status, looking at single versus all others and for current employment status, 
looking at part-time or full-time employment versus unemployed. 
 
2.1.3.2 Mini International Neuropsychiatric Interview (MINI) 
The MINI was administered at baseline in order assess patients for a current 
depressive episode or a previous history of MDD; it was also used at follow-up 
assessments for the detection of new onset cases of depression during IFN-α 
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therapy. The MINI is a structured diagnostic interview for psychiatric disorders 
according to the Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition (DSM-IV) and the International Statistical Classification of Diseases and 
Related Health Problems 10th Revision (ICD-10). With an administration time of 
approximately 15 minutes, the MINI was designed to meet the need for a short 
yet accurate, structured psychiatric interview for use in multi-centre clinical trials 
and epidemiology studies, and to be used as a first step in outcome tracking in 
non-research clinical settings (Sheehan et al., 1998). The interview includes 
diagnoses of 19 disorders, including 17 Axis I disorders, a suicidality module 
and one Axis II disorder: antisocial personality disorder. For the purpose of this 
study, we only focused on the detection and diagnosis of major depressive 
episode and not any other psychiatric disorders. All researchers were trained in 
administering the MINI with the use of training videos. The training videos were 
comprised of actors simulating symptoms of depression that are consistent with 
the information assessed by the MINI.  
 
2.1.3.3 Family History  
Information regarding family history of psychiatric diagnoses was obtained using 
the Family Interview for Genetic Studies (Maxwell, 1992) and supplemented by 
medical notes where available. 
 
2.1.3.4 Childhood Experiences of Care and Abuse (CECA) 
A modified version of the Childhood Experiences of Care and Abuse (CECA) 
Questionnaire was used to collect information about childhood trauma. The 
CECA questionnaire is a self-report measure designed to elicit information 
concerning childhood experiences before the age of 17 (Bifulco et al., 2005).. 
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This includes information about parental loss, separation from parents for 6 
months or more, physical and sexual abuse. Cut-off points were utilised to 
dichotomise responses on physical and sexual abuse variables. Using the cut-
off points published by Bifulco et al., physical abuse was defined as repeated 
exposure to physical violence, from either the main mother or main father figure 
before the age of 17 years. In order to be considered ‘severe’, these incidents 
had to meet at least two of the following criteria; (a) being hit with a belt/stick or 
being punched or kicked; (b) resulting in an injury, including broken limbs, black 
eyes or bruising; (c) the perpetrator was considered to be out of control. Mild 
forms of punishment such as being smacked or hit with a slipper were excluded. 
Sexual abuse was defined as when at least one of the screening questions for 
sexual abuse was present (“When you were a child or teenager, did you ever 
have any unwanted sexual experiences?”, “Did anyone force you or persuade 
you to have sexual intercourse against your wishes before age 17?”, “Can you 
think of any upsetting sexual experiences before age 17 with a related adult or 
someone in authority, e.g., a teacher?”). A composite variable was also created 
by adding together presence of one of the four dichotomised variables 
considered (loss of parents, separation from parents for 6 months or more, 
severe physical abuse and presence of sexual abuse); the score of this variable 
ranged from 0 (absence of any childhood trauma) to 4 (presence of all four 
types of childhood trauma investigated). This variable was then further 
dichotomised as 0 if no childhood trauma was experienced and 1 if one or more 
type of childhood trauma was experienced. 
 
74 
2.1.3.5 Brief Life Events (BLE) 
The Brief Life Events questionnaire was administered to assess recent stressful 
events (Brugha and Cragg, 1990). This is a self-report questionnaire examining 
the incidence of 12 categories of negative life events over the previous 6 
months. It assesses life stressors involving moderate or long-term threats such 
as illness or injury, the death of a close friend or relative, unemployment, 
financial loss and loss of important relationships. The questionnaire involves the 
reporting of any of the 12 events if they took place in the previous six months, 
together with a score of the emotional impact of each event at that time (‘how 
bad was it at that time: “not too bad”, “moderately bad” “very bad”’), allowing an 
assessment of both the number and the emotional impact of stressful life 
events. A dichotomised variable was created with 0 if no life events were 
experienced in the previous 6 months, and 1 if one or more type of life event 
was experienced in the previous 6 months prior to baseline. 
 
2.1.3.6 Substance Use 
All patients were asked about substance use using a modified version of the 
Cannabis Experience Questionnaire (Section 2 of CEQ) (Barkus et al., 2006). 
This questionnaire allowed detailed assessment of life time pattern of substance 
use looking at data such as age at first use and frequency of use of substances 
including cannabis, amphetamines and opioids. In my sample 36 out of 48 
patients reported using at least one type of substance, at least once in their 
lifetime. As such, I specifically focused on the use of opioids as a more severe 
form of substance use, and also due to the high risk of HCV transmission 
associated with intravenous drug use. I created a dichotomised variable with 0 if 
no lifetime use of opioids and 1 for a current or a history of opioid use. 
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2.1.3.7 Illness Perceptions (IPQ) 
The Illness Perceptions Questionnaire (IPQ) is comprised of five scales 
measuring the five components of illness representation specified in Leventhal’s 
self-regulatory model of illness. The five scales assess identity (the symptoms 
the patient associates with the illness), cause (personal ideas about aetiology), 
time line (the perceived duration of the illness), consequences (expected effects 
and outcome), and cure control (beliefs about potential for cure and control of 
the illness) (Weinman et al., 1996). Higher scores indicate a strong emotional 
response, perception that the illness is chronic, that it is cyclic in pattern, that it 
has serious consequences, and that control or cure is possible. Due to the fact 
that HCV infection is largely asymptomatic, I did not use the identity domain of 
this questionnaire in my data analysis.  
 
2.1.4 Clinical data collection at follow-up assessments 
The following clinical measures were used to assess symptoms preceding the 
baseline and at every subsequent monthly assessment in order to not only 
identify baseline risk/predictive factors but also monitor symptom development. 
Copies of all psychometric scales can be found in the Appendix. 
 
2.1.4.1 Inventory of Depressive Symptomatology (IDS) 
The IDS is a 30-item questionnaire asking subjects to rate how they have felt 
over the past week in order to assess frequency and, duration or severity of a 
wide range of depressive symptoms (Rush et al., 1986). The scale assesses all 
9 symptom domains needed to diagnose a DSM-IV major depressive episode 
and includes items to assess melancholic and atypical symptom features as 
well as commonly associated symptoms such as anxiety or pain. The IDS is 
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scaled to allow the detection of milder levels of depression and excludes 
uncommonly encountered symptoms such as depersonalisation (Lam et al., 
2006). Items on the IDS are scored on a 0-3 scale; however, respondents 
answer either question 11 or 12 (decreased appetite or increased appetite) and 
either question 13 or 14 (weight loss or weight gain). As such, the total score 
range is 0-84 with higher scores indicating greater symptom severity. The 
authors have suggested the following severity indications: <12, normal; 13-23, 
mild; 24-36, moderate; 37-46, moderate-severe and >47, severe (Rush et al., 
1986). 
 
2.1.4.2 Hospital Anxiety and Depression Scale (HADS) 
The HADS is a 14-item self-report questionnaire designed to screen for the 
presence and severity of depression and anxiety symptoms in medical patients 
over the past week (Zigmond and Snaith, 1983). This questionnaire is 
comprised of a 7-item depression sub-scale and a 7-item anxiety sub-scale, 
both of which omit somatic symptoms in order to reduce the likelihood of false 
positives (Lam et al., 2006). For the purpose of this study, I focused only on the 
anxiety sub-scale. Items on the HADS are scored on a 0-3 scale, and each sub-
scale of 7 questions is summed to give a total score range of 0-21. Scores in 
the range of 0-7 are considered normal; 8-10, mild; 11-14, moderate; and 15-
21, severe.  
 
2.1.4.3 Chalder Fatigue Scale (CFQ) 
The CFQ has been widely used to measure the severity of fatigue and consists 
of 11 questions measuring fatigue-related symptoms over the previous month. 
The CFQ contains 7 items which address physical fatigue and 4 items 
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addressing mental fatigue. Items are scored on a 0-3 scale, giving total scores 
ranging from 0-33 with higher scores indicating more fatigue (Chalder et al., 
1993). Scores of ≤18 are considered to be within normal range for fatigue 
(White et al., 2013, White et al., 2007). 
 
2.1.4.4 Perceived Stress Scale (PSS) 
The 10-item Perceived Stress Scale measures the degree to which situations in 
one’s life are appraised as stressful (Cohen and Williamson, 1988). In this 
study, the 10-item version was used, where each item asks the subject to rate 
how often they have perceived an event in their life over the last month (e.g. “In 
the last month how often have you felt difficulties piling up so high that you 
could not overcome them?”). Response options are assessed using a 5-point 
scale (0=never to 4=very often). Four items are worded in the opposite direction 
(e.g. “In the last month how often have you felt that things were going your 
way?”) and are reverse-scored. The total score is computed by summing all 10 
items, with a range of 0-40. 
 
2.1.4.5 Medical Outcomes Study Short-Form 36 (SF-36) 
The SF-36 is a self-report measure of general health and has been extensively 
used to assess health status in patients with mood and anxiety disorders (Ware 
et al., 1993). It assesses both physical and emotional well-being based on how 
an individual has functioned over the previous 4 weeks. The SF-36 assesses 8 
primary dimensions: physical functioning, physical role limitation, bodily pain, 
social functioning, mental health, emotional role limitation, vitality (energy 
versus fatigue) and general health. The items are scored in a yes/no fashion, 
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and on 3, 5 and 6-point scales. The 8 sub-scales have score ranges of 0-100, 
where higher scores indicate better health status. 
 
2.1.5 Laboratory methods 
2.1.5.1 Salivary Cortisol 
Saliva samples were collected to measure salivary cortisol, at baseline and at 
treatment week 24 (end of treatment). I used a salivette device (Sarstedt, 
Leicester, UK) in which saliva is absorbed. Subjects were instructed to collect 
saliva samples by placing the salivette on their tongue for 60 seconds. Samples 
were collected at 6 time points in a single day; immediately after awakening (0 
minutes) and 15, 30 and 60 minutes after awakening, and again at 12pm and at 
8pm. Subjects were instructed to wake up before 10 am, to take the first sample 
while still in bed, and then not to have breakfast or brush their teeth during the 
first hour of awakening, and then again in the 30 minutes before taking the 
samples at 12pm and 8pm. This is in order to avoid falsely high cortisol values 
due to plasma exudates from minor bleeding in the oral cavity, or from meal-
stimulated rises in cortisol. During collection, subjects were instructed not to 
touch the samples with their hands. At each time point the subjects were also 
instructed to write on “information sheets” provided (see Appendix), the time of 
collection, if they had accidentally had anything to eat or drink before taking the 
sample, and if they had experienced any difficult or tense situations before 
taking the sample. Samples were kept in the refrigerator overnight and then 
collected at the visit appointment or sent back in the post in the morning.  
 
On arrival to the laboratory, the samples were frozen at -20°C. After thawing, 
saliva samples were centrifuged at 3000 rev/min for 15 minutes at room 
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temperature, which resulted in a clear supernatant of low viscosity. 
Determination of cortisol levels was achieved using the High Sensitivity Salivary 
Cortisol ELISA KIT from Salimetrics, following the recommended procedure. 
Briefly, 25 µl of saliva and standards were assayed in duplicates, by incubation 
on a microtitre plate coated with monoclonal antibodies against cortisol. Cortisol 
linked to horseradish peroxidase was then added, to compete with cortisol in 
the standards and unknowns for the antibody binding sites. After incubation, 
unbound components were washed away and bound cortisol peroxidase 
measured by reaction of the peroxidase enzyme on the substrate 
tetramethylbenzidine. The amount of cortisol peroxidase detected, as measured 
by the intensity of colour developed, is inversely proportional to the amount of 
cortisol present. Optical density was read at 450 nm with correction at 620 nm, 
using a Beckman Coulter DTX 880 plate reader, with Multimode Detection 
Software 2.0.0.12. Values of cortisol were calculated using SoftMax Pro 4.8 
software, following a 4-parameter fit. All of the analyses were conducted by Dr. 
Patricia Zunszain, senior laboratory co-ordinator in my research group. 
 
To investigate the cortisol response to awakening, I calculated the Area Under 
the Curve of the increase (AUCi) of cortisol levels after awakening, considering 
the changes of cortisol levels from baseline (0 minutes) to 15, 30, and 60 
minutes after awakening (See Figure 2.1). To investigate the cortisol levels 
during the day, I calculated the Area Under the Curve (AUC) of cortisol levels at 
0 minutes after the awakening, at noon and at 8pm (See Figure 2.2). Both 
formulas for the calculation of the AUCs were derived from the trapezoid 







Figure 2.1 Area under the curve of the increase 
 
The triangles and rectangles illustrate the composition of the area under the curve with respect 
to the increase (AUCi). m1 to m6 denote the measurements and t1 to t5 denote the time interval 
between the measurements. In this example the time interval between the measurements is 
identical; however individual time intervals were different in my sample (e.g. for the awakening 
response; 15 minutes between the baseline and 15 measurements, and the 15 and 30 
measurements, but 30 minutes between the 30 and 60 measurements). Figure from (Preussner 
et al., 2003): Two formulas for the computation of the area under the curve represent measures 







Figure 2.2 Area under the curve 
 
The triangles and rectangles illustrate the composition of the area under the curve (AUC). m1 to 
m6 denote the measurements and t1 to t5 denote the time interval between the measurements. 
In this example the time interval between the measurements is identical; however individual 
time intervals were different in my sample (e.g. for the awakening response; 15 minutes 
between the baseline and 15 measurements, and the 15 and 30 measurements, but 30 minutes 
between the 30 and 60 measurements). Figure from (Preussner et al., 2003): Two formulas for 
the computation of the area under the curve represent measures of total hormone concentration 
versus time-dependent change. Psychoneuroendocrinology, 28, 916-31. 
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2.1.5.2 Kynurenine and Tryptophan pathway 
Blood samples were collected using 9ml VACUETTE® plasma separation, 
sodium heparin tubes, at baseline and at treatment weeks 8 and 24. On arrival 
to the laboratory, the samples were centrifuged at 500 rev/min for 10 minutes at 
room temperature, and then plasma removed and frozen at -80°C. After 
thawing, high performance liquid chromatography (HPLC) with a reverse phase 
c-18 column was used to measure plasma levels of tryptophan (TRP), 
kynurenine (KYN), kynurenic acid (KYNA) and 3-hydroxykynurenine (3-HK). 
The measurement was performed according to the method of Hervé et al. with 
some modifications (Herve et al., 1996). The recently published method using 
HPLC (Oades et al., 2010) was used to measure 3-HK. Briefly, KYN was 
detected spectrophotometrically at 365 nm. KYNA was detected fluorimetrically 
at an excitation wavelength of 334 nm and an emission wavelength of 388 nm. 
KYNA was analysed in plasma that was de-proteinised using perchloric acid. 3-
HK was measured at a wavelength of 365 nm by UV detection. The 3-HK 
analysis method has been validated showing an absolute recovery of 85.8%, 
intra-day precision of 3.9%, and inter-day precision of 7.5%. The intra and inter-
assay coefficients of variation ranged from 5% to 7% for all of the metabolites. 
All of the analyses were conducted by Dr. Aye-Mu Myint at Ludwig-Maximilians-
University, Munich, Germany. 
 
2.1.5.3 Gas Liquid Chromatography for PUFA analysis 
Blood samples were collected using 2ml K3EDTA tubes at baseline and at all 
subsequent treatment weeks. On arrival to the laboratory, the samples were 
centrifuged at 1500 rev/min for 15 minutes at room temperature and then 
plasma removed and frozen at -80°C. After thawing, 100 µl of plasma was 
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aliquoted precisely in to glass tubes with Teflon-lined caps. An internal standard 
consisting of 50 µg to 300 µg of pentadechanoic acid dissolved in 2 ml of 
methanol-toluene (4:1) was mixed precisely with acetyl chloride at a ratio of 
10:1. 220 µl of this mixture was added to the plasma samples and then 
subjected to methanolysis at 60°C for 2 hours. Afte r tubes had been cooled at 
room temperature, 5 ml of 6% potassium carbonate solution was slowly added 
to stop the reaction and neutralize the mixture. The tubes were then shaken and 
centrifuged, and an aliquot of the benzene upper phase was collected and 
placed in injection vials for analysis. Fatty acid methyl esters were analysed on 
a 25 mm x 22 mm internal diameter silica column (BP70X; SGE, Melbourne, 
VIC, Australia) using hydrogen as a carrier gas on an Agilent chromatograph 
6890 (Agilent, Stockport, Cheshire, UK) in split mode (50:1). Initially, oven 
temperature was set at 160°C for 4 minutes and then  the temperature was 
increased by 10°C/min until 200°C and held at this final temperature for 10 
minutes. Peaks were integrated using ChemStation (revision B4.01) software. 
Fatty acids were identified by comparison with reference standards 189-1, 189-
2 (Sigma, Poole, Dorset, UK) and by a methyl ester preparation of MAXEPA to 
identify long chain omega-3 fatty acids. The levels of PUFAs were generated as 
percentage of total fatty acids. I conducted all the analyses of PUFA levels. 
 
2.1.5.4 Gene Expression 
Blood samples were collected in PAXgene Blood RNA Tubes (PreAnalytiX, 
Switzerland) using standard protocols at baseline and at treatment week 4. 
After blood samples were drawn, PAXgene tubes were inverted 5-10 times and 
then kept upright at room temperature for 2 hours. After this, samples were 
placed in -20°C for 48 hours and then transferred t o -80°C for storage until they 
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were processed. Isolation of total RNA (mRNA and miRNA) was performed 
using the PAXgene blood miRNA kit according to the manufacturer’s 
recommended protocol (PreAnalytiX, Switzerland). In brief, blood was pelleted, 
washed, and then re-suspended with a lysis buffer and proteinase K to digest 
cellular proteins. Samples were then passed through PAXgene Shredder spin 
columns to homogenise the lysate and filter out cell debris. The supernatant of 
the flow-through was then passed through the PAXgene RNA spin column 
where the silica membrane selectively binds to the RNA. The RNA was DNase 
treated and after several wash steps it was eluted and heat-denatured. RNA 
quantity and quality were assessed by evaluation of the A260/280 and 
A260/230 ratios using a Nanodrop spectrophotometer (NanoDrop 
Technologies, USA). 
 
Gene expression microarray assays were performed using Affymetrix® Human 
Gene 1.1 ST Array strips, on the GeneAtlas® platform according to the protocol 
(http://media.affymetrix.com/support/downloads/manuals/geneatlas_wt_expkit_
manual.pdf). Partek Genomics Suite 6.6 software was used for data 
visualization, statistical testing of affymetrix CEL files and quality control. Data 
quality was assessed using histograms of signal intensities, scatter plots, and 
hierarchical clustering of samples. All samples passed the criteria for 
hybridization controls, labelling controls and 30/50 Metrics. Robust MultiChip 
Average method was used for background correction and Quantiles 
normalization. Summarization was performed using a median polish algorithm 
(Tukey, 1977).  
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Gene expression data were analysed using two approaches. Firstly, I used a 
hypothesis-free approach including pathway analysis using Ariadne Pathway 
Studio Software. Secondly, I used a candidate gene approach to investigate 
genes expression differences and changes based on evidence from previous 
studies. I selected genes known to be involved in tryptophan and PUFA 
metabolism (See Figure 1.5 and Figure 1.7), some of which have previously 
been implicated in the development of IFN-α-induced depression (Smith et al., 
2011a, Su et al., 2010). I selected genes involved in inflammation, namely 
cytokines, for which altered serum levels have been demonstrated in IFN-α 
treated patients or in MDD outside of the context of IFN-α. Specifically, 
interleukin (IL) – 1, IL-2, IL-6 and their receptors, as well as IL-8, IL-10, tumor 
necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ), have been 
previously demonstrated to be altered in the serum of IFN-α patients 
(Bonaccorso et al., 2001, Grungreiff et al., 1999, Loftis et al., 2008, Wichers et 
al., 2007, Wichers et al., 2006) or in gene expression studies of MDD patients 
(Cattaneo et al., 2012, Tsao et al., 2006). Interleukin 18 (IL-18) is an important 
modulator of immune responses that has been found to be elevated in MDD 
patients (Kokai et al., 2002, Merendino et al., 2002). Polymorphisms in the IL-
28β gene have been shown to predict IFN-α treatment response (Ge et al., 
2009) and one study has investigated the association between IL-28β and IFN-
α-induced side-effects (Lotrich et al., 2011). As such, I also included IL-28β in 
my list of candidate genes. A previous gene expression study in IFN-α treated 
patients, found alterations in the expression of TNF receptor associated factor-6 
(TRAF6) and transforming growth factor beta-1 (TGF-β1), and so these were 
also included in my list of inflammation related candidate genes (Birerdinc et al., 
2012). Finally, I also selected genes which are involved in neuroplasticity. 
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Lower levels of brain-derived neurotrophic factor (BDNF) have been previously 
shown to be involved in IFN-α-induced depression (Kenis et al., 2010). 
Furthermore, gene expression levels of BDNF as well as other neurotrophic 
factors such as VGF and vascular endothelial growth factor (VEGF) have been 
shown to be altered in MDD patients when compared to controls (Cattaneo et 
al., 2012, Cattaneo et al., 2010, Iga et al., 2007, Pandey et al., 2010). The 
expression of the glucocorticoid receptor (NR3C1) and its chaperones and co-
chaperones, such as FK506 binding protein (FKBP)-4 and FKBP-5 have also 
been shown to be altered in MDD patients when compared to controls 
(Cattaneo et al., 2012). 
 
I completed all the RNA extraction, while the gene expression microarray 
assays and subsequent bioinformatics analyses were conducted by Dr. 
Annamaria Cattaneo, a post-doctoral researcher in the team expert in this 
research approach. 
 
2.1.6 Data Analysis 
All data were analysed using IBM SPSS statistical software version 20 and 
STATA version 10. Whenever appropriate, data are presented as Mean±SEM 
(standard error of the means). Graphs are presented as mean and 95% 
confidence intervals. The independent-samples t test was used to compare 
means of continuous variables between patients with and without IFN-α-induced 
depression. All comparisons of categorical data were examined using the chi-
squared (x2) test. Correlations between baseline values of clinical and biological 
data were tested with Pearson’s analysis. ANOVA analyses were performed to 
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identify significantly different genes between patients with and without IFN-α-
induced depression, and between baseline and treatment week 4.  
 
Random intercept regression models with maximum likelihood effects were 
used to investigate changes in psychopathological scales and biological 
variables as a function over time. This method of analysis is an ideal way to 
model repeated measures as it can handle missing data. The dataset is 
changed from wide to long format and clustered by individual. Random intercept 
regression models with maximum likelihood effects were also used to assess 
the predictive effects of baseline demographic, psychosocial stress, cognitive, 
psychopathology, health status and biological factors on subsequent 
psychopathological scale scores. In order to give a clearer index of the variance 
explained by individual predictors, an overall R2 value is given for significant 
predictors. All graphs are presented as means and 95% confidence intervals. 
Throughout the thesis statistically significant P values are indicated in bold. 
 
It is important to note that due to the large number of predictor variables I have 
assessed, there is a potential for increased type 1 error as multiple comparisons 
were not corrected for. However, frequently used procedures such as the 
Bonferroni method are conservative, not appropriate for a large number of tests 
and diminish statistical power (Bland and Altman, 1995). Furthermore, methods 
to adjust for multiple testing in studies such as this which collect repeated 
measurements are rare as these comparisons occur for between-subject 




2.2 Qualitative study on nursing staff 
2.2.1 Study Design 
A qualitative interview study was conducted among clinical staff involved in the 
care of patients with hepatitis C receiving IFN-α therapy, using the perspective 
of naturalistic decision making.  
 
2.2.2 Participants Selection 
Purposive sampling was used to select participants most able to provide 
information relevant to the study objectives. The participants were staff 
members working in outpatient liver clinics in three large teaching hospitals in 
South London. All clinical nurse specialists (n=9) from all three centres were 
approached and agreed to participate. All were involved directly in the care of 
patients receiving IFN-α treatment and had at least one year’s experience 
(mean 6.4 years, range 1-11 years) working in this field. Participants were 
initially approached via email. All participants gave written informed consent 
after receiving an information sheet detailing the nature and purpose of the 
research and being given an opportunity to ask questions.  
 
2.2.3 Data Collection 
A semi-structured interview guide was developed (See Appendix), and 
interviews lasting approximately 30 minutes were conducted individually with 
each member of staff. The interviews were organised into the following 
sections: background information on training and experience providing HCV 
care; current clinical practices/protocols for monitoring and identifying 
psychiatric side-effects, including referrals to psychiatrists; and personal 
attitudes to the use of decision making tools and access to resources. Standard 
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probes, such as verification, were used to fully clarify specific responses. All 
interviews were conducted jointly by myself and one other experienced social 
science interviewer; Dr. Naonori Kodate. All interviews took place between 
November 2010 and April 2011. Interviews were tape recorded, transcribed 
verbatim and then imported into the qualitative data analysis package (QSR 
NVivo 8.0 data analysis software) to facilitate data handling.  
 
2.2.4 Data Analysis 
Data were analysed using thematic framework analysis to identify key themes 
which were then used to code the interview data (Ritchie and Spencer, 1994). 
Framework analysis is a method that is particularly suited to studies in which at 
least some of the themes and concepts can be identified a priori (Dixon-Woods, 
2011, Ritchie et al., 2003). Questions of relevance to the research aims are 
used as an initial thematic framework for the analysis, but the approach also 
allows for the inductive identification of emergent themes (Dixon-Woods, 2011, 
Pope et al., 2000). The initial coding framework was based on the interview 
schedule and further themes were identified as the analysis progressed. The 
framework was refined iteratively by comparing and discussing interpretations 
of the data and a final coding framework developed along with detailed 
descriptions of each theme to increase the reliability of coding. In order to 
further ensure the reliability of the analysis, Dr. Naonori Kodate and I 
independently examined portions of the transcripts and resolved any 
differences. The final coding framework consisted of major factors influencing 
identification and monitoring of depression and subsequent decision making. 
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2.2.5 My contribution 
I contributed to the study design, protocol and set-up. This included completing 
the ethical approval, as well as R&D approvals from all three study sites. I 
collected approximately 80% of the data (clinical and biological), with help from 
placement students whom I supervised and co-ordinated for the remainder of 
the data collection. All of the cortisol samples were analysed by Dr. Patricia 
Zunszain, senior laboratory co-ordinator in my research group. I collected and 
processed approximately 80% of the blood samples, again with the help of 
placement students, in order to obtain plasma for kynurenine and tryptophan 
pathway analysis, as well as PUFA analysis. All of the kynurenine and 
tryptophan pathway metabolites were measured by Dr. Aye-Mu Myint at 
Ludwig-Maximilians-University, Munich, Germany. I conducted all the analyses 
of PUFA levels. I also completed all of the mRNA extraction, before the 
microarray assays and subsequent bioinformatics analyses were conducted by 
Dr. Annamaria Cattaneo. For the qualitative study, I jointly conducted all the 
interviews with Dr. Naonori Kodate. I alone transcribed all of the interviews 
before jointly analysing the data. I alone completed all of the data entry as well 




3 Results  
In this Results section, I will first discuss the characteristics of the sample 
(socio-demographics, exposure to psychosocial stressors, illness perceptions, 
baseline psychopathology and baseline health status). Then I will look at the 
changes over time due to IFN-α treatment in the whole sample, for the clinical 
(depression, fatigue, stress, anxiety and general health status) and biological 
variables (cortisol, kynurenine and tryptophan pathway, PUFA levels and gene 
expression). Then I will look at the incidence of IFN-α-induced depression and 
compare the same clinical and biological variables, in patients with and without 
IFN-α-induced depression, at baseline and over the course of IFN-α treatment. 
This will be followed by investigating the above-listed clinical and biological 
variables as predictors of depression, fatigue, stress and anxiety during IFN-α 
treatment. Finally, I will present the results of the qualitative study looking at the 
predictors or risk factors for depression currently assessed by clinical nurse 
specialists, followed by methods of co-ordinating actions, sources of uncertainty 
and suggested areas of improvement. 
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3.1 Study on patients undergoing IFN-α therapy 
3.1.1 Characteristics of the sample  
Forty-eight patients were consented and completed at least one follow-up 
assessment during IFN-α treatment. 
 
3.1.1.1 Socio-demographic characteristics 
The sample had an age range of 18-63 with a mean age of 43.3. The sample 
was predominantly male (75%) and of a white British background (48%). At 
baseline, no patients met criteria for a current MDD diagnosis, were taking any 
antidepressant medication or were being treated for an anxiety disorder. 
However, 17 patients (35%) had a self-reported history of MDD and 13 patients 
(27%) had a family history of psychiatric illness. Furthermore, 17 patients (35%) 
had a history of substance use, specifically use of opioids. There was some 
overlap in these characteristics; 5 patients (39%) with a family history of MDD 
also had a self-reported history of MDD, and 7 patients (41%) with a history of 
substance use also had a self-reported history of MDD. Only 2 patients reported 
a history of all three of these characteristics. The sample was predominantly 
comprised of patients with HCV genotype 3 (65%). The mean baseline viral 
load of the sample (that is, the number of viral particles per ml of blood 
presented in millions) was 2.1±0.4. The severity of the liver disease was also 
measured by a fibroscan to assess scarring of the liver, which is rated as a 
specific score in kilopascals (KPa). In viral hepatitis, a score of less than 7 
means no or insignificant liver fibrosis; a score of more than 12.5 KPa is severe 
fibrosis or cirrhosis, and intermediate results suggest moderate fibrosis. The 
sample had a mean fibroscan score of 8.9±1.2 indicating moderate fibrosis. 
These data are presented in Table 3.1. 
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Table 3.1 Socio-demographic characteristics 
  
Patients 












































































3.1.1.2 Psychosocial stress characteristics 
The psychosocial stress characteristics of the sample including recent life 
events within the previous 6 months, as well as childhood traumatic events are 
shown in Table 3.2. Almost half of the sample (46%) reported experiencing at 
least one stressful life event in the 6 months before initiation of IFN-α treatment. 
Nineteen patients (40%) reported experiencing at least one form of childhood 
traumatic event. The most frequently reported form of childhood trauma was 
parental separation as reported by 12 patients (25%). 
 
3.1.1.3 Illness perceptions characteristics 
Patients showed good illness coherence, with a mean score of 18.3 out of a 
possible 20. They also held strong beliefs that treatment is an effective way of 
controlling their illness, with a mean score of 21.4 out of a possible 25, as well 
as strong beliefs about their personal ability to control symptoms, with a mean 
score of 22.9 out of a possible 30. Patients’ beliefs about the seriousness of 
their illness and its consequences were not as strong, with a mean score of 
18.2 out of a possible 30, as were their emotional representations, with a mean 
score of 17.5 out of a possible 30. Participants perceived their illness to be 
acute rather than chronic, with a mean score of 14.7 out a possible 30, and also 
did not see their illness as being cyclical in nature, with a mean score of 9.2 out 
of a possible 20 for this dimension. These data are presented in Table 3.3. 
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Table 3.2 Psychosocial stress characteristics 
  
Patients 
n = 48 
 








































Table 3.3 Illness perceptions scores 
  
Patients 
































3.1.2 Psychopathological changes during IFN-α treatment 
As part of the first aim of this thesis, I prospectively monitored the impact of 
IFN-α treatment on a number of psychopathological factors. Changes in 
depression, fatigue, stress and anxiety scores during IFN-α treatment are 
shown in Figure 3.1-Figure 3.4. Both depression and fatigue scores increased 
rapidly between baseline and treatment week 4 and remained elevated until the 
end of treatment. A random intercept regression model with maximum likelihood 
effects showed a significant effect of treatment week on increasing depression 
scores (Coefficient=0.1, p=0.041). Similarly, there was also a significant effect 
of treatment week on increasing fatigue scores (Coefficient=0.1, p=0.010). 
 
Stress scores gradually increased between baseline and treatment week 12 
and remained elevated until the end of treatment. There was a significant effect 
of treatment week on increasing stress scores (Coefficient=0.1, p=0.014). 
Finally, changes in anxiety scores were less pronounced but nonetheless there 
was a continuous gradual increase in scores between baseline and the end of 
treatment. There was a significant effect of treatment week on increasing 













Figure 3.1 Changes in mean depression scores during IFN-α treatment 
 
Changes in mean scores on the Inventory of Depressive Symptomatology (IDS) across the 24 







Figure 3.2 Changes in mean fatigue scores during IFN-α treatment 
 
Changes in mean scores on the Chalder Fatigue Questionnaire (CFQ) across the 24 weeks of 








Figure 3.3 Changes in mean stress scores during IFN-α treatment 
 
Changes in mean scores on the Perceived Stress Scale (PSS) across the 24 weeks of 










Figure 3.4 Changes in mean anxiety scores during IFN-α treatment 
 
Changes in mean scores on the anxiety sub-scale of the Hospital Anxiety and Depression Scale 




3.1.2.1 Changes in health status during IFN-α treatment 
I also investigated the impact of IFN-α treatment on patients’ health status. 
Changes in mean scores for the 8 health status dimensions of the SF-36 during 
IFN-α treatment are shown in Figure 3.5-Figure 3.12. As mentioned previously, 
for all 8 dimensions, higher scores represent better functioning with a score of 
100 indicating optimal functioning/well-being. Over the course of IFN-α 
treatment, scores decreased across all 8 dimensions. There was a significant 
negative effect of treatment week on decreasing scores on the physical 
functioning, vitality, mental health and social functioning dimensions 
(Coefficient=-0.4, p<0.001; Coefficient=-0.3, p=0.018; Coefficient=-0.4, p=0.001 
and Coefficient=-0.6, p<0.001, respectively). There were no significant effects of 
treatment week for scores on the physical role limitation, emotional role 







Figure 3.5 Changes in mean physical functioning scores during IFN-α treatment 
 
Changes in mean scores on the physical functioning dimension of the Medical Outcomes Study 






Figure 3.6 Changes in mean physical role limitation scores during IFN-α 
treatment 
 
Changes in mean scores on the physical role limitation dimension of the Medical Outcomes 






Figure 3.7 Changes in mean emotional role limitation scores during IFN-α 
treatment 
 
Changes in mean scores on the emotional role limitation dimension of the Medical Outcomes 






Figure 3.8 Changes in mean vitality scores during IFN-α treatment 
 
Changes in mean scores on the vitality dimension of the Medical Outcomes Study Short-Form 







Figure 3.9 Changes in mean mental health scores during IFN-α treatment 
 
Changes in mean scores on the mental health dimension of the Medical Outcomes Study Short-







Figure 3.10 Changes in mean social functioning scores during IFN-α treatment 
 
Changes in mean scores on the social functioning dimension of the Medical Outcomes Study 






Figure 3.11 Changes in mean bodily pain scores during IFN-α treatment 
 
Changes in mean scores on the bodily pain dimension of the Medical Outcomes Study Short-







Figure 3.12 Changes in mean general health scores during IFN-α treatment 
 
Changes in mean scores on the general health dimension of the Medical Outcomes Study 




As shown in Table 3.4, baseline scores of depression, fatigue, stress and 
anxiety were all highly correlated with each other. I also examined the 
relationship between baseline SF-36 scores and the baseline scores of 
depression, fatigue, stress and anxiety. As shown in Table 3.5, baseline scores 
for all 8 dimensions of the SF-36 were significantly, negatively correlated with 
baseline scores of depression, fatigue and stress. Only 4 out of the 8 
dimensions of the SF-36 were significantly, negatively correlated with baseline 
anxiety scores. Specifically, these were emotional role limitation, vitality, mental 
health, social functioning (Coefficient=-0.4, p=0.005; Coefficient=-0.5, p<0.001; 
Coefficient=-0.8, p<0.001 and Coefficient=-0.4 p=0.013). There were no 
significant correlations between baseline scores of the physical functioning, 
physical role limitation, bodily pain or general health dimensions of the SF-36 




Table 3.4 The relationship between baseline scores of depression, fatigue, 


















































 p<0.001 p<0.001 p<0.001  
 
Correlation analyses between baseline scores on the Inventory of Depressive Symptomatology 
(IDS), Chalder Fatigue Questionnaire (CFQ), Perceived Stress Scale (PSS) and the anxiety 
sub-scale of the Hospital Anxiety and Depression Scale (HADS-A) (n ranging from 45-48).  
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Table 3.5 The relationship between baseline scores for the 8 dimensions of the 
































































































































Correlation analyses between baseline scores on the 8 dimensions of the SF-36, and baseline 
scores on the Inventory of Depressive Symptomatology (IDS), Chalder Fatigue Questionnaire 
(CFQ), Perceived Stress Scale (PSS) and the anxiety sub-scale of the Hospital Anxiety and 
Depression Scale (HADS-A) (n ranging from 45-48).  
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3.1.3 Biological changes during IFN-α treatment 
As the final part of the first aim of this thesis, I prospectively monitored the 
impact of IFN-α treatment on three biological systems; HPA axis function, 
tryptophan and kynurenine pathway and PUFA levels. Furthermore, I also 
investigated gene expression changes. 
 
3.1.3.1 Cortisol 
Nineteen patients completed cortisol collection at baseline and 13 patients 
completed cortisol collection at treatment week 24 (end of treatment). To 
investigate changes in cortisol levels during IFN-α treatment, I firstly looked at 
the cortisol awakening response at baseline and at treatment week 24. These 
data are presented in Figure 3.13 and Figure 3.14. To further investigate the 
cortisol awakening response, I then calculated the area under the curve of the 
increase (AUCi) of the cortisol awakening response, considering cortisol levels 
at 0 minutes, 15 minutes, 30 minutes, and 60 minutes after awakening. 
Changes in the AUCi of the cortisol awakening response from baseline to 
treatment week 24 of IFN-α treatment are shown in Figure 3.15. There is a 
decrease in the average cortisol awakening response from baseline to 














Figure 3.15 Changes in the area under the curve of the increase (AUCi) of the 





I also investigated the changes in cortisol levels during the day. I firstly looked 
at the changes in the raw values of cortisol at 0 minutes (awakening), noon and 
8pm from baseline to treatment week 24 of IFN-α treatment. These data are 
shown in Figure 3.16 and Figure 3.17. There was no significant effect of 
treatment week on cortisol levels at either noon or 8pm (p=0.4 and p=0.3). To 
further investigate the cortisol levels during the day, I then calculated the area 
under the curve (AUC) of cortisol levels at 0 minutes (awakening), at noon and 
at 8pm. Changes in the AUC of cortisol during the day from baseline to 
treatment week 24 of IFN-α treatment are shown in Figure 3.18. There is an 
increase in the AUC of cortisol during the day from baseline to treatment week 
24, however, this effect of treatment week was not significant (p=0.6). 
 
Finally, I investigated the relationship between baseline cortisol levels (AUCi of 
the cortisol awakening response and AUC of cortisol during the day) and 
baseline scores of depression, fatigue, stress and anxiety. Neither baseline 
cortisol awakening response, nor cortisol levels during the day were significantly 
correlated with baseline depression, fatigue, stress or anxiety scores. These 
















Figure 3.18 Changes in the area under the curve (AUC) of cortisol during the 
day from baseline to treatment week 24 of IFN-α treatment (n=10) 
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Table 3.6 The relationship between baseline cortisol levels and baseline 















































Correlation analyses between the baseline area under the curve of the increase (AUCi) of the 
cortisol awakening response and the baseline area under the curve (AUC) of cortisol during the 
day, with baseline scores on the on the Inventory of Depressive Symptomatology (IDS), Chalder 
Fatigue Questionnaire (CFQ), Perceived Stress Scale (PSS) and the anxiety sub-scale of the 
Hospital Anxiety and Depression Scale (HADS-A) (n ranging from 17-19). 
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3.1.3.2 Kynurenine and Tryptophan pathway 
Kynurenine and tryptophan pathway metabolites were measured in 38 patients 
at baseline, treatment week 8 and treatment week 24 (end of treatment). 
Changes in the levels of kynurenine and tryptophan pathway metabolites during 
IFN-α treatment are shown in Figure 3.19-Figure 3.23. Tryptophan levels 
decreased during IFN-α treatment, with a significant effect of treatment week 
(Coefficient=-0.04, p=0.054). Moreover, this decrease in tryptophan levels was 
accompanied by increased kynurenine levels, with a significant effect of 
treatment week on increasing kynurenine levels (Coefficient=3.1, p=0.003).  
 
Levels of three-hydroxykynurenine also increased during IFN-α treatment, 
however this was not significant (Coefficient=0.1, p=0.1). Levels of the 
neuroprotective metabolite; kynurenic acid, decreased during IFN-α treatment 
with a significant effect of treatment week (Coefficient=-0.04, p=0.0045). Finally, 
the ratio of kynurenine to tryptophan increased during IFN-α treatment with a 






Figure 3.19 Changes in tryptophan levels during IFN-α treatment 
 







Figure 3.20 Changes in kynurenine levels during IFN-α treatment 
 








Figure 3.21 Changes in 3-hydroxykynurenine levels during IFN-α treatment 
 
Changes in plasma levels of 3-hydroxykynurenine (3-HK) across the 24 weeks of treatment (n 







Figure 3.22 Changes in kynurenic acid levels during IFN-α treatment 
 
Changes in plasma levels of kynurenic acid (KYNA) across the 24 weeks of treatment (n 






Figure 3.23 Changes in the kynurenine/tryptophan ratio during IFN-α treatment 
 
Changes in the kynurenine/tryptophan ratio (KYN/TRP) across the 24 weeks of treatment (n 




The relationship between baseline levels of kynurenine and tryptophan pathway 
metabolites and baseline scores of depression, fatigue, stress and anxiety are 
presented in Table 3.7. Baseline levels of tryptophan, kynurenine, 3-
hydroxykynurenine and the kynurenine/tryptophan ratio were not significantly 
correlated with baseline scores of any of the four outcome measures. However, 
baseline kynurenic acid levels were significantly negatively correlated with 
baseline scores for both fatigue and stress (r=-0.4, p=0.031 and r=-0.4, p=0.023 
respectively). These significant correlations can be seen in Figure 3.24 and 
Figure 3.25).  
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Table 3.7 The relationship between baseline kynurenine and tryptophan 



























































































Correlation analyses between baseline levels of plasma tryptophan, plasma kynurenine, plasma 
3-hydroxykynurenine (3-HK), plasma kynurenic acid and the ratio of kynurenine to tryptophan, 
with baseline scores on the on the Inventory of Depressive Symptomatology (IDS), Chalder 
Fatigue Questionnaire (CFQ), Perceived Stress Scale (PSS) and the anxiety sub-scale of the 








Figure 3.24 The correlation between baseline levels of KYNA and baseline CFQ 
scores. 
 
A scatterplot of baseline levels of plasma kynurenic acid (KYNA) and baseline scores on the 










Figure 3.25 The correlation between baseline levels of KYNA and baseline PSS 
scores. 
 
A scatterplot of baseline levels of plasma kynurenic acid (KYNA) and baseline scores on the 





3.1.3.3 Polyunsaturated fatty acids (PUFAs) 
PUFA levels were measured in 45 patients at all time points. Changes in 
omega-3 and omega-6 PUFAs during IFN-α treatment are shown in Figure 
3.26-Figure 3.31. Eicosapentaenoic acid (EPA) average levels decreased 
slightly between baseline and treatment week 12; however, there was no 
significant effect of treatment week (p=0.9). Docosahexaenoic acid (DHA) levels 
also decreased during IFN-α treatment, and there was a significant effect of 
treatment week (Coefficient=-0.01, p=0.033). Levels of the omega-3 PUFA 
alpha-linolenic acid (ALA) increased between baseline and treatment week 12, 
and then decreased between treatment week 12 and treatment week 24. 
However, there was no significant effect of treatment week on changes in ALA 
levels (p=0.4). The two omega-6 PUFAs that were measured – arachidonic acid 
(AA) and linoleic acid (LA) - both decreased during IFN-α treatment. There was 
a significant effect of treatment week on decreasing AA levels (Coefficient=-
0.01, p=0.017). However, there was no significant effect of treatment week on 
changes in LA levels. Similarly, there was no significant effect of treatment 





Figure 3.26 Changes in EPA levels during IFN-α treatment 
 
Changes in plasma levels of the omega-3 PUFA, eicosapentaenoic acid (EPA) across the 24 







Figure 3.27 Changes in DHA levels during IFN-α treatment 
 
Changes in plasma levels of the omega-3 PUFA, docosahexaenoic acid (DHA) across the 24 







Figure 3.28 Changes in ALA levels during IFN-α treatment 
 
Changes in plasma levels of the omega-3 PUFA, alpha-linolenic acid (ALA) across the 24 







Figure 3.29 Changes in AA levels during IFN-α treatment 
 
Changes in plasma levels of the omega-6 PUFA, arachidonic acid (AA) across the 24 weeks of 






Figure 3.30 Changes in LA levels during IFN-α treatment 
 
Changes in plasma levels of the omega-6 PUFA, linoleic acid (LA) across the 24 weeks of 







Figure 3.31 Changes in the AA/(EPA+DHA) ratio during IFN-α treatment 
 
Changes in ratio of the omega-6 PUFA, arachidonic acid (AA), to the omega-3 PUFAs; 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), across the 24 weeks of 




The relationship between baseline PUFA levels and baseline scores of 
depression, fatigue, stress and anxiety are presented in Table 3.8. Only 
baseline levels of the omega-3 PUFA ALA were significantly negatively 
correlated with baseline anxiety scores (r=-0.3, p=0.024). This significant 
correlation can also be seen presented in Figure 3.32. There were no other 
significant correlations between baseline PUFA levels and baseline scores of 
depression, fatigue, stress or anxiety. 
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Table 3.8 The relationship between baseline PUFA levels and baseline 





































































































Correlation analyses between baseline levels of plasma eicosapentaenoic acid (EPA), plasma 
docosahexaenoic acid (DHA), plasma alpha-linolenic acid (ALA), plasma arachidonic acid (AA), 
plasma linoleic acid (LA) and the ratio of omega-6 to omega-3 PUFAs, with baseline scores on 
the on the Inventory of Depressive Symptomatology (IDS), Chalder Fatigue Questionnaire 
(CFQ), Perceived Stress Scale (PSS) and the anxiety sub-scale of the Hospital Anxiety and 








Figure 3.32 The correlation between baseline levels of ALA and baseline 
HADS-A scores 
 
A scatterplot of baseline levels of plasma alpha-linolenic acid (ALA) and baseline scores on the 





3.1.3.4 Gene Expression 
Gene expression using microarray was measured in all 48 patients at baseline 
and at treatment week 4. To investigate gene expression changes as a result of 
IFN-α treatment, I compared gene expression at treatment week 4 with gene 
expression at baseline. Firstly, I used a hypothesis-free approach, identifying 
genes with an absolute fold change of 1.4 and a p value cut-off of p<0.05. 
There were a total of 516 genes that were modulated by IFN-α treatment. These 
individual genes are not presented. However, pathway analysis revealed these 
genes belong to five pathways: mitogen-activated protein kinase (MAPK) 
signalling, calcium signalling, neurotrophin signalling, cancer and prostate 
cancer pathways. 
 
Secondly, I used a hypothesis-driven approach and looked at changes in the 
expression of candidate genes, again comparing treatment week 4 with 
baseline. I chose genes belonging to 4 important and interlinked domains: 
genes related to tryptophan metabolism, genes related to PUFA metabolism, 
genes related to inflammation, and genes related to neuroplasticity. These data 
are presented in Table 3.9 and Table 3.10. Due to the fact that many of the 
genes had small fold changes (less than 1.1), fold change in these tables are 
presented to 2 decimal places. Of note, such low fold changes are likely to be 
false positives, are difficult to validate with real-time polymerase chain reaction 
(PCR) techniques and so are not considered as biologically relevant changes 
(Mutch et al., 2002, Ryan et al., 2010). 
 
There were significant changes in the expression of kynureninase (KYNU) and 
tryptophan 2,3-dioxygenase (TDO2) as a result of IFN-α treatment (p=0.009 
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and p=0.030, respectively). Expression of KYNU was higher and expression of 
TDO2 was lower at treatment week 4 when compared to baseline. With regards 
to genes related to PUFA metabolism, there was significantly higher expression 
of Cyclooxygenase 2 (COX2), Cyclooxygenase 3 (COX3) and Phospholipase 
A2, group III (PLA2G3) at treatment week 4 when compared to baseline 
(p=0.047, p=0.004 and p=0.006, respectively). Furthermore, there was 
significantly higher expression of fatty acid desaturase 2 (FADS2) at treatment 




Table 3.9 Differentially expressed candidate genes at treatment week 4 













IDO1 Indoleamine 2,3-dioxygenase 1  -1.11 0.3 
IDO2 Indoleamine 2,3-dioxygenase 2 -1.07 0.1 
KMO 
 






KYNU Kynureninase  1.05 0.009 
HAAO 3-hydroxyanthranilate 3,4-dioxygenase -1.03 0.1 
TDO2 Tryptophan 2,3-dioxygenase  -1.03 0.030 
TPH1 Tryptophan hydroxylase 1 1.02 0.1 
 
PUFA metabolism 
COX1 Cyclooxygenase 1 -1.09 0.5 
COX2 Cyclooxygenase 2 -1.05 0.047 
COX3 Cyclooxygenase 3 -1.20 0.004 
FADS1 Fatty acid desaturase 1 1.13 0.2 
FADS2 Fatty acid desaturase 2 1.53 0.006 
PLA2G2A 
 








Within the candidate genes involved in inflammation, there was significantly 
lower expression of interleukin 1 beta (IL-1B), interleukin 4 (IL-4), interleukin 6 
receptor (IL-6R) and interleukin 28 beta (IL-28B) at treatment week 4 when 
compared with baseline (p<0.001, p<0.001, p<0.001 and p=0.031, 
respectively), but a significantly higher expression of interleukin 10 (IL-10) 
(p=0.010).  
 
The only significant change in the expression of genes involved in 
neuroplasticity as a result of IFN-α treatment, was lower expression of nuclear 
receptor subfamily 3, group C, member 1 (NR3C1) (p<0.001), that is, of the 
glucocorticoid receptor (GR). 
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Table 3.10 Differentially expressed candidate genes at treatment week 4 













IL-1A Interleukin 1, alpha  -1.01 0.5 
IL-1B Interleukin 1, beta -1.41 <0.001 
IL-1R1 Interleukin 1 receptor, type 1 -1.61 0.1 
IL-2 Interleukin 2 -1.07 0.2 
sIL-2R Soluble interleukin 2 receptor 1.01 0.9 
IL-4 Interleukin 4 -1.04 <0.001 
IL-6 Interleukin 6  -1.02 0.8 
IL-6R Interleukin 6 receptor -1.40 <0.001 
IL-8 Interleukin 8 1.04 0.3 
IL-10 Interleukin 10 1.12 0.010 
IL-18 Interleukin 18 1.20 4.0 
IL-28B Interleukin 28, beta -1.01 0.031 
IFNG Interferon, gamma 1.03 0.1 
TGFB1 Transforming growth factor, beta 1 1.08 0.3 
TNFA Tumor necrosis factor, alpha 1.02 0.6 
TRAF6 TNF receptor associated factor 6 1.12 0.1 
 
Neuroplasticity 
BDNF Brain-derived neurotrophic factor  -1.02 0.6 
FKBP4 FK506 binding protein 4 1.01 0.1 
FKBP5 FK506 binding protein 5 1.07 0.7 
NR3C1 Nuclear receptor subfamily 3, group C, 
member 1 
-1.10 <0.001 
VEGFA Vascular endothelial growth factor A -1.04 0.2 
VGF VGF nerve growth factor inducible -1.00 0.8 
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3.1.4 Risk of IFN-α-induced depression 
In order to understand any risk factors associated with the development of IFN-
α-induced depression, I investigated differences in the baseline characteristics 
of patients with and without IFN-α-induced depression. As before, I investigated 
socio-demographics, psychosocial stressors, illness perceptions, baseline 
psychopathology and baseline health status. In order to divide the patients into 
those with and without IFN-α-induced depression, I used the MINI diagnostic 
interview to confirm a diagnosis of MDD. A total of 19 patients (40%) developed 
IFN-α-induced depression at some point during the course of the 24-week 
therapy, while 29 patients (60%) did not develop IFN-α-induced depression. The 
cumulative percentage of patients that developed IFN-α-induced depression at 
each week is presented in Figure 3.33.  
 
3.1.4.1 Socio-demographic characteristics of patients with and without IFN-α-
induced depression 
Patients who developed IFN-α-induced depression had a higher prevalence of 
unemployment as well as a higher prevalence of a previous history of MDD, 
when compared with patients who did not develop IFN-α-induced depression 
(p=0.010 and p=0.044 respectively). There were no significant differences 
between the two groups for age, gender, education level, relationship status, 
family history of psychiatric illness or for history of substance use (opioids). The 
two groups were also not significantly different in their HCV genotype, their viral 
load or their fibroscan scores (p=0.6, p=0.8 and p=0.8, respectively). These 
























Figure 3.33 The cumulative percentage of patients who developed IFN-α-
induced depression 
 
The cumulative percentage of patients meeting a MINI diagnosis of current major depressive 
















































n = 19 
 
No MDD 



































































































































t=0.9, df=44, p=0.8 
 











t=0.2, df=36, p=0.8 
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3.1.4.2 The psychosocial stress characteristics of patients with and without 
IFN-α-induced depression 
Patients with IFN-α-induced depression had a higher prevalence of 
experiencing at least one stressful life event when compared with patients 
without IFN-α-induced depression, however this was not statistically significant 
(58% vs. 38%, p=0.1). The two groups were also not significantly different in 
their reports of any of the four forms of childhood traumatic events. These data 
are presented in Table 3.12. 
 
3.1.4.3 The illness perceptions scores of patients with and without IFN-α-
induced depression 
The two groups were not significantly different in their scores of any of the 
seven illness perceptions dimensions. However, patients with IFN-α-induced 
depression had slightly higher scores on the timeline as well as the 
consequences dimensions suggesting that they perceived their illness to be 
more chronic in nature and with more negative consequences when compared 
with patients without IFN-α-induced depression (16.1±1.2 vs. 13.8±1.2 and 
18.7±1.2 vs. 17.9±1.2, respectively). Furthermore, patients with IFN-α-induced 
depression had slightly lower scores on the personal control dimension when 
compared with patients without IFN-α-induced depression (21.8±0.7 vs. 
23.6±0.8), thus perceiving themselves to be less able to control their symptoms 
and their illness. These data are presented in Table 3.13. 
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n = 19 
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n = 29 
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3.1.4.4 The baseline psychopathology of patients with and without IFN-α-
induced depression  
Although not statistically significant, patients who developed IFN-α-induced 
depression had higher baseline depression scores (p=0.1). Moreover, baseline 
scores of these patients were already above the cut-off considered to be within 
normal range (<12) and were within the range considered to be mild depression 
(13-23). Patients who developed IFN-α-induced depression also had slightly 
higher baseline fatigue scores however, both groups were within the normal 
range (≤18), and this difference was not significant (p=0.1). Similarly, patients 
who developed IFN-α-induced depression had slightly higher baseline stress 
scores, however this difference was also not significant (p=0.3). Baseline 
anxiety scores were comparable between the two groups (p=0.7). These data 
are presented in Table 3.14. 
 
3.1.4.5 The baseline health status of patients with and without IFN-α-induced 
depression  
On the 8 dimensions of the SF-36 (where lower scores indicate worse 
functioning), there were significant differences at baseline between the two 
groups on 3 of the 8 dimensions; vitality, bodily pain and general health. 
Patients who later developed IFN-α-induced depression already had lower 
vitality scores, more bodily pain and worse general health when compared to 
patients who did not develop IFN-α-induced depression (p=0.036, p=0.026 and 
p=0.024, respectively). The two groups were not significantly different in their 
scores for the physical functioning, physical or emotional role limitation, mental 
health or social functioning dimensions of the SF-36 (p=0.1, p=0.8, p=0.2, p=0.2 
and p=0.4, respectively). These data are presented in Table 3.15. 
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t=2.3, df=46, p=0.024 
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3.1.5 Psychopathological changes in patients with and without IFN-α-induced 
depression 
For this section, I have again divided the patients in to those with and without 
IFN-α-induced depression and present the effect of depression status on each 
variable using a random intercept regression model with maximum likelihood 
effects. Depression scores were higher in patients with IFN-α-induced 
depression at baseline and throughout the treatment period, with a rapid 
increase in scores in both groups between baseline and treatment week 4. 
However, depression scores of patients with IFN-α-induced depression 
continued to increase until treatment week 12. Of note, depression scores of 
patients without IFN-α-induced depression remained within the range 
considered to be mild depression (13-23) whereas depression scores of 
patients with IFN-α-induced depression reached the range considered as 
moderate depression (24-36). As expected, there was a significant association 
between depression status and depression scores (Coefficient=15.6, p<0.001). 
This remained significant after adjusting for baseline depression scores 
(p<0.001), indicating that depression status is associated with increased 
depression scores during treatment irrespective of baseline depression levels. 
These data are presented in Figure 3.34 and Figure 3.35. 
 
Fatigue scores increased in both groups but remained slightly higher in patients 
with IFN-α-induced depression. However, there was no significant association 





Figure 3.34 Changes in mean depression scores of patients with and without 
IFN-α-induced depression 
 
Changes in mean scores on the Inventory of Depressive Symptomatology (IDS) across the 24 
weeks of treatment in patients with (n ranging from 15-19) and patients without IFN-α-induced 








Figure 3.35 Changes in mean fatigue scores of patients with and without IFN-α-
induced depression 
 
Changes in mean scores on the Chalder Fatigue Questionnaire (CFQ) across the 24 weeks of 
treatment in patients with IFN-α-induced depression (n ranging from 15-19) and patients without 




Changes in stress and anxiety scores during IFN-α treatment in patients with 
and without IFN-α-induced depression are presented in Figure 3.36 and Figure 
3.37. Stress scores gradually increased between baseline and treatment week 
12 and remained elevated until the end of treatment in patients with IFN-α-
induced depression. Interestingly, in patients without IFN-α-induced depression 
there were very little changes, and stress scores remained relatively stable 
throughout the treatment period. There was a significant association between 
depression status and stress scores (Coefficient=9.1, p<0.001) which remained 
significant after adjusting for baseline stress scores (p<0.001) indicating that 
depression status is associated with increased stress scores during treatment 
irrespective of baseline stress levels.  
 
Finally, similar to stress scores, anxiety scores gradually increased between 
baseline and treatment week 12 and remained elevated until the end of 
treatment in patients with IFN-α-induced depression. In patients without IFN-α-
induced depression, anxiety scores decreased slightly but remained relatively 
stable throughout the treatment period. Of note, anxiety scores of patients 
without IFN-α-induced depression remained within the range considered to be 
normal (0-7) whereas anxiety scores of patients with IFN-α-induced depression 
reached the range considered to be mild anxiety (8-10). There was a significant 
association between depression status and anxiety scores (Coefficient=4.2, 
p<0.001) which remained significant after adjusting for baseline anxiety scores 
(p<0.001) indicating that depression status is associated with increased anxiety 





Figure 3.36 Changes in mean stress scores of patients with and without IFN-α-
induced depression 
 
Changes in mean scores on the Perceived Stress Scale (PSS) across the 24 weeks of 
treatment in patients with IFN-α-induced depression (n ranging from 15-19) and patients without 






Figure 3.37 Changes in mean anxiety scores of patients with and without IFN-α-
induced depression 
 
Changes in mean scores on the anxiety sub-scale of the Hospital Anxiety and Depression Scale 
(HADS-A) across the 24 weeks of treatment in patients with IFN-α-induced depression (n 




3.1.6 Health status changes in patients with and without  
IFN-α-induced depression 
I also investigated the changes in health status (SF-36 scores) of patients with 
and without IFN-α-induced depression across the treatment course. These data 
are presented in Figure 3.38-Figure 3.45. As mentioned previously, for all 8 
dimensions, higher scores represent better functioning with a score of 100 
indicating optimal well-being. There was a significant association between 
depression status and scores on the physical functioning, physical role limitation 
and social functioning dimensions (Coefficient=-16.0, p=0.010; Coefficient=-
25.3, p=0.008 and Coefficient=-19.3, p=0.007, respectively). These effects all 
remained significant after adjusting for the baseline scores for these dimensions 
(p=0.037, p=0.004 and p=0.011, respectively). There was a particularly strong 
association between depression status and scores on the emotional role 
limitation and mental health domains (Coefficient=-37.9, p<0.001 and 
Coefficient=-23.2, p<0.001) with both remaining highly significant even after 
adjusting for the respective baseline scores (p<0.001 and p<0.001). These data 
indicate that depression status is associated with decreased well-being in these 
health status dimensions irrespective of baseline levels of well-being. Lastly, 
there was a significant association between depression status and scores on 
the vitality, bodily pain and general health dimensions (Coefficient=-14.9, 
p=0.029; Coefficient=-17.8, p=0.006 and Coefficient=-15.8, p=0.008, 
respectively). However, after adjusting for baseline scores in these three 
dimensions, these effects were no longer significant (p=0.4, p=0.1 and p=0.1, 
respectively) indicating that baseline vitality, bodily pain and general health 






Figure 3.38 Changes in mean physical functioning scores of patients with and 
without IFN-α-induced depression 
 
Changes in mean scores on the physical functioning dimension of the Medical Outcomes Study 
Short-Form 36 (SF-36) across the 24 weeks of treatment in patients with IFN-α-induced 







Figure 3.39 Changes in mean physical role limitation scores of patients with and 
without IFN-α-induced depression 
 
Changes in mean scores on the physical role limitation dimension of the Medical Outcomes 
Study Short-Form 36 (SF-36) across the 24 weeks of treatment in patients with IFN-α-induced 







Figure 3.40 Changes in mean emotional role limitation scores of patients with 
and without IFN-α-induced depression 
 
Changes in mean scores on the emotional role limitation dimension of the Medical Outcomes 
Study Short-Form 36 (SF-36) across the 24 weeks of treatment in patients with IFN-α-induced 








Figure 3.41 Changes in mean vitality scores of patients with and without IFN-α-
induced depression 
 
Changes in mean scores on the vitality dimension of the Medical Outcomes Study Short-Form 
36 (SF-36) across the 24 weeks of treatment in patients with IFN-α-induced depression (n 






Figure 3.42 Changes in mean mental health scores of patients with and without 
IFN-α-induced depression 
 
Changes in mean scores on the mental health dimension of the Medical Outcomes Study Short-
Form 36 (SF-36) across the 24 weeks of treatment in patients with IFN-α-induced depression (n 







Figure 3.43 Changes in mean social functioning scores of patients with and 
without IFN-α-induced depression 
 
Changes in mean scores on the social functioning dimension of the Medical Outcomes Study 
Short-Form 36 (SF-36) across the 24 weeks of treatment in patients with IFN-α-induced 







Figure 3.44 Changes in mean bodily pain scores of patients with and without 
IFN-α-induced depression 
 
Changes in mean scores on the bodily pain dimension of the Medical Outcomes Study Short-
Form 36 (SF-36) across the 24 weeks of treatment in patients with IFN-α-induced depression (n 






Figure 3.45 Changes in mean general health scores of patients with and without 
IFN-α-induced depression 
 
Changes in mean scores on the general health dimension of the Medical Outcomes Study 
Short-Form 36 (SF-36) across the 24 weeks of treatment in patients with IFN-α-induced 




3.1.7 Biological changes in patients with and without IFN-α-induced depression 
In order to investigate biological differences, I have again divided the patients in 
to those with and without IFN-α-induced depression. I present the effect of 
depression status on each biological variable using a random intercept 
regression model with maximum likelihood effects. 
 
3.1.7.1 Cortisol  
Differences in baseline cortisol output in patients with and without IFN-α-
induced depression are shown in Table 3.16. These analyses were conducted 
on a small number of patients (4 depressed and 15 non-depressed, since 
overall the cortisol samples were only available in a sub-sample). There were 
no significant cortisol differences between patients with and without IFN-α-
induced depression at baseline. 
 
Changes in the cortisol awakening response from baseline to treatment week 
24 in patients with and without IFN-α-induced depression are presented in 
Figure 3.46 and Figure 3.47. At baseline, although not significant, patients who 
later develop IFN-α-induced depression appear to have an increased cortisol 
awakening response compared to patients without IFN-α-induced depression 
(p=0.1). However, this difference is completely diminished at treatment week 24 
(Coefficient=0.4, p=0.9). I then investigated changes in the AUCi of the cortisol 
awakening response from baseline to treatment week 24, in patients with and 
without IFN-α-induced depression, as shown in Figure 3.48. There was a 
decrease in the AUCi of the cortisol awakening response from baseline to 
treatment week 24 in patients with IFN-α-induced depression, and no change in 
patients without IFN-α-induced depression. However, there was no significant 
171 
effect of depression status on the change in the AUCi of the cortisol awakening 
response (p=0.3). Independent samples t-tests also confirmed there was no 
significant difference in the AUCi of the cortisol awakening response between 
the two patient groups at baseline (t=-1.4, df=15, p=0.2) or at treatment week 
24 (t=-0.1, df=9, p=0.9) however this may be due to the small sample size. 
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Figure 3.46 The cortisol awakening response at baseline of patients with (n=4) 
and without (n=15) IFN-α-induced depression 
 
 
Figure 3.47 The cortisol awakening response at treatment week 24 of patients 





Figure 3.48 Changes in the area under the curve of the increase (AUCi) of the 
cortisol awakening response from baseline to treatment week 24 in patients with 
(n=2) and without (n=9) IFN-α-induced depression 
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I also investigated the changes in cortisol levels during the day from baseline to 
treatment week 24 in patients with and without IFN-α-induced depression. 
Again, I firstly looked at the changes in the raw values of cortisol at 0 minutes 
(awakening), noon and 8pm from baseline to treatment week 24 of IFN-α 
treatment as shown in Figure 3.49 and Figure 3.50. At baseline, patients with 
IFN-α-induced depression have a flattening of the cortisol response that is, a 
smaller difference between the morning peak and the evening trough. However, 
this effect is diminished at treatment week 24 at which point the two groups are 
very similar. However, there was no significant effect of depression status on 
cortisol levels during the day at either baseline or treatment week 24 (p=0.4 and 
p=0.9, respectively).  
 
As shown in Figure 3.51, I then also investigated the change in the AUC of 
cortisol during the day from baseline to treatment week 24 in the two groups. 
There was an increase in the AUC of cortisol during the day from baseline to 
treatment week 24 in patients with IFN-α-induced depression whereas patients 
without IFN-α-induced depression appear to have no change. However, there 
was no significant effect of depression status on the changes in the AUC of 





Figure 3.49 Cortisol levels during the day at baseline of patients with (n=4) and 
without (n=15) IFN-α-induced depression 
 
 
Figure 3.50 Cortisol levels during the day at treatment week 24 of patients with 





Figure 3.51 Changes in the area under the curve (AUC) of cortisol during the 





3.1.7.2 Kynurenine and Tryptophan pathway 
The differences in baseline levels of kynurenine and tryptophan pathway 
metabolites in patients with and without IFN-α-induced depression are shown in 
Table 3.17. There were no significant differences between the two groups for 
any of the kynurenine and tryptophan pathway metabolites. Changes in the 
levels of kynurenine and tryptophan pathway metabolites in patients with and 
without IFN-α-induced depression during the treatment period are shown in 
Figure 3.52-Figure 3.56. There was no significant effect of depression status on 
tryptophan or kynurenic acid levels (p=0.8 and p=0.7, respectively). Kynurenine 
and three-hydroxykynurenine levels increased in both groups with no significant 
effect of depression status (p=0.8 and p=0.9, respectively). Finally, there was 
no significant effect of depression status on the ratio of kynurenine to 
tryptophan (p=0.6). Independent samples t-tests also confirmed that there were 
no significant differences between patients with and without IFN-α-induced 
depression for any of the kynurenine and tryptophan pathway metabolites at 
treatment week 8 or at treatment week 24, indicating that IFN-α-induced 
changes in kynurenine and tryptophan metabolites are the same in all patients. 
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Table 3.17 Baseline kynurenine and tryptophan pathway metabolites levels in 
patients with and without IFN-α-induced depression 
  
MDD 
n = 17 
 
No MDD 





















































Figure 3.52 Changes in tryptophan levels in patients with and without IFN-α-
induced depression 
 
Changes in plasma levels of tryptophan (TRP) in patients with (n ranging from 16-21) and 







Figure 3.53 Changes in kynurenine levels in patients with and without IFN-α-
induced depression 
 
Changes in plasma levels of kynurenine (KYN) in patients with (n ranging from 16-21) and 







Figure 3.54 Changes in 3-hydroxykynurenine levels in patients with and without 
IFN-α-induced depression 
 
Changes in plasma levels of 3-hydroxykynurenine (3-HK) in patients with (n ranging from 16-21) 








Figure 3.55 Changes in kynurenic acid levels in patients with and without IFN-α-
induced depression 
 
Changes in plasma levels of kynurenic acid (KYNA) in patients with (n ranging from 16-21) and 







Figure 3.56 Changes in the kynurenine/tryptophan ratio in patients with and 
without IFN-α-induced depression 
 
Changes in the kynurenine/tryptophan ratio (KYN/TRP) in patients with (n ranging from 16-21) 





3.1.7.3 Polyunsaturated fatty acids (PUFAs) 
The differences in baseline PUFA levels in patients with and without IFN-α-
induced depression are shown in Table 3.18. There were no significant 
differences between the two groups for any of the PUFAs. Changes in PUFA 
levels in patients with and without IFN-α-induced depression during the 
treatment period are shown in Figure 3.57-Figure 3.62. There was no significant 
effect of depression status on EPA, DHA or ALA levels (p=0.8, p=0.9 and p=0.2 
respectively). As mentioned earlier, the two omega-6 PUFAs that were 
measured – AA and LA, both appeared to decrease during IFN-α treatment. 
However, there was no significant effect of depression status on AA or LA levels 
(p=0.3 and p=0.1, respectively). Finally, there was no significant effect of 
depression status on the ratio of omega-6 to omega-3 PUFAs (p=0.4). 
Independent samples t-tests also confirmed that there were no significant 
differences between patients with and without IFN-α-induced depression for any 
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Figure 3.57 Changes in EPA levels in patients with and without IFN-α-induced 
depression 
 
Changes in plasma levels of the of the omega-3 PUFA, eicosapentaenoic acid (EPA) in patients 
with (n ranging from 19-29) and without (n ranging from 15-19) IFN-α-induced depression, 







Figure 3.58 Changes in DHA levels in patients with and without IFN-α-induced 
depression 
 
Changes in plasma levels of the omega-3 PUFA, docosahexaenoic acid (EPA) in patients with 
(n ranging from 19-29) and without (n ranging from 15-19) IFN-α-induced depression, across 







Figure 3.59 Changes in ALA levels in patients with and without IFN-α-induced 
depression 
 
Changes in plasma levels of the omega-3 PUFA, alpha-linolenic acid (ALA) in patients with (n 
ranging from 19-29) and without (n ranging from 15-19) IFN-α-induced depression, across the 







Figure 3.60 Changes in AA levels in patients with and without IFN-α-induced 
depression 
 
Changes in plasma levels of the omega-6 PUFA, arachidonic acid (AA) in patients with (n 
ranging from 19-29) and without (n ranging from 15-19) IFN-α-induced depression, across the 








Figure 3.61 Changes in LA levels in patients with and without IFN-α-induced 
depression 
 
Changes in plasma levels of the omega-6 PUFA, linoleic acid (LA) in patients with (n ranging 








Figure 3.62 Changes in the AA / (EPA+DHA) ratio in patients with and without 
IFN-α-induced depression 
 
Changes in ratio of the omega-6 PUFA, arachidonic acid (AA), to the omega-3 PUFAs; 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in patients with (n ranging from 





3.1.7.4 Gene expression 
To examine differences in baseline gene expression in patients with and without 
IFN-α-induced depression, I firstly used a hypothesis-free approach, to identify 
genes with an absolute fold change of 1.4 and a p-value cut-off of p<0.005. 
Eight differentially expressed genes were identified and are presented in Table 
3.19. Among these most significant differentially expressed genes, of interest 
there was glutathione S-transferase mu 4 (GSTM4), which plays an important 
role in detoxifying various toxicants such as reactive oxygen species, which are 
known to induce oxidative stress. At baseline there was a lower expression of 
GSTM4 in patients who later developed IFN-α-induced depression. 
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Table 3.19 Differentially expressed genes at baseline in patients who develop 











AIM2 Absent in melanoma 2 -1.6 0.003 
CAPSL Calcyphosine-like 1.7 0.003 
DUX4L7 Double homeobox 4 like 7 1.8 0.004 
ERICH1 Glutamate-rich 1 -1.4 0.004 
GSTM4 Glutathione S-transferase mu 4  -1.6 0.001 
NBEAL1 Neurobeachin-like 1  -1.4 <0.001 
PNPT1 Polyribonucleotide nucleotidyltransferase 1 -1.4 0.005 
RNF144B 
 








Secondly, using a hypothesis-driven approach, I explored differences in the 
baseline expression of candidate genes in patients with and without IFN-α-
induced depression. These data are presented in Table 3.20 and Table 3.21. 
This included the same genes belonging to 4 interlinked domains relevant for 
the development of depression, as in the previous tables. Patients who 
developed IFN-α-induced depression had significantly lower expression of IDO1 
and KYNU (p=0.021 and p=0.037, respectively). There were no significant 
differences between the two groups in their expression of genes related to 
PUFA metabolism. Patients who developed IFN-α-induced depression had 
significantly higher expression of interleukin-1 alpha (IL-1A), IL-4 and IL-28B at 
baseline when compared to patients without IFN-α-induced depression 
(p=0.022, p=0.018 and p=0.032, respectively). They also had significantly lower 
expression of TNF receptor associated factor 6 (TRAF6) at baseline when 
compared to patients who did not develop IFN-α-induced depression (p=0.020). 
Finally, patients who developed IFN-α-induced depression had significantly 
lower expression of NR3C1 (GR) (p=0.011). 
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Table 3.20 Differentially expressed candidate genes at baseline in patients who 













IDO1 Indoleamine 2,3-dioxygenase 1  -1.36 0.021 
IDO2 Indoleamine 2,3-dioxygenase 2 1.02 0.5 
KMO 
 






KYNU Kynureninase  -1.21 0.037 
HAAO 3-hydroxyanthranilate 3,4-dioxygenase 1.05 
0.1 
TDO2 Tryptophan 2,3-dioxygenase  1.06 0.1 
TPH1 Tryptophan hydroxylase 1 1.01 0.8 
 
PUFA metabolism 
COX1 Cyclooxygenase 1 1.01 0.6 
COX2 Cyclooxygenase 2 -1.02 0.7 
COX3 Cyclooxygenase 3 1.04 0.5 
FADS1 Fatty acid desaturase 1 -1.01 0.9 
FADS2 Fatty acid desaturase 2 1.08 0.7 
PLA2G2A 
 








Table 3.21 Differentially expressed candidate genes at baseline in patients who 













IL-1A Interleukin 1, alpha  1.06 0.022 
IL-1B Interleukin 1, beta -1.04 0.7 
IL-1R1 Interleukin 1 receptor, type 1 -1.24 0.1 
IL-2 Interleukin 2 1.02 0.4 
sIL-2R Soluble interleukin 2 receptor -1.07 1.0 
IL-4 Interleukin 4 1.05 0.018 
IL-6 Interleukin 6  1.02 0.6 
IL-6R Interleukin 6 receptor 1.01 0.9 
IL-8 Interleukin 8 -1.15 0.3 
IL-10 Interleukin 10 1.07 0.1 
IL-18 Interleukin 18 -1.12 0.3 
IL-28B Interleukin 28, beta 1.15 0.038 
IFNG Interferon, gamma 1.02 0.7 
TGFB1 Transforming growth factor, beta 1 1.00 0.9 
TNFA Tumor necrosis factor, alpha -1.13 0.1 
TRAF6 TNF receptor associated factor 6 -1.12 0.020 
 
Neuroplasticity 
BDNF Brain-derived neurotrophic factor  1.01 0.8 
FKBP4 FK506 binding protein 4 -1.07 0.3 
FKBP5 FK506 binding protein 5 1.02 0.8 
NR3C1 Nuclear receptor subfamily 3, group C, 
member 1 
-1.10 0.011 
VEGFA Vascular endothelial growth factor A -1.01 0.8 
VGF VGF nerve growth factor inducible 1.09 0.1 
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Changes in gene expression in patients with and without IFN-α-induced 
depression from baseline to treatment week 4 of IFN-α treatment were 
investigated using an absolute fold change of 1.4 and a p-value cut-off of 
p<0.05. Firstly, when comparing the gene expression profile of patients with 
IFN-α-induced depression at treatment week 4 versus baseline, approximately 
750 differentially expressed genes were obtained. This analysis was repeated in 
patients without IFN-α-induced depression only obtaining in this case 
approximately 400 differentially expressed genes at treatment week 4 when 
compared to baseline. Further investigation revealed 322 genes to be in 
common between the two groups of patients, whereas 442 genes were 
modulated by IFN-α only in patients with IFN-α-induced depression, and 46 
genes were modulated by IFN-α only in patients without IFN-α-induced 
depression. These data are presented in Figure 3.63.  
 
As the focus of this thesis was the development of depression, pathway 
analysis of the 442 genes modulated by IFN-α specifically in patients with IFN-
α-induced depression was conducted. Eight pathways were found to be 
regulated: Phosphatidylinositol (PIP) signalling system, long term potentiation 
(LTP) signalling, gap junction and notch signalling pathways were all down-
regulated. The Janus kinase-signal transducers and activators of transcription 
(JAK-STAT) signalling, natural killer cells mediated cell cytotoxicity, DNA 








Figure 3.63 Venn diagram of genes modulated by IFN-α in patients with and without 
IFN-α-induced depression 
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Changes in the expression of candidate genes from baseline to treatment week 
4, in patents with and without IFN-α-induced depression are presented in Table 
3.22 and Table 3.23. Patients with IFN-α-induced depression had significantly 
lower expression of TDO2 at treatment week 4 when compared to baseline 
(p=0.002), whereas patients without IFN-α-induced depression had no change 
in TDO2 expression (p=0.6). Patients without IFN-α-induced depression also 
had a lower expression of IDO2 at treatment week 4 when compared to 
baseline (p=0.044) whereas this was unchanged in patients with IFN-α-induced 
depression (p=0.1).  
 
Regarding genes related to PUFA metabolism, both patients with and without 
IFN-α-induced depression had significantly higher expression of FADS2 at 
treatment week 4 when compared to baseline (p=0.007 and p=0.029, 
respectively). Both patients with and without IFN-α-induced depression had 
significantly lower expression of COX1 at treatment week 4 when compared to 
baseline (p=0.001 and p=0.022, respectively). Finally, patients with IFN-α-
induced depression had significantly lower expression of COX3 (p=0.019). 
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Table 3.22 Differentially expressed candidate genes at treatment week 4 
compared to baseline in patients with and without IFN-α-induced depression 
   
MDD 
n = 19 
 
No MDD 





















Indoleamine 2,3  
dioxygenase 1  -1.15 0.4 -1.07 0.7 
IDO2 
Indoleamine 2,3  














KYNU Kynureninase  1.11 0.4 -1.01 0.9 
HAAO 
3-hydroxyanthranilate 3,4-
dioxygenase -1.00 0.9 -1.07 0.1 
TDO2 Tryptophan 2,3-dioxygenase  -1.08 0.002 1.01 0.6 
TPH1 Tryptophan hydroxylase 1 1.01 0.9 1.03 0.6 
 
PUFA metabolism 
COX1 Cyclooxygenase 1 -1.11 0.001 -1.07 0.022 
COX2 Cyclooxygenase 2 -1.04 0.4 -1.06 0.2 
COX3 Cyclooxygenase 3 -1.23 0.019 -1.17 0.1 
FADS1 Fatty acid desaturase 1 1.11 0.2 1.14 0.1 
FADS2 Fatty acid desaturase 2 1.61 0.007 1.46 0.029 
PLA2G2A 
 












Both patients with and without IFN-α-induced depression had significantly lower 
expression of IL-1B, IL-1R1 and IL-6R at treatment week 4 when compared to 
baseline (p=0.001; p<0.001; p<0.001 and p<0.001; p<0.001; p<0.001, 
respectively). Patients with IFN-α-induced depression also had significantly 
lower expression of IL-2 and IL-4 (p=0.039 and p=0.001, respectively). There 
was no change in the expression of these genes in patients without IFN-α-
induced depression (p=0.5 and p=0.9 respectively). Patients with IFN-α-induced 
depression also had higher expression of interleukin-2 receptor gamma (IL-
2RG), interleukin-18 (IL-18) and transforming growth factor beta-1 (TGFB1) 
(p=0.021, p=0.006 and p=0.040, respectively) at treatment week 4 when 
compared to baseline. There were no changes in the expression of these genes 
in patients without IFN-α-induced depression (p=0.4, p=0.4 and p=0.1, 
respectively). Furthermore, patients without IFN-α-induced depression had a 
higher expression of IL-10 at treatment week 4 when compared to baseline 
(p=0.018) whereas there was no significant change in IL-10 expression in 
patients with IFN-α-induced depression (p=0.1). 
 
Finally, only patients without IFN-α-induced depression had lower expression of 
NR3C1 (GR) at treatment week 4 when compared to baseline (p=0.002). 
Neither patient group had any other significant changes in their expression of 





Table 3.23 Differentially expressed candidate genes at treatment week 4 
compared to baseline in patients with and without IFN-α-induced depression 
   
MDD 
n = 19 
 
No MDD 




















IL-1A Interleukin 1, alpha  -1.05 0.1 1.02 0.4 
IL-1B Interleukin 1, beta -1.38 0.001 -1.44 <0.001 
IL-1R1 Interleukin 1 receptor, type 1 -1.59 <0.001 -1.63 <0.001 
IL-2 Interleukin 2 -1.05 0.039 1.01 0.5 
sIL-2R Soluble interleukin 2 receptor 1.08 0.5 1.05 0.6 
IL-4 Interleukin 4 -1.08 0.001 -1.00 0.9 
IL-6 Interleukin 6  -1.01 0.8 -1.02 0.5 
IL-6R Interleukin 6 receptor -1.48 <0.001 -1.32 <0.001 
IL-8 Interleukin 8 1.08 0.4 1.00 1.0 
IL-10 Interleukin 10 1.10 0.1 1.13 0.018 
IL-18 Interleukin 18 1.31 0.006 1.09 0.4 
IL-28B Interleukin 28, beta -1.09 0.1 1.08 0.2 
IFNG Interferon, gamma 1.08 0.2 -1.02 0.8 
TGFB1 
 










TNFA Tumor necrosis factor, alpha 1.06 0.4 -1.01 0.9 
TRAF6 
 











BDNF Brain-derived neurotrophic 
factor  
-1.03 0.3 -1.01 0.8 
FKBP4 FK506 binding protein 4 1.03 0.5 -1.00 0.9 
FKBP5 FK506 binding protein 5 1.05 0.6 1.09 0.3 
NR3C1 Nuclear receptor subfamily 3, 
group C, member 1 
-1.07 0.1 -1.13 0.002 
VEGFA 
 










VGF VGF nerve growth factor 
inducible 
-1.02 0.7 1.01 0.8 
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3.1.8 Clinical predictors of depression scores 
Given that there were increases in depression scores in the whole sample, even 
in patients who did not meet criteria for MDD diagnosis, I investigated predictors 
of depression scores during IFN-α treatment as a continuous variable. In order 
to test the second and third primary aims of this thesis, I investigated six groups 
of predictors: socio-demographics, psychosocial stressors, cognitive factors, 
baseline psychopathology, baseline health status and biological factors.  
 
The socio-demographic predictors are presented in Table 3.24. There were no 
socio-demographic factors that significantly predicted subsequent depression 
scores during IFN-α treatment. Furthermore, there were also no significant 
predictive effects of the liver disease parameters that were investigated. 
 
The predictive effects of psychosocial stressors are presented in Table 3.25. 
There were no significant predictive effects of any of the psychosocial stressors 
on depression scores during IFN-α treatment. 
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Table 3.24 Socio-demographic predictors of depression scores during IFN-α 
treatment 
  
Post baseline  
IDS scores 
 
Post baseline IDS scores 






























































































































































































Table 3.25 Psychosocial stress predictors of depression scores during IFN-α 
treatment 
  
Post baseline  
IDS scores 
 
Post baseline IDS scores 


















































































































The cognitive predictors (illness perceptions) are presented in Table 3.26. 
There was a significant effect of perceptions about timeline in predicting 
depression scores (Coefficient=1.0, p<0.001) and this remained significant after 
adjusting for baseline depression scores (p=0.032) and the overall model 
accounted for 31% of the variance (R2=0.31). There were also significant effects 
of the consequences, timeline cyclical, personal control and emotional 
representations dimensions (Coefficient=0.9, p=0.003; Coefficient=1.5, 
p=0.002; Coefficient=-1.3, p=0.009 and Coefficient=0.9, p=0.001, respectively). 
However, all of these effects were no longer significant after adjusting for 
baseline depression scores (p=0.1, p=0.1, 0.2 and p=0.1, respectively) 
indicating these effects are in driven by baseline depression status.  
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Table 3.26 Cognitive predictors of depression scores during IFN-α treatment  
  
Post baseline  
IDS scores 
 
Post baseline IDS scores 



































































































































The predictive effects of baseline psychopathology are presented in Table 3.27. 
There were significant effects of baseline scores of depression, fatigue, stress 
and anxiety on subsequent depression scores during IFN-α treatment 
(Coefficient=0.8, p<0.001; Coefficient=1.3, p<0.001; Coefficient=1.0, p<0.001 
Coefficient=0.2 and p<0.001, respectively). However, after adjusting for 
baseline depression scores, none of these effects remained significant (p=0.2, 
p=0.9 and p=0.1, respectively) indicating that baseline depression scores drive 
the association between baseline fatigue, stress and anxiety scores, and 
subsequent depression scores. 
 
All 8 health status dimensions of the SF-36 significantly predicted subsequent 
depression scores as presented in Table 3.28. After adjusting for baseline 
depression scores, significant negative effects of baseline scores remained for 
the emotional role limitation, social functioning and bodily pain dimensions 
(Coefficient=-0.2, R2=0.36, p=0.046; Coefficient=-0.2, R2=0.37, p=0.019 and 
Coefficient=-0.2, R2=0.37, p=0.001, respectively). There were no longer any 
significant effects of baseline scores on the physical functioning, physical role 
limitation, vitality, mental health and general health dimensions (p=1.0, p=0.9, 
p=0.6, p=0.1 and p=0.1 respectively) indicating that these effects were driven 
by baseline depression status. 
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Table 3.27 Baseline psychopathology predictors of depression scores during 
IFN-α treatment 
  
Post baseline  
IDS scores 
 
Post baseline IDS scores 
















































1.0 0.2 <0.001 -0.1 0.6 0.9 
HADS-A 
 










Post baseline IDS scores 








































-0.1 0.1 0.032 -0.2 0.1 0.046 
Vitality 
 
-0.3 0.1 <0.001 -0.1 0.1 0.6 
Mental health 
 




-0.2 0.1 <0.001 -0.2 0.1 0.019 
Bodily pain 
 
-0.3 0.1 <0.001 -0.2 0.1 0.001 
General health 
 
-0.3 0.1 <0.001 -0.2 0.1 0.1 
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3.1.9 Biological predictors of depression scores 
The biological predictors of depression scores during IFN-α treatment are 
presented in Table 3.29. After adjusting for baseline depression scores, there 
was a significant negative effect of the baseline AUC of cortisol during the day 
as well as the noon cortisol values in predicting depression scores 
(Coefficient=-<0.01, R2=0.57, p=0.006 and Coefficient=-2.2, R2=0.58, p=0.006, 
respectively). These data suggest the association between baseline cortisol 
activity and subsequent depression scores are mediated by baseline 
depression scores.  
 
There was only a significant negative effect of kynurenic acid levels in predicting 
subsequent depression scores (Coefficient=-2.2, p=0.010). This remained 
significant after adjusting for baseline depression scores (p=0.035) and the 
overall model accounted for 44% of the variance (R2=0.44). 
 
There was no effect of baseline levels of any of the PUFAs measured. 
However, after adjusting for baseline depression scores, there was a significant 
negative effect of the omega-6 PUFA, arachidonic acid (AA) in predicting 
subsequent depression scores (Coefficient=-2.2, R2=0.37, p=0.032).  
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Table 3.29 Biological predictors of depression scores during IFN-α treatment 
  
Post baseline  
IDS scores 
 
Post baseline IDS 
scores 

















































































































































































































































































3.1.10 Clinical predictors of fatigue scores 
The socio-demographic predictors of fatigue scores during IFN-α treatment are 
presented in Table 3.30. There was a significant negative effect of ethnicity, 
specifically being of a non-white British ethnicity (Coefficient=-3.0, p=0.038). 
This effect remained significant after adjusting for baseline fatigue scores 
(p=0.025) and the overall model accounted for 21% of the variance (R2=0.21). 
There were no other socio-demographic factors that significantly predicted 
fatigue scores during treatment. Furthermore, there were also no significant 
predictive effects of the liver disease parameters that were investigated.  
 
The predictive effects of psychosocial stressors are presented in Table 3.31. 
There was a significant predictive effect of having experienced a stressful life 
event (Coefficient=3.0, p=0.035). However, this was no longer significant after 
adjusting for baseline fatigue scores (p=0.4) indicating that this effect is driven 





Table 3.30 Socio-demographic predictors of fatigue scores during IFN-α 
treatment 
  
Post baseline  
CFQ scores 
 
Post baseline CFQ scores 






























































































































































































Table 3.31 Psychosocial stress predictors of fatigue scores during IFN-α 
treatment 
  
Post baseline  
CFQ scores 
 
Post baseline CFQ scores 
















































































































The cognitive predictors (illness perceptions) of fatigue scores are presented in 
Table 3.32. There was a significant effect of the consequences dimension 
(Coefficient=0.4, p=0.002). This effect remained significant after adjusting for 
baseline fatigue scores (p=0.031) and the overall model accounted for 11% of 
the variance (R2=0.11). There was a significant effect of the emotional 
representations dimension (Coefficient=0.3, R2=0.11, p=0.003). This effect also 
remained significant after adjusting for baseline fatigue scores (p=0.020) and 
the overall model accounted for 11% of the variance (R2=0.11). There was also 
a significant effect of perceptions about timeline in predicting fatigue scores 
(Coefficient=0.3, p=0.005) however; this was no longer significant after 
adjusting for baseline fatigue scores (p=0.1) indicating that this effect was 
driven by baseline fatigue scores.   
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Table 3.32 Cognitive predictors of fatigue scores during IFN-α treatment 
  
Post baseline  
CFQ scores 
 
Post baseline CFQ scores 


































































































































The predictive effects of baseline psychopathology are presented in Table 3.33. 
There were significant effects of baseline depression, fatigue, stress and 
anxiety scores on subsequent fatigue scores during IFN-α treatment 
(Coefficient=0.2, p=0.001; Coefficient=0.6, p=0.001; Coefficient=0.3, p=0.002 
and Coefficient=0.6, p<0.001, respectively). However, after adjusting for 
baseline fatigue scores, none of these effects remained significant (p=0.9, 
p=0.4 and p=0.3, respectively) indicating that baseline fatigue scores were 
driving these associations. 
 
There were significant effects for baseline scores on 6 out of the 8 health status 
dimensions including, physical functioning, physical role limitation, vitality, 
mental health, bodily pain and general health (Coefficient=-0.1, p=0.018; 
Coefficient=-0.04, p=0.026; Coefficient=-0.1, p<0.001; Coefficient=-0.1, 
p=0.004; Coefficient=-0.1, p=0.008 and Coefficient=-0.1, p=0.001, respectively). 
However, after adjusting for baseline fatigue scores, there was only a significant 
negative effect of baseline scores on the general health dimension 
(Coefficient=-0.1, R2=0.21, p=0.044).  
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Table 3.33 Baseline psychopathology predictors of fatigue scores during IFN-α 
treatment 
  
Post baseline  
CFQ scores 
 
Post baseline CFQ scores 


































0.6 0.2 0.001 - - - 
PSS 
 
0.3 0.1 0.002 0.1 0.1 0.4 
HADS-A 
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Post baseline CFQ scores 








































-0.04 0.02 0.1 -0.01 0.02 0.7 
Vitality 
 
-0.1 0.03 <0.001 -0.1 0.04 0.1 
Mental health 
 




-0.1 0.03 0.1 -0.02 0.02 0.3 
Bodily pain 
 
-0.1 0.03 0.008 -0.04 0.03 0.3 
General health 
 




3.1.11 Biological predictors of fatigue scores 
The biological predictors of fatigue scores during IFN-α treatment are presented 
in Table 3.35. There was no significant effect of cortisol activity on subsequent 
fatigue scores. However, after adjusting for baseline fatigue scores, there was a 
significant negative effect of the baseline AUC of cortisol during the day as well 
as noon cortisol values in predicting fatigue scores during treatment 
(Coefficient=-<0.01, R2=0.32, p=0.001 and Coefficient=-1.2, R2=0.24, p=0.014, 
respectively). 
 
There was only a significant negative effect of kynurenic acid levels in predicting 
subsequent fatigue scores (Coefficient=-1.0, p=0.002). This effect remained 
significant after adjusting for baseline fatigue scores (p=0.019) and the overall 
model accounted for 24% of the variance (R2=0.24). 
 









Post baseline CFQ 
scores adjusting for 
















































































































































































































































































3.1.12 Clinical predictors of stress scores 
The socio-demographic predictors of stress scores during IFN-α treatment are 
presented in Table 3.36. There was a large significant effect of having a 
previous history of MDD (Coefficient=7.6, p<0.001). This effect remained 
significant after adjusting for baseline stress scores (p=0.006) and the overall 
model accounted for 43% of the variance (R2=0.43). There were no other socio-
demographic factors that significantly predicted fatigue scores during treatment. 
Furthermore, there were also no significant predictive effects of the liver disease 
parameters that were investigated.  
 
The predictive effects of psychosocial stressors are presented in Table 3.37. 
There was a significant predictive effect of having experienced a stressful life 
event on stress scores during IFN-α treatment (Coefficient=4.4, p=0.048). 
However, this effect was no longer significant after adjusting for baseline stress 
scores (p=0.4) indicating that this association is driven by baseline stress 
scores. There were no other significant predictive effects of psychosocial 




Table 3.36 Socio-demographic predictors of stress scores during IFN-α 
treatment 
  
Post baseline  
PSS scores 
 
Post baseline PSS 
scores adjusting for 





























































































































































































Table 3.37 Psychosocial stress predictors of stress scores during IFN-α 
treatment 
  
Post baseline  
PSS scores 
 
Post baseline PSS scores 


















































































































The cognitive predictors (illness perceptions) are presented in Table 3.38. 
There was a significant effect of the emotional representations dimension 
(Coefficient=0.7, p<0.001). This effect remained significant after adjusting for 
baseline stress scores (p=0.043) and the overall model accounted for 36% of 
the variance (R2=0.36). There was also significant effects of perceptions about 
timeline, consequences, timeline cyclical dimension, personal control and 
illness coherence in predicting stress scores (Coefficient=0.7, p<0.001; 
Coefficient=0.7, p<0.001; Coefficient=1.3, p<0.001; Coefficient=-1.1, p<0.001 
and Coefficient=-0.6, p=0.046, respectively). However, all of these effects were 
no longer significant after adjusting for baseline stress scores (p=0.2; p=0.1; 
p=0.1, p=0.3 and p=0.6, respectively) indicating that these associations are 
driven by baseline stress scores.  
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Table 3.38 Cognitive predictors of stress scores during IFN-α treatment 
  
Post baseline  
PSS scores 
 
Post baseline PSS scores 


































































































































The predictive effects of baseline psychopathology are presented in Table 3.39. 
There were significant effects of baseline depression, fatigue and anxiety 
scores on subsequent stress scores during IFN-α treatment (Coefficient=0.4, 
p<0.001; Coefficient=1.0, p<0.001; Coefficient=1.2 p<0.001, respectively). After 
adjusting for baseline stress scores, there was still a significant effect of 
baseline depression and anxiety scores (Coefficient=0.2, R2=0.41, p=0.047 and 
Coefficient=0.6, R2=0.41, p=0.041, respectively) indicating that these affects are 
largely independent of baseline stress scores. 
 
There were significant negative effects of baseline scores on all 8 health status 
dimensions, on subsequent stress scores during IFN-α treatment. These data 
are presented in Table 3.40. After adjusting for baseline stress scores, 
significant effects remained for the vitality, mental health and general health 
dimensions (Coefficient=-0.1, R 2=0.41, p=0.041, Coefficient=-0.1, R2=0.42, 
p=0.045 and Coefficient=-0.1, R 2=0.43, p=0.005, respectively). The effects for 
physical functioning, physical role limitation, emotional role limitation, social 
functioning and bodily pain were no longer significant (p=1.0, p=0.8, p=0.1, 
p=0.5 and p=0.3, respectively), indicating that these effects were driven by 
baseline stress scores. 
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Table 3.39 Baseline psychopathology predictors of stress scores during IFN-α 
treatment 
  
Post baseline  
PSS scores 
 
Post baseline PSS scores 
















































0.8 0.1 0.1 - - - 
HADS-A 
 
1.2 0.3 <0.001 0.6 0.3 0.041 
   
 










Post baseline PSS scores 








































-0.1 0.03 0.001 -0.04 0.02 0.1 
Vitality 
 
-0.2 0.04 <0.001 -0.1 0.05 0.041 
Mental health 
 




-0.1 0.04 <0.001 -0.02 0.04 0.5 
Bodily pain 
 
-0.1 0.01 0.003 -0.04 0.04 0.3 
General health 
 




3.1.13 Biological predictors of stress scores 
Finally, the biological predictors of stress scores during IFN-α treatment are 
presented in Table 3.41. After adjusting for baseline stress scores, there was a 
significant effect of the difference of cortisol values from awakening, at 60 
minutes after awakening, in predicting stress scores during treatment 
(Coefficient=0.4, R2=0.68, p=0.039).  
 
There was also a significant negative effect of kynurenic acid levels in predicting 
subsequent stress scores (Coefficient=-1.3, p=0.014) however; this effect was 
no longer significant after adjusting for baseline stress scores (p=0.2) indicating 
that this association was driven by baseline stress scores. 
 
There were no significant effects of any of the PUFAs measured. However, after 
adjusting for baseline stress scores there was a significant negative effect of the 






Table 3.41 Biological predictors of stress scores during IFN-α treatment 
  
Post baseline  
PSS scores 
 
Post baseline PSS 
scores adjusting for 
















































































































































































































































































3.1.14 Clinical predictors of anxiety scores 
The socio-demographic predictors of anxiety scores during IFN-α treatment are 
presented in Table 3.42. There was a significant effect of having a previous 
history of MDD (Coefficient=2.9, p=0.010) however, this was no longer 
significant after adjusting for baseline anxiety scores (p=0.1) indicating that this 
effect is driven by baseline anxiety scores. There were no other significant 
socio-demographic predictors. 
 
The predictive effects of psychosocial stressors are presented in Table 3.43. 
There were no significant predictive effects of psychosocial stressors on 




Table 3.42 Socio-demographic predictors of anxiety scores during IFN-α 
treatment 
  
Post baseline  
HADS-A scores 
 
Post baseline HADS-A 
scores adjusting for 






























































































































































































Table 3.43 Psychosocial stress predictors of anxiety scores during IFN-α 
treatment 
  
Post baseline  
HADS-A scores 
 
Post baseline HADS-A 
scores adjusting for 

















































































































The cognitive predictors (illness perceptions) are presented in Table 3.44. 
There were significant effects of the timeline, consequences, timeline cyclical, 
personal control and emotional representations dimensions in predicting anxiety 
scores (Coefficient=0.3, p<0.001; Coefficient=0.3, p<0.001; Coefficient=0.5, 
p<0.001; Coefficient=-0.5, p<0.001 and Coefficient=0.3, p<0.001, respectively). 
All of these remained significant after adjusting for baseline anxiety scores 
(R2=0.27, p=0.043; R2=0.31, p=0.005; R2=0.35, p=0.002; R2=0.32, p=0.014 and 
R2=0.27, p=0.012, respectively) indicating that these effects are independent of 




Table 3.44 Cognitive predictors of anxiety scores during IFN-α treatment 
  
Post baseline  
HADS-A scores 
 
Post baseline HADS-A 
scores adjusting for 

































































































































The predictive effects of baseline psychopathology are presented in Table 3.45. 
There were significant effects of baseline depression, fatigue, stress and 
anxiety scores on subsequent anxiety scores during IFN-α treatment 
(Coefficient=0.3, p<0.001; Coefficient=0.4, p<0.001; Coefficient=0.3, p<0.001 
and Coefficient=0.6, p<0.001, respectively). After adjusting for baseline anxiety 
scores, there was still a significant effect of baseline depression scores 
(Coefficient=0.2, R2=0.35, p<0.001).  
 
There were significant effects of baseline scores of all 8 health status 
dimensions on subsequent anxiety scores during IFN-α treatment. These data 
are presented in Table 3.46. Furthermore, after adjusting for baseline anxiety 
scores, there were still significant negative effects of baseline scores on the 
physical functioning, vitality, mental health, social functioning, bodily pain and 
general health dimensions (Coefficient=-0.1, R2=0.34, p=0.002; Coefficient=-
0.1, R2=0.35, p=0.003; Coefficient=-0.1, R2=0.33, p=0.015; Coefficient=-0.1, 
R2=0.37, p=0.001; Coefficient=-0.1, R2=0.35, p=0.002 and Coefficient=-0.1, 
R2=0.41, p<0.001, respectively). The effects of physical role limitation and 
emotional role limitation were no longer significant (p=0.1 and p=0.1, 
respectively), indicating that the effect of these two dimension were driven by 




Table 3.45 Baseline psychopathology predictors of anxiety scores during IFN-α 
treatment 
  
Post baseline  
HADS-A scores 
 
Post baseline HADS-A 
scores adjusting for 

































0.4 0.1 <0.001 0.1 0.1 0.3 
PSS 
 
0.3 0.1 <0.001 0.2 0.1 0.058 




Table 3.46 Baseline health status predictors of anxiety scores during IFN-α 
treatment 
  
Post baseline HADS-A 
scores 
 
Post baseline HADS-A 
scores adjusting for 







































-0.04 0.01 0.005 -0.02 0.01 0.1 
Vitality 
 
-0.1 0.02 <0.001 -0.1 0.02 0.003 
Mental health 
 




-0.1 0.02 <0.001 -0.1 0.02 0.001 
Bodily pain 
 
-0.1 0.02 0.003 -0.1 0.02 0.002 
General health 
 




3.1.15 Biological predictors of anxiety scores 
The biological predictors of anxiety scores during IFN-α treatment are presented 
in Table 3.47. There was a significant predictive effect of the difference from 
awakening, of cortisol values at 60 minutes after awakening (Coefficient=0.5, 
p=0.004). However, this effect was no longer significant after adjusting for 
baseline anxiety scores (p=0.1) indicating that this association is driven by 
baseline anxiety scores.  
 
There were no significant predictive effects of any of the kynurenine and 
tryptophan pathway metabolites.  
 
There were no significant predictive effects of any of the PUFAs measured on 




Table 3.47 Biological predictors of anxiety scores during IFN-α treatment 
  
Post baseline  
HADS-A scores 
 
Post baseline HADS-A 


















































































































































































































































































3.2 Qualitative study on nursing staff 
Interviewees from all three sites were asked to describe the standard care 
processes for providing care for hepatitis C patients. Four key themes were 
identified and are demonstrated below.  
 
3.2.1 Assessing patient risk factors 
The participants discussed factors that they identify when assessing the risk of 
patients developing depression (at baseline) and when assessing any 
subsequent development of symptoms during the course of IFN-α treatment. 
The same factors were identified by staff as being relevant when assessing 
both the risk for depression at baseline, and the development of depression 
throughout the treatment course. These have been divided into two categories, 














Mental health history 9 
Use of medications/anti-depressants 8 
Seen by a psychiatrist and/or mental health team 7 
Mental health history of family/relatives 4 
Previous self-harm 2 
 
Signs and symptoms (verbal) 
 
Depression 8 
Low mood 6 
Emotional changes and deterioration   6 
Angry/irritable/aggressive 5 
Description of ‘how they are feeling’ 5 
Suicidal thoughts 3 
 
Signs and symptoms (non-verbal) 
 
Eye contact 6 
Tearful 5 
Changes in behaviour 4 
Agitation/fidgety 3 
General demeanour 3 
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Sleep pattern/deprivation 7 
Alcohol/drug abuse 6 
Employment 6 
Housing arrangement  4 
Life events (e.g. bereavement) 4 
Medical history 4 
Weight/diet/appetite 4 
Medical co-morbidities 4 
Activities/social life 2 
Relationship/marital status 2 





3.2.2 Co-ordinating action 
Further actions clinical nurse specialists take when risks are recognised either 
prior to or during treatment were also assessed. Four types of actions were 
identified: involvement of patients and/or relatives, referral to liaison 
psychiatrists, referral to other resources (community services/GPs) and 
discussion with nursing staff.  
 
First, the staff emphasised that the decision to refer a patient to a psychiatrist or 
other mental health professional has to be made jointly with patients, as their 
engagement is the key to successful treatment. Concerns raised by patients’ 
relatives can also initiate the referral process.   
 
“We say that it’s not just a one way street, you might come to me and say 
well I really would like to be referred so it’s not always me who says well 
we would like you to see somebody.”  
 
“We do have relatives who phone us and obviously if they talk to us then 
we will listen, we might not necessarily comment, but we’ll then act on it 
nonetheless.”  
 
Second, in the trusts where liaison psychiatrists are available, their advice is 
often sought prior to making any formal referrals.  
 
“we do work very closely with our liaison consultant psychiatrist, and so if 
we do feel that we need further advice and we’re not quite sure about 
something, then we will always have an open discussion with him.”  
 
“I’d rather contact the psychiatrist and explain what the symptoms are, 
what the situation is and then he will decide and he will advise us on what 
to do, how to deal with it.”  
 
Third, clinical nurse specialists can contact a community mental health team 
and/or patients’ GP to co-ordinate their actions. This can either be as an 
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alternative to, or in conjunction with liaison psychiatry involvement, depending 
on existing patient involvement in such services as well as the availability of 
liaison psychiatry services.  
 
“If I think someone is going to need some support during treatment, I will 
get them referred to the community mental health team.”  
 
“We do sometimes refer patients to the counselling psychotherapy 
department or recommend that they go to their GP if they are feeling quite 
low.”  
 
Additionally, informal discussions about patients take place within the nursing 
team, when nurses perceive a risk regarding patients’ well-being. This is on a 
patient-by-patient basis and serves not only as an information exchange but 
also as a resource for making decisions. 
 
“We also talk about patients a lot if for example, someone’s come in and 
there’s been some difficulty, we’ll either email everybody to say can you 
keep an eye on this patient because at clinic they weren’t quite right…”  
 
“We will also go round and discuss patients within the team “what did you 
pick up on?” and quite a lot of interesting things come out of that, where 
we use each other as a resource quite a lot.” 
 
3.2.3 Sources of uncertainty and available strategies to reduce them 
Almost all the staff noted that, based on many years of experience, they were 
confident in their ability to detect signs of psychological deterioration in patients. 
However, several sources of uncertainty still exist for clinical nurse specialists 
when making decisions regarding patient welfare. These include familiarity with 
patient, language barriers and being able to distinguish psychological symptoms 

















“I think if it’s the first time you’ve met a patient, its actually 
quite difficult for me to gauge those things.” 
 “I keep encouraging patients to not keep it in. If there are 
problems they need to tell us so we can do something 








“Sometimes it’s difficult to separate out which is a physical 
things and which is related to their psychological health but 
I think they’re probably all related.” 
“It’s hard to know what’s sort of a physical symptom from 





to refer to 
psychiatrist 
 
“There’s always those more borderline cases where you’re 
not quite sure; should I refer or shouldn’t I.” 
“I feel that somebody may benefit from input from the likes 
of Dr. XXX (liaison psychiatrist), and yet the individual may 
not feel that, so that could be a little bit more of a difficult 
one where I've actually gone back and discussed with other 









“also, we’re never quite sure if what we want to say is 
translated to the patient and also if what the patient wants 
to say to us is translated and I get exactly what they want to 
say.” 
“some of them will speak English to a limited degree and 
when you’re chatting to them, after a while, once you’ve 
heard yes yes yes so many times, you suddenly realise 
that, or you ask them a question and they give you the 
wrong answer, I will ask them a question, expecting and 
knowing what the answer should be and they’ll give me the 
wrong answer and I’ll know that they’re not understanding.” 
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Developing a good rapport with patients was repeatedly mentioned by nurse 
specialists as one of the key aspects in the care process, and the key strategy 
to reduce uncertainty.  
 
‘‘I used to have my own patients in a Monday clinic and I knew them really 
well and I would know instantly if something was wrong. Now we kind of 
rotate through the clinics so if you don’t know someone, it might take a 
couple of times before you can pick up that they’re not quite themselves.’’ 
 
Another uncertainty reduction strategy is good communication among team 
members and also with the wider multidisciplinary group. Despite all the above-
mentioned sources of uncertainty, staff felt that they are generally well 
supported by their own nursing staff, liaison psychiatrists and other community 
teams. This close-knit team allows them to use each other as a source of 
information to reduce uncertainty about making decisions on the appropriate 
course of action. 
 
‘‘We’ve got a good relationship between the different doctors and within 
the team as well so that’s probably helping as well. Supporting each other 
is very important in these kind of case scenarios because it’s difficult to 
deal with someone who’s becoming very unwell and knowing that I’ve got 
the support from doctors and the other nurses, can make it easier as well.’’  
 
‘‘We’re all in the same office and there’s quite a good relationship, rapport 
between us all. I mean, if there’s anything that you’ve seen, you know, Mr 
so and so, and you know he seems a bit wound up or emotional, we do 
tend to sort of tell each other what our observations are.’’  
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3.2.4 Suggested areas of improvement 
Interviewees made suggestions for improving their current practice and care 
processes, including extra time with patients, staff training in mental health, 
additional support (appointment of liaison psychiatrists and dual qualified 
nurses, in particular) and the development of a protocol for referrals to 
psychiatric services.  
 
‘‘. . .discussing things with the consultant psychiatrist, which we do, but, it 
would be nice to have a little more time to do that and to kind of probably 
set up a formal meeting with him monthly or something that would be very 
useful.’’  
 
 ‘‘I’ve often wondered if we had a nurse who was dual qualified so had a 
mental health qualification as well as a general one, whether that would be 
of any benefit.’’ 
 
However, the staff emphasised that they feel confident to overcome these 
issues, and expressed pride in the way they deliver holistic care for patients 
through management of psychological, physical and social needs. They were 
asked whether a decision-making support tool would enhance the accuracy of 
clinical judgements. Although most respondents agreed that such a tool could 
be utilised as a back-up for their mostly intuitive ways of assessing risks, or as 
an effective communication aid when different health care professionals are 
involved in care processes, they emphasised the importance of their own 
clinical judgement based on knowledge of the patients. 
 
‘‘You’ve always got your own gut instinct, that you will rely on and perhaps 
you would use a tool as a backup really just to confirm what your hunch 
is.’’  
 
‘‘I would not solely rely on a tool. I would also communicate with other 
people about the findings. Yeah, I think it needs both, it’s important to 





4.1 Summary of findings 
This is the first study to extensively investigate the cognitive, biological and 
psychosocial predictors of IFN-α-induced depression in patients with chronic 
HCV infection. The main findings in relation to the original aims of this thesis are 
reported below: 
 
The first primary aim of this thesis was to monitor the impact of IFN-α treatment 
on a number of clinical and biological. I predicted that: 
- IFN-α would lead to an increase in depression, fatigue, stress and anxiety 
scores. 
- IFN-α would lead to a decrease in health status and well-being measures. 
- IFN-α would lead to a decrease in tryptophan levels, with a subsequent 
increase in kynurenine and its neurotoxic metabolites, and a decrease in 
the levels of the neuroprotective metabolite; kynurenic acid. 
- IFN-α would lead to a decrease in the level of omega-3 PUFAs and an 
increase in omega-6 contents. 
- IFN-α would lead to a number of gene expression changes particularly 
increased expression of genes involved in: tryptophan metabolism, PUFA 
metabolism and inflammation, and reduced expression of genes involved 
in GR functionality and neuroplasticity. 
 
Indeed, consistent with a multitude of studies, IFN-α treatment led to an 
increase in depression, fatigue, stress and anxiety scores. This is accompanied 
by worsening of health status and decreased well-being. IFN-α treatment also 
led to changes in a number of the biological systems and metabolites 
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investigated. Specifically, there is a decrease in tryptophan and kynurenic acid 
levels accompanied by an increase in kynurenine levels. There is also a 
decrease in the omega-3 PUFA docosahexaenoic acid (DHA) and in the 
omega-6 PUFA arachidonic acid (AA). However, there are no significant 
changes in cortisol levels as a result of IFN-α treatment, although the smaller 
number of patients with these data may have affected the findings. IFN-α 
treatment also led to changes in the expression of genes involved in 5 different 
pathways, as well as several candidate genes. 
 
The second primary aim of this thesis was to identify novel clinical predictors of 
IFN-α-induced depression and assess the contribution of a number of clinical 
and lifestyle factors on the subsequent development of IFN-α-induced 
depression. I predicted that: 
- A previous history of depression, a family history of psychiatric illness and 
baseline psychopathology would be associated with the development of 
IFN-α-induced depression.  
- Exposure to recent stressful life events as well as childhood trauma 
(physical and sexual abuse, parental loss or parental separation) would be 
associated with the development of IFN-α-induced depression.  
- Negative illness perceptions would be associated with IFN-α-induced 
depression.  
 
Indeed, I find evidence for a predictive effect of a number of clinical and 
demographic factors on increasing depression scores during IFN-α treatment. In 
particular, baseline psychopathology (depression, fatigue, stress and anxiety 
scores) and negative illness perceptions at baseline predict higher subsequent 
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depression scores. However, there is no contribution of family history of 
psychiatric illness, psychosocial stressors, education level or relationship status. 
 
The third primary aim of this thesis was to investigate the contribution of specific 
biological systems to the development of IFN-α-induced depression. I predicted 
that: 
- Increased cortisol awakening response as well as increased cortisol during 
the day would be associated with IFN-α-induced depression.  
- Lower levels of tryptophan and higher kynurenine metabolite contents 
would be associated with the development of IFN-α-induced depression. 
- Lower omega-3 PUFAs and higher omega-6 PUFAs would be associated 
with the development of IFN-α-induced depression.  
- Increased expression of genes involved in tryptophan metabolism, PUFA 
metabolism and inflammation accompanied by reduced expression of 
genes involved in GR functionality and neuroplasticity would be associated 
with associated with IFN-α-induced depression. 
 
Indeed, I provide evidence that some biological variables predict higher 
depression scores during IFN-α treatment, independent of baseline depression 
scores. These include lower baseline cortisol levels during the day and lower 
baseline kynurenic acid levels. Interestingly, there is also an effect of lower 
levels of the (theoretically pro-inflammatory) omega-6 PUFA arachidonic acid 
(AA) on subsequent depression scores. Furthermore, at baseline, there are a 
number of gene expression differences associated with IFN-α-induced 
depression. These genes are involved in domains important for depression 
such as tryptophan metabolism, PUFA metabolism, inflammation, and 
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neuroplasticity. Moreover, there is also differential expression of IL-28β which 
has been previously shown to be associated with treatment response. Finally, 
pathway analysis also shows differential expression of genes belonging to 
MAPK and neurotrophin signalling pathways.  
 
The final aim of this thesis was to gain an in-depth understanding of staff 
experiences of, and attitudes towards the identification and monitoring of IFN-α-
induced-depression, and their decision-making processes. Specifically, I wanted 
to investigate the following questions: 
 
 - What factors do clinical nurse specialists see as important in determining 
risk of developing depression, at initial consultation and in on-going 
monitoring? 
 - What are the sources of uncertainty for clinical nurse specialists and 
available reduction strategies? 
 
This qualitative component of the study demonstrates that clinical nurse 
specialists assess a variety of risk factors for depression development during 
IFN-α treatment, using a range of information and cues. This informs their 
decisions on the type of action to take with regards to patients developing IFN-
α-induced depression. This part of the study also highlights areas for 
improvement such as: staff training in mental health, additional support, and the 





Additional exploratory analyses were also conducted to understand if the clinical 
and biological predictors identified were specific for the development of 
depression, or if they also predicted the development of other symptoms. 
Indeed, aspects of negative illness perceptions such as perceived 
consequences and emotional representations are also predictive of subsequent 
fatigue, stress and anxiety scores. Baseline depression is predictive of both 
subsequent stress and anxiety scores. In keeping with the findings for 
depression, higher baseline cortisol levels during the day and kynurenic acid 
levels are also predictive of lower subsequent fatigue scores. Interestingly, I 
also find that higher baseline levels of the omega-3 PUFA alpha-linolenic acid 




4.2 Development of depression and other neuropsychiatric effects 
during IFN-α treatment 
IFN-α led to an increase in depression scores with 40% of the sample 
developing clinically significant depression. This incidence is consistent with the 
findings from most prospective studies in which the occurrence of depression is 
20-45% (Asnis and De La Garza, 2006, Capuron and Miller, 2004, Raison et al., 
2005b). I also find a significant increase in fatigue, stress and anxiety scores 
during IFN-α treatment. Indeed, depression is not a single symptom but rather a 
syndrome comprised of emotional, cognitive and neurovegetative abnormalities. 
In dimensional analyses, it has been previously observed that neurovegetative 
symptoms, such as fatigue, occur early in IFN-α treatment and tend to persist, 
whereas depression-specific symptoms develop significantly later in treatment 
(Capuron and Miller, 2004). Indeed, my findings are consistent with this as I find 
that fatigue scores increase rapidly, early in IFN-α treatment, and persist. In 
fact, using the Chalder Fatigue Questionnaire cut-off point of >18, by treatment 
week 4, 20 individuals (42%) are already fatigued and this rate remains 
between 20 and 40 (42-83% of the total sample) throughout the treatment 
course. On the other hand, there is a cumulative increase in the development of 
depression as illustrated in Figure 3.33. In my study, I also observe a decline in 
health status and well-being which also occurs early on in treatment and 
persists. General health status and well-being as well as other measures of 
quality of life have not been extensively investigated in IFN-α patients before 
and therefore provide valuable insights in to the broad range of side-effects that 




4.3 Biological changes during IFN-α treatment 
IFN-α led to changes in a number of the biological systems and metabolites 
measured. Specifically, there is a decrease in the area under the curve of the 
increase (AUCi) of the cortisol awakening response and an increase in the area 
under the curve (AUC) for cortisol during the day, at treatment week 24 when 
compared to baseline. Unfortunately, these effects were not significant and this 
is likely due to a lack of statistical power. However, these findings are in line 
with previous studies. It has been demonstrated that there is hyper-reactivity of 
the HPA axis in response to acute cytokine administration (Capuron et al., 
2003b). However, chronic cytokine exposure is associated with a flattening of 
the diurnal cortisol curve and increased evening cortisol concentrations, which 
in turn, are associated with adverse behavioural effects such as depression and 
fatigue (Capuron and Miller, 2011, Raison et al., 2010a). It must be noted that in 
my sample there is not a clear cortisol awakening response. This may be due to 
methodological limitations such as the use of salivettes as opposed to cotton 
swabs which are able to absorb a larger volume of saliva. It is also possible that 
HCV infection itself can have an effect on endocrine function (Antonelli et al., 
2009), which in turn may impact on the cortisol awakening response. Indeed, 
studies have shown that in chronic medical illnesses such as cardiovascular 
disease and cancer, there is a flattening of the diurnal cortisol curve and 
increased evening cortisol concentrations (Matthews et al., 2006, Sephton et 
al., 2000) 
 
I also find a reduction in tryptophan and kynurenic acid levels and an increase 
in kynurenine, 3-hydroxykynurenine and the kynurenine/tryptophan ratio, in all 
patients over the course of IFN-α treatment. This is in line with several studies 
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which have also shown reductions in tryptophan and increases in kynurenine 
levels, as well as levels of quinolinic acid as a result of IFN-α (Bonaccorso et al., 
2002b, Raison et al., 2010b, Wichers et al., 2005).  
 
With regards to changes in the levels of PUFAs during IFN-α treatment, I find a 
significant decrease in the levels of the omega-3 fatty acid docosahexaenoic 
acid (DHA). Additionally, I also find a decrease in the levels of the omega-6 fatty 
acid arachidonic acid (AA). This is in contrast to my hypothesis that a reduction 
in omega-3 PUFA levels would be accompanied by an increase in omega-6 
contents. Only one other study has investigated IFN-α-induced changes in 
PUFA levels, with a specific focus on genetic polymorphisms in two key 
enzymes of PUFA metabolism (Su et al., 2010). The authors demonstrate “at 
risk” genotypes to be associated with lower levels of DHA and eicosapentaenoic 
acid (EPA) during IFN-α treatment. However, the authors do not comment on 
IFN-α related changes in PUFA levels in all patients. Finally, changes in gene 
expression as a result of IFN-α treatment will be discussed later. 
 
4.4 Clinical predictors of depression during IFN-α treatment 
4.4.1 Baseline psychopathology 
The most replicated clinical predictor for developing depression during IFN-α 
treatment is the presence of mood or anxiety symptoms prior to treatment 
(Lotrich et al., 2007, Raison et al., 2005a). Indeed, the results from this study 
support this. Dimensions of baseline psychopathology (fatigue, stress and 
anxiety scores) significantly predict subsequent depression scores, but after 
adjusting for baseline depression scores these effects are no longer significant. 
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In other words, patients with more severe baseline fatigue, stress and anxiety 
have higher depression scores during treatment, but this is mediated by their 
high baseline depression scores. However, it must be noted that the baseline 
assessment was conducted on the first day of IFN-α treatment; as such the 
emotional impact of starting treatment may have had an effect on baseline 
psychopathology.  
 
4.4.2 Baseline health status 
For the first time in this study, the effect of baseline health status and well-being 
on subsequent depression scores is also investigated. Emotional role limitation, 
worse social functioning and having more bodily pain at baseline are all 
predictive of higher depression scores during IFN-α treatment, independent of 
baseline depression scores. Taken together, these data suggest that it is not 
only baseline psychopathology but also baseline health status and quality of life 
that can predict the development of depression during IFN-α treatment. 
 
4.4.3 Cognitive predictors 
This is the first study to investigate the role of illness perceptions on the 
development of depressive symptoms during IFN-α treatment. Although there 
are no significant differences in illness perception scores between patients with 
and without a diagnosis of IFN-α-induced depression, there are significant 
predictive effects of illness perceptions on increasing depression scores during 
treatment. Specifically, negative beliefs about timeline that is, believing your 
illness will last a long time, predict higher depression scores. This is in line with 
previous studies conducted in other populations also showing aspects of illness 
perceptions such as strong perceived consequences to be predictive of poorer 
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health outcomes (Bijsterbosch et al., 2009, Foster et al., 2008, Scharloo et al., 
2000). These findings are of clinical importance as, unlike other factors such as 
socio-demographic variables, these links between beliefs and behaviour provide 
considerable potential for developing preventative cognitive based 
interventions. Identifying negative thinking associated with subsequent 
depression development could help to develop an intervention geared towards 
fostering more adaptive models and expectations, in order to improve 
outcomes. 
 
4.4.4 Psychosocial stressors 
This is also the first study to investigate the role of psychosocial stressors on 
the development of IFN-α-induced depression. There is evidence linking 
exposure to stress, such as childhood trauma, with inflammation and 
depression in adulthood (Archer et al., 2012, Caspi et al., 2003, Danese et al., 
2009, Nanni et al., 2012). However, to date no studies have investigated this 
relationship in patients undergoing IFN-α treatment. In my study, when looking 
at the effects of early life stress, there is no significant difference in reports of 
childhood traumatic events between patients with and without IFN-α-induced 
depression, or a predictive effect of childhood trauma on depression scores 
during IFN-α treatment. This lack of association between exposure to childhood 
trauma and IFN-α-induced depression may be due to the fact that in my sample 
there is already a much higher prevalence of childhood trauma than in the 
general population. A recent UK survey of young adults stated that 16% of 
respondents experienced some form of childhood maltreatment (May-Chahal 
and Cawson, 2005). In my sample, the prevalence of childhood trauma is more 
than twice this at, 40%. Furthermore, due to the small sample size, when 
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investigating the individual types of childhood trauma there are very small 
numbers. For example, only two patients with IFN-α-induced depression and 
five patients without IFN-α-induced depression reported experiencing physical 
abuse in childhood. So the lack of association found between childhood trauma 
sub-types and subsequent depression scores may be due to decreased 
statistical power. Finally, there is no predictive effect of exposure to stressful life 
events in the 6 months prior to treatment on subsequent depression scores. 
This may seem to be in contrast to the abovementioned findings for baseline 
perceived stress; however, these measures assess different types of stressors 
over different time frames. Moreover, although not statistically significant, 
patients who develop IFN-α-induced depression do have a higher prevalence of 
experiencing at least one stressful life event in the 6 months prior to starting 
treatment, when compared with patient who do not develop IFN-α-induced 
depression (57.9% vs. 37.9%). As such, this lack of association may again be 
due to decreased statistical power. 
 
4.4.5 Other predictors 
Other potential, but less frequently replicated clinical predictors, include a past 
history of MDD or a family history of psychiatric illness, as well as being female 
(Raison et al., 2005a, Raison et al., 2005b, Sockalingam and Abbey, 2009). In 
my study, patients developing IFN-α-induced depression have a significantly 
higher prevalence of a previous history of MDD when compared to patients who 
do not develop IFN-α-induced depression (52% vs. 24%). Indeed, of the 17 
patients reporting a previous history of MDD, 10 develop IFN-α-induced 
depression, compared with 9 out of 31 who did not have such history. However, 
a history of MDD does not have any significant predictive effect on subsequent 
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depression scores during IFN-α treatment, indicating that history of MDD before 
starting IFN-α therapy does not unequivocally predict the occurrence of IFN-α-
induced depression. Rates of IFN-α-induced depression are not significantly 
different between females and males or in those individuals with a family history 
of psychiatric illness. A few studies have also previously reported low academic 
level to be predictive of developing IFN-α-induced depression (Castellvi et al., 
2009, Su et al., 2010). The results of my study do not support this as there are 
no significant differences in education level between patients with and without 
IFN-α-induced depression and no predictive effect of education level on 
depression scores during treatment. However, I do find a significant difference 
in employment status between the two groups, with higher rates of 
unemployment in those who develop IFN-α-induced depression. This is in line 
with the findings of a previous study in which unemployment was associated 
with an increased risk of new-onset depression during IFN-α treatment (Evon et 
al., 2009). 
 
4.5 Biological predictors of depression during IFN-α treatment 
4.5.1 HPA axis 
In this study, I identify some predictive effects of baseline cortisol levels on 
subsequent depression. Specifically, I find higher cortisol levels at noon as well 
as a larger AUC for cortisol during the day to be predictive of lower depression 
scores. This is in apparent contrast to previous studies which found increased 
cortisol output in the day to be associated with IFN-α-induced increases in 
depression (Raison et al., 2008, Raison et al., 2010a). However, the findings of 
these studies assessed cortisol output in the day during IFN-α, not the 
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association between baseline cortisol and subsequent depression development 
as I have done. Although not significant, at baseline, patients with a diagnosis of 
IFN-α-induced depression appear to already have a higher difference of cortisol 
from awakening at 60 minutes after awakening when compared to patients who 
do not develop IFN-α-induced depression. Most previous studies have 
assessed the change in HPA axis function as a result of IFN-α rather than 
investigating baseline cortisol as a predictor for subsequent depression 
development. One study has shown that an exaggerated cortisol response to 
the first injection of IFN-α is a risk factor for developing IFN-α-induced 
depression. (Capuron et al., 2003b). 
 
4.5.2 Kynurenine and tryptophan pathway 
There is a significant predictive effect of baseline levels of kynurenic acid on 
subsequent depression scores during IFN-α treatment. Specifically, a higher 
baseline level of kynurenic acid is predictive of lower subsequent depression 
scores, indeed confirming the notion that kynurenic acid may have a protective 
role against IFN-α-induced depression. Kynurenic acid is an N-methyl-D-
aspartate (NMDA) receptor antagonist generally considered to be 
neuroprotective, and studies have shown depressed patients to have lower 
levels of kynurenic acid when compared to healthy controls (Myint et al., 2007). 
In IFN-α treated patients, several studies have investigated the effects of IFN-α 
on tryptophan metabolism and changes in kynurenine pathway metabolites 
(Bonaccorso et al., 2002b, Raison et al., 2010b, Wichers et al., 2005). However, 
this is the first study to assess the predictive effects of baseline levels of 
kynurenine and tryptophan pathway metabolites on the development of 
depression during IFN-α. My findings provide evidence for the potential use of 
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kynurenine pathway metabolites, in this case particularly kynurenic acid, as 
biomarkers for early detection of IFN-α-induced depression. 
 
4.5.3 Polyunsaturated fatty acids (PUFAs) 
I find a significant effect of higher baseline levels of the omega-6 PUFA, AA in 
predicting lower levels of subsequent depression during IFN-α treatment. This is 
in contrast to my hypothesis that higher levels of omega-6 fatty acids would be 
associated with more depressive symptoms, because of their presumed pro-
inflammatory action, and that higher levels of the anti-inflammatory omega-3 
fatty acids would be protective against depression. Few studies have previously 
investigated the role of PUFAs in IFN-α treated patients. One study has shown 
higher baseline levels of the omega-3 fatty acid DHA to be protective against 
the development of depression during IFN-α treatment (Su et al., 2010). A 
second study has shown an elevated ratio of omega-6 to omega-3 PUFAs to 
predict depression during IFN-α treatment (Lotrich et al., 2012). My findings do 
not support either of these studies and this may be due to some methodological 
differences. For example, the study by Su et al. was conducted in a Chinese 
population and so there may be some ethnic variances as well as cultural 
difference with respect to diet, when compared to my sample. Furthermore, Su 
et al. conducted PUFA analysis using erythrocytes whereas I measured PUFA 




4.5.4 Gene expression 
4.5.4.1 Hypothesis-free approach investigating baseline gene expression 
differences  
I investigated the role of gene expression changes in IFN-α-induced depression 
firstly using a hypothesis-free approach. Using a criteria of an absolute fold 
change of 1.4 and a p-value cut-off of p<0.005, I find 8 differentially expressed 
genes at baseline, in patients who later develop IFN-α-induced depression 
when compared to patients who do not develop IFN-α-induced depression. Of 
interest, there is lower expression of Glutathione S-transferase mu 4 (GSTM4) 
at baseline in patients who develop IFN-α-induced depression when compared 
to patients who do not develop IFN-α-induced depression. GSTM4 plays an 
important role in detoxifying various toxicants such as reactive oxygen species 
which are known to induce oxidative stress (Franco et al., 2007). This suggests 
that oxidative stress may be involved in the development of IFN-α-induced 
depression. Indeed, there is evidence that clinical depression and animal 
models of depression are accompanied by oxidative stress as well as 
nitrosative stress (Leonard and Maes, 2012, Maes et al., 2011). However, no 
studies have previously investigated this in IFN-α treated patients. 
 
To date, only three studies have investigated gene expression changes in 
relation to the development of IFN-α-induced depression (Birerdinc et al., 2012, 
Felger et al., 2012, Krueger et al., 2011). Only one of these studies specifically 
investigated differentially expressed genes at baseline which predict the 
development of IFN-α-induced depression (Birerdinc et al., 2012). The authors 
report an up-regulation of TNF receptor associated factor-6 (TRAF6) and a 
down-regulation of transforming growth factor beta-1 (TGF-β1). These two 
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genes were not within the list of 8 differentially expressed that I find in my 
sample. However, this may be due to the stringent fold change and p-value 
criteria that I used. Instead, I have investigated these genes in my hypothesis-
driven candidate gene approach. 
 
4.5.4.2 Hypothesis-free approach investigating gene expression changes 
during IFN-α treatment 
Of the other two gene expression studies investigating gene expression 
changes in relation to the development of IFN-α-induced depression, one study 
specifically identified genes which are differentially expressed as a result of IFN-
α administration (Felger et al., 2012). Specifically, the authors found differential 
expression of 368 genes at treatment week 12 of IFN-α treatment when 
compared to HCV patients who are not undergoing treatment. These genes 
were found to be involved in seventeen pathways including those related to 
antiviral and inflammatory responses such as interleukin-17 signalling, 
interferon signalling and communication between innate and adaptive immune 
cells pathway. In my sample, I also investigated IFN-α-related changes in gene 
expression and I find a total of 516 genes, belonging to five pathways, to be 
differentially expressed at treatment week 4 when compared to baseline. Of 
interest, the “mitogen-activated protein kinase” (MAPK) pathway and the 
“neurotrophin signalling pathway” were both down-regulated. MDD may also 
involve an inability of neuronal systems, especially under stress conditions, to 
show adaptive plasticity, a mechanism known as neuronal plasticity (Pittenger 
and Duman, 2008). Molecular correlations underlying the mechanisms of the 
stress response involve the regulation of several neurotrophic factors, such as 
brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic 
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factor (GDNF) and neurotrophin-3 (NT-3), all of which have been previously 
found to be reduced in MDD patients (Cattaneo et al., 2010, Otsuki et al., 2008, 
Pandey et al., 2011). Furthermore, it has been demonstrated that the protective 
function of BDNF is dependent on MAPK, and inhibition of MAPK activity blocks 
the neuroprotective effects of BDNF (Yang et al., 2012). This down-regulation of 
BDNF as a result of reduced MAPK activity can also be reversed through the 
use of antidepressants (Qi et al., 2009). As such, the down-regulation of these 
two pathways, early on in the course of IFN-α treatment, may be important for 
the development of depression. 
 
The study by Felger et al. also provides evidence for gene expression changes 
upon IFN-α administration that are associated with depression development. 
Specifically, they report an up-regulation of 2’-5’-oligoadenylate synthetase 2 
(OAS2), a gene linked to chronic fatigue syndrome, to be differentially 
expressed in patients with IFN-α-induced depression or fatigue, and to correlate 
with depression and fatigue scores at treatment week 12. The third previous 
gene expression study in IFN-α treated patients, also found evidence for gene 
expression changes upon IFN-α administration that were associated with 
depression development. Specifically, IL-10 levels were found to be decreased 
in depressed patients and increased in non-depressed patients at treatment 
week 4 when compared to baseline (Krueger et al., 2011). Interestingly, the 
authors also report a non-significant reduction in IL-1β expression in both 
patient groups at treatment week 4 when compared to baseline.  
 
Based on these findings, I also investigated gene expression changes from 
baseline to treatment week 4 in patients with and without IFN-α-induced 
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depression. I find 442 genes to be modulated by IFN-α only in patients who 
develop IFN-α-induced depression. In contrast only 46 genes were modulated 
only in patients who did not develop IFN-α-induced depression. Of note, these 
are predictive changes and are not linked to a presence of depression, as only 
4 out of the 19 depressed patients were already depressed at treatment week 4. 
This indicates that patients, who subsequently develop IFN-α-induced 
depression, are more biologically sensitive to the effects of IFN-α. Similarly, in a 
recent gene expression study, MDD patients have been shown to be less 
sensitive to the effects of dexamethasone when compared to healthy controls, 
indicating increased GR resistance (Menke et al., 2012). 
 
Pathway analysis of the 442 genes modulated by IFN-α only in patients who 
develop IFN-α-induced depression, shows these genes to belong to eight 
pathways. Of interest, the “Janus kinase-signal transducers and activators of 
transcription” (JAK-STAT) signalling pathway is up-regulated. Acutely, IFN-α 
binds to type-I IFN receptors expressed on immune cells, activating JAK-STAT 
and tyrosine kinase signalling, which then increases the expression of cytokines 
and immunoregulatory genes (Felger et al., 2012). Furthermore, IFN-α-induced 
activation of JAK-STAT signalling is thought to reduce GR-mediated 
transcription thus causing impaired GR function (Hu et al., 2009, Pace et al., 
2011). “Natural killer cells mediated cell cytotoxicity”, which is an immune 
response related pathway, is also up-regulated at treatment week 4 when 
compared to baseline in patients with IFN-α-induced depression. It has been 
recently reported that the induction of cytotoxic natural killer cell function by 
IFN-α, correlates with viral response to therapy (Ahlenstiel et al., 2011). An 
association between activation of this pathway with depression development 
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during IFN-α treatment has not been previously reported. However, there is 
evidence indicating an activation of natural killer cell activity, in association with 
stress and depression development, in co-morbidity with other infectious 
diseases such as HIV (Cruess et al., 2005). Increased natural killer activity has 
also been demonstrated in MDD patients following the Trier Social Stress Test 
(Pace et al., 2006). 
 
Finally, “phosphatidylinositol” (PIP) signalling system and “long term 
potentiation” (LTP) signalling are both down-regulated at treatment week 4 
when compared to baseline in patients who develop IFN-α-induced depression. 
Both of these signalling pathways are involved in neuronal plasticity, which as 
mentioned earlier refers to the ability of the nervous system to respond and 
adapt to environmental challenges (Pittenger and Duman, 2008). However, in a 
broader sense, neuronal plasticity is intimately linked to cellular responsiveness, 
and failure of such mechanisms might enhance the susceptibility to 
environmental challenges, such as stress, and ultimately lead to 
psychopathology. Indeed, in various brain regions, structural and synapse-
related findings seem consistent with a deficit in LTP in depression (Marsden, 
2013). Furthermore, there is a wealth of evidence indicating a reduction in 
various neurotrophic factors in the plasma and serum, and more recently in 
gene expression of MDD patients (Cattaneo et al., 2010, Otsuki et al., 2008, 
Pandey et al., 2011). The lower expression of both LTP and PIP signalling that I 
find at treatment week 4 in patients who subsequently develop IFN-α-induced 
depression may thus indicate one of the substrates of vulnerability for 




4.5.4.3 Hypothesis-driven candidate gene approach investigating baseline 
gene expression differences 
I also investigated candidate genes belonging to 4 important and interlinked 
domains: tryptophan metabolism, PUFA metabolism, inflammation, and 
neuroplasticity. I firstly investigated baseline gene expression differences in 
patients with and without subsequent IFN-α-induced depression. Patients who 
develop IFN-α-induced depression have significantly lower expression of 
indoleamine 2,3-dioxygenase 1 (IDO1) and kynureninase (KYNU) at baseline 
compared to patients who do not develop IFN-α-induced depression. This is 
theoretically in contrast to previous findings of increased IDO activity upon IFN-
α administration (Bonaccorso et al., 2002b, Wichers et al., 2005). However, 
these studies did not investigate baseline IDO activity, and also IDO activity is a 
functional measure while here I am measuring the expression of the gene, all of 
which may explain the difference in my findings. 
 
Patients who develop IFN-α-induced depression have significantly higher 
expression of interleukin-28 beta (IL-28β) at baseline when compared to 
patients without IFN-α-induced depression. Recent genome-wide association 
studies have specifically identified polymorphisms in the IL-28β gene to be 
predictive of IFN-α treatment response (Ge et al., 2009). Interestingly, only one 
study has investigated the association between a polymorphism in the IL-28β 
gene and side-effects during IFN-α treatment. The authors report the C allele of 
the rs1297860 polymorphism to be associated with both improved treatment 
response as well as more somatic complaints (Lotrich et al., 2011). Studies of 
other IL-28β polymorphisms have also shown treatment response-favourable 
genotypes to be associated with higher expression of IL-28β (Suppiah et al., 
272 
 
2009). As such it is possible that higher expression of IL-28β, also as a 
consequence of these genetic variants, may confer vulnerability to the 
development of neuropsychiatric effects during IFN-α treatment.  
 
Patients who develop IFN-α-induced depression also have significantly higher 
expression of interleukin-1 alpha (IL-1α) and interleukin 4 (IL-4) at baseline 
when compared to patients who do not develop IFN-α-induced depression. IL-
1α is a pro-inflammatory cytokine and its expression has been previously shown 
to be up-regulated in the prefrontal cortex of MDD patients (Shelton et al., 
2011). Furthermore, in cells, IL-1α has been shown to inhibit GR function (Wang 
et al., 2004). Indeed, reduced GR function coupled with high levels of cortisol 
are indicators of HPA axis dysfunction and are some of the most consistent 
biological findings in depression (Pariante and Lightman, 2008). It is surprising 
that I find an increased expression of IL-4 at baseline in patients with 
subsequent IFN-α-induced depression, as IL-4 is an anti-inflammatory cytokine. 
However, it is possible that this up-regulation may be in response to the 
increase in other cytokines such IL-1α. Lastly, patients who develop IFN-α-
induced depression have significantly lower expression of TRAF6 at baseline 
when compared to patients who do not develop IFN-α-induced depression. This 
is in contrast to the previous study by Birerdinc et al. who reported that pre-
treatment up-regulation of TRAF6 predicted the development of depression 
during IFN-α treatment (Birerdinc et al., 2012).  
 
Patients who develop IFN-α-induced depression have significantly lower 
expression of NR3C1 (GR) at baseline. Lower expression levels of GR and GR-
related molecules in peripheral blood have been previously demonstrated in 
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MDD patients, particularly in those in a current depressive state (Cattaneo et 
al., 2012, Fujimoto et al., 2008, Katz et al., 2012). As mentioned, above IFN-α is 
thought to reduce GR-mediated transcription, thus causing impaired GR 
function, via the activation of JAK-STAT signalling (Hu et al., 2009, Pace et al., 
2011). However, my study is the first to provide evidence indicating there may 
already be impaired GR function prior to starting IFN-α treatment, and this may 
confer vulnerability to develop IFN-α-induced depression.  
 
Finally, there were no significant differences between patients with and without 
IFN-α-induced depression, in their baseline expression of genes related to 
PUFA metabolism. This may also explain the lack of differences I find in plasma 
levels of PUFAs between the two groups. 
 
4.5.4.4 Hypothesis-driven candidate gene approach investigating gene 
expression changes during IFN-α treatment 
I then compared changes in the expression of these candidate genes from 
baseline to treatment week 4 in the two patient groups. Patients without IFN-α-
induced depression have a lower expression of indoleamine 2,3-dioxygenase 2 
(IDO2) at treatment week 4 when compared to baseline, whereas there is not 
significant change in patients with IFN-α-induced depression. As such, it is 
possible that there is a difference in the two groups in their breakdown of 
tryptophan. There may also be a difference in the subsequent metabolites 
produced as end products of this breakdown. Specifically, patients with IFN-α-
induced depression could have a higher synthesis of quinolinic acid when 
compared to patients without IFN-α-induced depression. Indeed, IFN-α-induced 
increases in quinolinic acid have been shown to be associated with increased 
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depression scores (Raison et al., 2010b). However, quinolinic acid was not 
measured in my sample and so this association warrants further investigation. 
 
Although there are no differences in the expression of PUFA related genes at 
baseline between patients with and without IFN-α-induced depression, there are 
IFN-α related changes in the expression of these genes. Both patients with and 
without IFN-α-induced depression have significantly higher expression of fatty 
acid desaturase 2 (FADS2) at treatment week 4 when compared to baseline. 
FADS2 is an enzyme causing desaturation of fatty acids, and its expression has 
been previously shown to be elevated in bipolar disorder patients as well as 
schizophrenia patients (Liu et al., 2009, Liu and McNamara, 2011). However, 
both patients with and without IFN-α-induced depression also have significantly 
lower expression of cyclooxygenase 1 (COX1) at treatment week 4 when 
compared to baseline. COX1 is involved in the conversion of the omega-6 
PUFA arachidonic acid (AA) to prostaglandin E2 (PGE2) (Botting, 2006). As 
such, it is not only involved in PUFA metabolism but also inflammation. It is 
surprising that COX1 expression is decreased at treatment week 4 when 
compared to baseline as previous studies have shown an over expression of 
the other isoform of COX, cyclooxygenase 2 (COX2), in MDD patients when 
compared to healthy controls (Galecki et al., 2012). Although genetic 
polymorphisms in the COX2 gene have been previously shown to be associated 
with IFN-α-induced depression (Su et al., 2010), the expression levels of other 
COX isoforms have not been previously investigated in these patients and thus 




Both patients with and without IFN-α-induced depression have significantly 
lower expression of interleukin 1 beta (IL-1β), interleukin 1 receptor type 1 (IL-
1R1) and interleukin 6 receptor (IL-6R) at treatment week 4 when compared to 
baseline. Moreover, not only is this down-regulation significant, but the fold 
changes are also substantial in both patient groups. This is in contrast to 
previous studies where increased levels of IL-1β and IL-6 have been 
demonstrated in MDD patients as compared with controls (Dowlati et al., 2010, 
Howren et al., 2009), and in IFN-α treated patients (Bonaccorso et al., 2002b, 
Loftis et al., 2008). However, the lower expression of IL-1β is in line with the 
abovementioned gene expression study by Krueger et al. Although not 
significant, they also find lower expression IL-1β at treatment week 4 in both 
depressed and non-depressed patients. Of note, patients with IFN-α-induced 
depression also have significantly lower expression IL-4 at treatment week 4 
when compared to baseline, whereas the expression of IL-4 in patients without 
IFN-α-induced depression does not change. As mentioned previously, IL-4 is an 
anti-inflammatory cytokine and so the down-regulation I find only in patients with 
IFN-α-induced depression suggests that it may be protective against the 
development of IFN-α-induced depression. Patients with IFN-α-induced 
depression also have higher expression of interleukin 18 (IL-18) at treatment 
week 4 when compared to baseline, whereas the expression of IL-18 is 
unchanged in patients without IFN-α-induced depression. IL-18 is a pro-
inflammatory cytokine and has been previously found to be elevated in the 
plasma and serum of depressed patients (Kokai et al., 2002, Merendino et al., 
2002). Furthermore, IL-18 is not only produced by cells of the immune system 
but it is also found in endocrine tissues such as the adrenal and pituitary glands 
(Sugama and Conti, 2008). As such, IL-18 may be involved in the 
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pathophysiology of IFN-α-induced depression via both inflammation and stress 
pathways. Finally, patients with IFN-α-induced depression also have higher 
expression of TGFβ-1 at treatment week 4 when compared to baseline, 
whereas the expression of TGFβ-1 is not significant changed in patients without 
IFN-α-induced depression. Again, this is in contrast to the findings from 
Birerdinc et al. who report pre-treatment down-regulation of TGFβ-1 predicted 
the development of depression during IFN-α (Birerdinc et al., 2012). However, 
the authors only investigated pre-treatment gene expression whereas I have 
looked at the change in TGFβ-1 as a result of IFN-α administration.  
 
Patients without IFN-α-induced depression have lower expression of NR3C1 
(GR) at treatment week 4 when compared to baseline. This is also surprising as 
I had hypothesised reduced expression of genes involved in GR functionality to 
be predictive of IFN-α-induced depression. However, it must be noted that 
patients who develop IFN-α-induced depression already have lower expression 
of NR3C1 at baseline when compared to patients who do not develop IFN-α-
induced depression. As such, patients without IFN-α-induced depression 
display a lower expression of NR3C1 at treatment week 4 when compared to 
baseline; it may be the baseline difference that plays a more important role and 




4.6 Clinical predictors of fatigue, stress and anxiety during IFN-α 
treatment 
Although the main focus of this thesis is the identification of factors contributing 
to the development of depression during IFN-α treatment, I also investigated 
predictors of other outcomes, such as fatigue, stress and anxiety.  
 
4.6.1 Baseline psychopathology 
Interestingly, baseline depression has a significant effect on subsequent stress 
and anxiety scores even after adjusting for baseline depression scores. This 
provides further evidence for the importance of baseline psychopathology, and 
indicates that it does not only confer vulnerability to depression development 
but also to the development of other symptoms during IFN-α treatment. 
 
4.6.2 Baseline health status 
When looking at the effects of baseline health status and well-being, better 
general health status is predictive of lower fatigue and lower stress scores 
during IFN-α treatment. Many of the health status and well-being dimensions 
measured are also predictive of subsequent anxiety scores. Specifically, having 
more energy, better mental health, better social functioning, less bodily pain and 
better general health at baseline are all predictive of lower subsequent anxiety 
scores. These data highlight the importance of not only monitoring health 
outcomes during and after IFN-α treatment, but actually assessing these prior to 
commencing treatment in order to identify more vulnerable individuals, not only 




4.6.3 Cognitive predictors  
There are significant predictive effects of illness perceptions on fatigue, stress 
and anxiety scores. Specifically, believing your illness to be more serious and 
with more consequences, and assigning more emotional representations to 
your illness, are all predictive of higher fatigue scores. Having more emotional 
representations is also predictive of higher subsequent stress scores. Anxiety 
scores are also predicted by the timeline, consequences, timeline cyclical, and 
emotional representations dimensions of the illness perceptions questionnaire. 
Additionally, there is an effect of the personal control dimension whereby having 
stronger beliefs about one’s own ability to control their symptoms is predictive of 
lower subsequent anxiety scores. Taken together, this is further evidence to 
support the notion that identifying negative thinking, and encouraging and 
improving positive illness beliefs, could provide individuals with more adaptive 
cognitive models and expectations, and improve outcomes. Indeed, in other 
populations, interventions aimed at changing illness perceptions have been 
shown to improve functional health outcomes (Petrie et al., 2002).  
 
4.6.4 Psychosocial stressors 
There are no significant effects of psychosocial stressors on stress, fatigue or 
anxiety scores. However, this may again be due to the higher prevalence of 
childhood trauma seen in my sample compared to the general population as 
discussed earlier. 
 
4.6.5 Other predictors 
There is a strong predictive effect of a history of MDD on subsequent stress and 
anxiety scores. There is also a significant predictive effect of ethnicity on 
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subsequent fatigue scores. Specifically, being from a white British background 
is predictive of higher fatigue scores during IFN-α treatment. Relatively few 
studies have examined fatigue levels among different ethnic groups, none in 
IFN-α patients. Most evidence points towards increased fatigue in minority 
groups (Jason et al., 1999, Torres-Harding et al., 2008). In my study, the results 
show the opposite effect; however, this may be due to the fact that the sample 
is predominantly of a white British background. Furthermore, due to the smaller 
number of individuals from a variety of different ethnic backgrounds, I 
dichotomised ethnicity in to white British versus all others. This may also 
contribute to the opposite results seen in my sample. 
 
4.7 Biological predictors of fatigue, stress and anxiety during IFN-α 
treatment 
4.7.1 HPA axis 
A larger increase of cortisol from awakening at 60 minutes after awakening, 
significantly predicts higher subsequent stress scores. This is again in keeping 
with the data from Capuron et al. who also found the cortisol response to the 
first injection of IFN-α to be associated with anxiety symptoms at treatment 
week 8 (Capuron et al., 2003b). This is further indication that hyper-reactivity of 
the HPA axis may be a risk factor for IFN-α-induced neuropsychiatric effects. 
Also in line with the findings for depression, higher baseline cortisol levels at 
noon as well as a larger AUC for cortisol during the day are also predictive of 
lower fatigue scores. This is again in contrast to previous studies which have 
found increased cortisol output in the day to be associated with IFN-α-induced 
increases in fatigue as well as depression (Raison et al., 2008, Raison et al., 
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2010a). However, as outlined above, the study by Raison et al. did not 
investigate specifically the association between baseline cortisol and the 
subsequent development of IFN-α-induced symptoms. 
 
4.7.2 Kynurenine and tryptophan pathway 
A higher baseline level of kynurenic acid is also predictive of lower subsequent 
fatigue and stress scores during IFN-α treatment. Further to its actions at 
receptors, kynurenic acid also has antioxidant properties and can inhibit 
oxidative stress (Lugo-Huitron et al., 2011). Interestingly, there is emerging 
evidence to suggest oxidative stress levels contribute to the pathophysiology 
and clinical symptoms of conditions such as chronic fatigue syndrome (Kennedy 
et al., 2005, Logan and Wong, 2001). This may explain the association I find 
between higher levels of kynurenic acid at baseline and lower levels of fatigue. 
There is also evidence that clinical depression is accompanied by oxidative 
stress (Leonard and Maes, 2012). Taken together, it is possible that higher 
baseline levels of kynurenic acid may be involved in the reduction of oxidative 
stress and consequently be associated with lower levels of depression and 
fatigue. 
 
4.7.3 Polyunsaturated fatty acids (PUFAs) 
A higher baseline level of the omega-3 PUFA alpha-linolenic acid (ALA) is 
predictive of lower subsequent stress scores. Indeed, in a clinical trial, 
administration of ALA has been shown to reduce self-reported stress levels as 
well as cortisol levels in a group of otherwise healthy college students (Yehuda 
et al., 2005). I do not find any other associations between baseline PUFA levels 
and fatigue, stress or anxiety scores during IFN-α treatment.  
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4.7.4 Gene expression 
To limit potential false positive findings due to the high number of variables and 
multiple testing required for the gene expression analyses, I decided to focus 
only on gene expression in relation to depression. 
 
4.8 Current clinical practice 
The qualitative part of this study investigates how clinical nurse specialists 
currently identify and monitor patient risk factors before and during IFN-α 
treatment, and make decisions on the appropriate course of action in order to 
control these risks. The results provide valuable insights into the complex 
clinical processes that take place and also reveal the multifaceted nature of risk 
factors staff are presented with and must assess within limited resources. There 
are two main findings that I will discuss. 
 
Firstly, all clinical nurse specialists employ a combination of verbal and non-
verbal cues to gather information about patients’ status on all psychological, 
biological and social dimensions. Staff frequently mention ‘eye contact’ with 
patients as a useful indicator, although more subtle and intangible cues 
including ‘changes in behaviour’ and ‘general demeanour’ are also described as 
important. Recognition of depressive symptoms is therefore made possible 
partially by building up familiarity and good rapport with patients over time. The 
importance of the patient-health professional relationship on both medical and 
psychosocial outcomes is also highlighted by a previous qualitative study 




Secondly, certain risk factors, for example, past mental health history, current or 
past use of medications such as antidepressants, current or past depression 
and level of available social support are almost unanimously recognised as 
important. This is in keeping with previous research which has also highlighted 
the importance of a history of mood disorders (Fontana et al., 2002) and social 
support (Evon et al., 2011), in vulnerability to IFN-α-induced depression. 
Interestingly, the importance of social support is also in keeping with previous 
research based on patients’ own experiences of Hepatitis C (Erim et al., 2010, 
Glacken et al., 2001). Other factors, as highlighted by Table 3.48 and Table 
3.49, are also taken into consideration and allow for a holistic approach. 
However, there is variability among nurses in their use of other information and 
this may in part be due to the current lack of available guidelines.  
 
In accordance with Naturalistic Decision Making (NDM) studies of experts in 
other domains, these findings suggest that staff base their judgements and 
decisions on intuition, drawing on their past experience to recognise patterns 
and identify risks (Bowers et al., 1990, Klein, 1998). Decisions are not an end 
point in the process of care, but occur as an on-going process of gathering 
information, planning and taking action as necessary. Staff see these patterns 
as subtle and often cannot describe precisely how they gather information or 
judge a situation as typical. As other studies suggest, intuition can be a highly 
efficient mode of decision making in limited-resource and time-critical 
environments (Currey and Botti, 2003, Xiao et al., 1997). However, accounts of 
adverse events and multiple sources of uncertainty also illuminate the fact that 
staff recognise the need for further support for enhancing the accuracy of 
clinical judgements. The lack of guidelines for prioritizing actions in current 
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clinical practice results in uncertainty and means that nurses rely on a 
combination of knowledge, intuition, experience and team support.  
 
An additional point this study raises is that organisational and team processes 
are important in supporting nursing staff’s decision making. This is supported by 
a previous study, which reported significantly greater adherence to antiviral 
therapy in a clinic based on an integrated mental health and medical approach 
(Knott et al., 2006). On the other hand, in the two hospitals with liaison 
psychiatry services, nurses report a tendency to over-rely on liaison 
psychiatrists, which may exceed the optimal level of referrals. Development of 
support aids could improve the accuracy of referrals, and therefore the 
effectiveness of clinical services for hepatitis C patients receiving IFN-α 
treatment. Finding the balance between precaution and overreliance on 
psychiatrists is identified by staff as a potential area for improvement. To this 





4.9 Methodological considerations 
There are a few methodological considerations and study limitations that need 
to be considered in the interpretation of the findings. Regarding the study in 
IFN-α patients, firstly blood samples were non-fasting and time of blood 
sampling was not standardised across the sample. This may be of particular 
importance for the PUFA measurements as they could be affected by diet. 
However, patients were always seen and assessed at their routine clinic 
appointments which were either in morning clinics or in afternoon clinics. As 
such, the blood samples for each patient would have been taken in the same 
clinic at every time point, therefore minimising some of the potential 
confounding effects. 
 
Second, I did not collect information about viral illness onset or duration of 
untreated HCV infection. This may be of particular importance with regards to 
the illness perceptions findings, as there may be differences between 
individuals who have had a more recent diagnosis when compared to those 
who have had a longer duration of illness. 
 
Third, the sample size is relatively small; however, it must be said that this is an 
extremely difficult group of patients to recruit, and great effort was made to 
increase recruitment and capture as many patients as possible. Despite 
increasing the number of study sites, the vast majority of patients who were 
starting IFN-α treatment were not eligible for this study due to a number of 
exclusions specified in the study design. For example, in the first year of 
recruitment, at one site alone, approximately 180 patients were screened and 
only 20 were eligible and recruited. Further to the exclusion criteria, due to the 
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fact recruitment took place at teaching hospitals, a large number of patients 
were also enrolled in to clinical trials using different treatment regimens to the 
standard combination therapy with IFN-α and ribavirin, as such these patients 
were also not eligible to take part in this study. Moreover, given the complexity 
of the assessments, not all participants completed the salivary cortisol 
collection, therefore further decreasing the power of the statistical analyses for 
this data. This should be taken into consideration when interpreting the data 
presented. 
 
Fourth, in this study I did not investigate changes in serum cytokine levels. 
However, I did conduct a pilot study using two different cytokine multiplex 
assays (Luminex and Randox) in approximately 15 samples. These analyses 
showed no significant changes in cytokine levels upon IFN-α treatment and in 
fact many of the samples were undetected using these assays. As such, I 
decided to focus on the changes in the gene expression levels of cytokines. For 
future work, I aim to measure serum cytokine levels based on the most 
significant gene expression findings from this PhD thesis. 
 
Moreover, a fifth limitation of this study is that the analyses in this thesis were 
not corrected for multiple testing and therefore there is a potential for increased 
type 1 error especially given the large number of predictors (around 55) and 
outcomes (around 30) that were analysed. However, it is important to stress 
that when investigating the predictive effects, I only focus on 5 major outcomes 
(depression diagnosis, depression scores, fatigue scores, stress scores and 
anxiety scores). Microarray gene expression analysis, by its very nature, also 
includes a large number of variables (individual genes) but strict p-value and 
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fold change criteria were used, and I only investigated gene expression 
changes in relation to one outcome variable - depression status. Furthermore, 
by conducting pathway analysis, the number of variables was reduced into 
biologically meaningful findings. 
 
A sixth limitation of the study is that the baseline assessment was conducted on 
the first day of treatment, immediately before the first administration of IFN-α. 
As such, it is possible that some of the baseline psychopathological ratings may 
have been affected by patients’ concerns and anxieties surrounding starting 
IFN-α treatment. A baseline assessment that is more remote from the beginning 
of therapy initiation may be more appropriate.  
 
Finally, there was no control or placebo group used within this study. However, 
the main aim of this study was not to test the depressive effect of IFN-α, as this 
is a well-established model, but instead to identify novel predictors for the 
development of this depression. As such, I used patients who did not develop 
IFN-α-induced depression as the comparison group against patients who did 
develop IFN-α-induced depression. Although some placebo control studies 
have been conducted in the past, it would be unethical to do so now. Instead 
the effects of IFN-α can be investigated by comparing patients who are 
undergoing treatment with their own pre-treatment assessments. Furthermore, 
given that all study assessments (including the collection of blood samples) 
were conducted alongside routine clinic appointments, it would be quite difficult 
to obtain the same wealth of data from HCV infected patients who were not 




With regards to the qualitative study conducted in clinical nurse specialists, 
limitations include the demographic profile of the three metropolitan, teaching 
hospitals, which may not be representative of other hospitals. Given that all 
three hospitals are located in London, the issue of language barriers may be 
particularly prevalent in this study, and not elsewhere. The relatively small 
number of participants in this study also raises the question of transferability of 
our findings to other settings. However, given the focus of this study on a 
relatively homogeneous professional group with special expertise (Guest et al., 
2006), it is likely that even with a small sample the most important factors 
affecting decision making were identified and that the results are generalisable 




4.10 Integration of the findings and implications for clinical  
practice and future research 
Despite some methodological limitations, this study still provides several lines of 
evidence for the impact of IFN-α on behaviour and the mechanisms involved. 
The findings have implications for clinical practice and provide evidence for 
potential therapeutic targets for treating and preventing depression.  
 
For example, the pathway analysis of my gene expression data provides 
evidence for the activation of JAK-STAT signalling pathways specifically in 
patients who develop IFN-α-induced depression. Furthermore, I find a lower 
expression of GR already at baseline in patients who later develop IFN-α-
induced depression when compared to patients who do not. As such, therapies 
which either block cytokine signalling pathways including JAK-STAT and/or 
increase GR function could be a point of potential intervention. The higher 
expression of IL-28β in patients who later develop depression when compared 
to those who do not could also be of clinical-relevance as a predictive 
biomarker. Moreover, whilst gene expression analyses may not be clinically 
practical, IL-28β genotyping is now routinely conducted in patients due to 
commence IFN-α treatment in order to assess likelihood of treatment response. 
As such, the association between IL-28β and the development of depressive 
symptoms warrants further investigation as there is a possibility to implement 
these findings, at least in this population. Future microarray studies with larger 
samples are needed to replicate the multitude of gene expression changes 





I also find evidence for a predictive effect of baseline kynurenic acid levels on 
the development of depression. Kynurenic acid levels could be used as a 
biomarker for the identification of at risk individuals, and aid clinicians in their 
decision to use antidepressants, or other interventions, prophylactically. Indeed, 
tryptophan metabolism involves crosstalk between different systems in the 
periphery and the central nervous system, as such the use of peripheral 
biomarkers as indirect evidence of central changes for diagnostic and 
prognostic purposes is not unrealistic. Interestingly, IDO is known to be 
activated by inflammation and oxidative stress and inhibited by the anti-
inflammatory cytokine IL-4. In this study, I show that patients who develop IFN-
α-induced depression have decreased expression of GSTM4, which plays an 
important role in detoxifying reactive oxygen species and therefore potentially in 
activating IDO. These patients also show decreased expression of IL-4 at 
treatment week 4 when compared to baseline, which again would lead to 
increased IDO activation. These findings provide evidence for the involvement 
and interaction of different biological processes in the development of IFN-α-
induced depression. It is important to note that tryptophan metabolism takes 
place mainly in the liver and so the involvement of this pathway may be of 
particular relevance to depression development in the context of medical 
disorders, especially if affecting liver function. 
 
Baseline depression is an important contributor to the development of IFN-α-
induced depression. As such, psychotherapeutic strategies or alternative 
medicine approaches which may serve to reduce stress and anxiety may be a 
possible preventative strategy in this and other forms of depression in the 
context of medical disorders. In this study, I also find consistent evidence for a 
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predictive effect of negative illness perceptions, not only for the development of 
depression, but also for other neuropsychiatric symptoms. This finding also 
provides evidence for the potential use of psychotherapeutic strategies within 
current clinical practice, such as preventative cognitive based interventions, for 
depression in the context of medical disorders. As this is the first study to 
investigate the role of illness perceptions in patients receiving IFN-α treatment, 
of course future studies would need to confirm this association. 
 
Of specific relevance to the clinical management of this population, the findings 
of this study also demonstrate that a history of MDD, alone does not predict the 
development of IFN-α-induced depression. This is of particular importance as 
previously in some cases, treatment has been withheld from patients with a 
psychiatric history. Moreover, the findings from the qualitative study show a 
history of psychiatric illness to be consistently considered as a risk factor by 
clinical nurse specialists. Findings from this and similar studies need to be 
incorporated into clinical guidelines and in to the training of nurses and clinic 




In conclusion, the findings of this study provide evidence for a number of 
cognitive, psychosocial and biological predictors of IFN-α-induced depression. 
In particular, negative illness perceptions consistently predict the development 
of IFN-α-induced depression as well as other neuropsychiatric symptoms. 
These findings provide a rationale to test the effect of preventative cognitive 
interventions in these patients. Furthermore, the findings of this study also 
indicate that lower baseline levels of kynurenic acid could be a biomarker and 
predictor of IFN-α-induced depression. Finally, the findings of the qualitative 
study highlight that detection and management of depression in this population 
is complex, and relies on the availability of clinical experts and good 
communication within a multidisciplinary team. Together, our observations may 
prove useful in the future development of clinical guidelines, biomarker tools 
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Social Data Schedule 
     
1) Sex 
 0  Male  
1  Female      
 
 
2) Date of birth 
 
 
3) Age                            
 
4) From the list below, how would you describe your ethnicity? 
0  White British 
1  Mixed 
2  Indian 
3  Pakistani 
4  Bangladeshi 
5  Other Asian 
6  Black Caribbean 
7  Black African 
8  Black Other 
9  Chinese 








5) Where did you live for the first 16 years of your life, starting with the place you were born? 






6) With whom do you live now? 
0 Alone 
1 Alone, with children 
2 Partner/Spouse 
3 Partner/Spouse and children 
4 Parents                
5 Other family 
6 Friends 
7 Other (specify) 
…..........................................................................................................................            
7) With whom did you live one year ago? 
0 Alone 
1 Alone, with children 
2 Partner 
3 Partner and children 
4 Parents                
5 Other family 
6 Friends 
7 Other (specify) 
….......................................................................................................................... 
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8) With whom did you live five years ago? 
0 Alone 
1 Alone, with children 
2 Partner 
3 Partner and children 
4 Parents                
5 Other family 
6 Friends 
7 Other (specify) 
….......................................................................................................................... 
                 
9) Since leaving your parents’ home, have you ever lived with others? 
 0  No 
1  Yes      
 
10) What is your relationship status now?  
0 Single 
1 Married/Living with someone                                                     
2 In steady relationship 
3 Divorced, Separated 
4 Widowed 
 
11) What was your relationship status one year ago?  
0 Single 
1 Married/Living with someone                                                     
2 In steady relationship 





12) What was your relationship status five years ago?  
0 Single 
1 Married/Living with someone                                                     
2 In steady relationship 
3 Divorced, Separated 
4 Widowed 
 
13) Have you ever been in a long-term relationship (1 or more years)? 
 0  No  
1 Yes      
 
14) What was the highest level of education you reached?  
0 No qualifications 
1 GCSE/O’ levels 
2 A’ levels 
3 Vocational/college (B. Tecs/NVQs etc.) 
4 University/Professional Qualifications 
 
15) Are you employed now? 
0 No, unemployed 
1 No, student 
2 Yes, full-time 
3 Yes, part-time 
 
16) Were you employed one year ago? 
0 No, unemployed 
1 No, student 
2 Yes, full-time 





17) Were you employed five years ago? 
0 No, unemployed 
1 No, student 
2 Yes, full-time 
3 Yes, part-time 
 
18) Have you ever been employed? 
 0  No 
1  Yes      
 
19) What is your first language? 
 0 English 





MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW 
 
 
MAJOR DEPRESSIVE EPISODE 
(      MEANS: GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC  
BOXES, AND MOVE TO THE NEXT MODULE) 
 
A1 Have you ever been consistently depressed or down, most of the day, nearly    NO YES 
 every day, for the past two weeks? 
 
A2 In the past two weeks, have you been less interested in most things or less    NO YES 
 able to enjoy things that you used to enjoy most of the time? 
 
 IS A1 or A2 CODED YES?         NO YES 
 
A3 Over the past two weeks, when you have depressed or uninterested: 
  
a. Was your appetite decreased or increased nearly every day? Did   NO YES 
your weight decrease or increase without trying intentionally (i.e.,  
by ±5% of body weight or ±8 Ibs. or ±3.5: kgs., for a 160 lb./70 kg.  
person in a month)? 
 
b. Did you have trouble sleeping nearly every night (difficulty   NO YES 
falling asleep, waking up in the middle of the night, early morning  
wakening or sleeping excessively)? 
 
c. Did you talk or move more slowly than normal or were you fidgety,  NO YES 
restless or having trouble sitting still almost every day? 
 
d. Did you feel tired or without energy almost every day?   NO YES 
 
e. Did you feel worthless or guilty almost every day?   NO YES 
 
f. Did you have difficulty concentrating or making decisions    NO YES 
almost every day?   
  
g. Did you repeatedly consider hurting yourself, feel suicidal, or wish   NO YES  
that you were dead?  
 
A4 ARE 3 OR MORE A3 ANSWERS CODED YES?  






IF PATIENT MEETS CRITERIA FOR MAJOR DEPRESSIVE EPISODE CURRENT: 
 
A5  
During your lifetime, did you have other periods of two    NO YES 
weeks or more  when you felt depressed or uninterested in  
most things, and had most of the problems we just talked about? 
 
b. Was there an interval of at least 2 months without  
depression/loss of  interest between your current episode and  




IS A5b CODED YES?  
 









MAJOR DEPRESSIVE EPISODE WITH MELANCHOLIC FEATURES 
(      MEANS: GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
IF THE PATIENT CODES POSITIVE FOR A CURRENT DEPRESSIVE EPISODE (A4 = YES), 
EXPLORE THE FOLLOWING: 
 
A6 a. IS A2 CODED YES?      NO YES  
 
 b. During the most severe period of the current depressive episode,  NO YES
 did you lose your ability to respond to things that previously gave  
     you pleasure, or cheered you up? 
 
IF NO: when something good happens, does it fail to make you feel better, even temporarily? 
 
IS EITHER A6a or A6b CODED YES?     NO YES  
 
A7 Over the past two week period, when you felt depressed and uninterested: 
 
a. Did you feel depressed in a way that is different from the    NO YES 
kind of feeling you experience when someone close to you dies? 
 
b. Did you feel regularly worse in the morning, almost every day?  NO YES 
 
c. Did you wake up at least 2 hours before the usual time of    NO YES 
awakening and have difficulty getting back to sleep almost every day? 
 
d. IS A3c CODED YES (RETARDATION OR AGITATION)?  NO YES 
 
e. IS A3a CODED YES (ANOREXIA OR WEIGHT LOSS)?   NO YES 
 
f. Did you feel excessive guilt or guilt out of proportion to the reality of  NO YES 




ARE 3 OR MORE A7 ANSWERS CODED YES? 
NO  YES 
Current Major Depressive 





(      MEANS: GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT 
MODULE) 
 
IF PATIENT’S CURRENTLY MEET CRITERIA FOR MAJOR DEPRESSIVE EPISODE, DO NOT 




B1 Was this period interrupted by your feeling OK for two months or more? NO YES 
 
B3 During this period of feeling depressed most of the time: 
 
 a. Did your appetite change significantly?    NO YES 
 
 b. Did you have trouble sleeping or sleep excessively?   NO YES 
 
 c. Did you feel tired or without energy?     NO YES 
 d. Did you lose your self-confidence?     NO YES 
 e. Did you have trouble concentrating or making decisions?   NO YES 
 f. Did you feel hopeless?      NO YES 
 
ARE 2 OR MORE B3 ANSWERS CODED YES?    NO YES 
 
B4 Did the symptoms of depression cause you significant distress or impair NO YES 





 IS B4 CODED YES? 







In the past month did you: 
 
C1 Think that you would be better off dead or wish you were dead?  NO YES  
 
C2 Want to harm yourself?      NO YES  
 
C3 Think about suicide?      NO YES  
 
C4 Have a suicide plan?      NO YES 
 
C5 Attempt suicide?       NO YES 
 
 In your lifetime: 
 




 IS AT LEAST 1 OF THE ABOVE CODED YES? 
 IF YES, SPECIFY THE LEVEL OF SUICIDE RISK  
 AS FOLLOWS: 
 
 C1 or C2 or C6 = YES: Low 
 
 C3 or (C2 + C6) = YES: Moderate 
 










Include Grandparents, parents, siblings and offspring aged 18 or above 
 





a) Feel very low for a couple of weeks or more, or have a diagnosis of 
depression? 
 
YES / NO If YES, who? ___________________________________ 
 
b) Attempt or complete suicide? 
 
YES / NO If YES, who? ___________________________________ 
 
c) Seem overexcited (or manic) day and night, or have a diagnosis  
of mania? 
 
YES / NO If YES, who? ___________________________________ 
 
d) Have visions, hear voices, or have beliefs that seem strange or 
unreal? 
 
YES /NO If YES, who? ___________________________________ 
 
e) Have unusual or bizarre behavior, or have a diagnosis of 
schizophrenia? 
 
YES / NO If YES, who? ___________________________________ 
 
f) Was anyone hospitalized for psychiatric problems? 
 






[Selected items from Childhood Experiences of  
Care & Abuse-Questionnaire (CECA-Q)] 
 
1) WHO BROUGHT YOU UP BEFORE AGE 17? 
 
Write below the PARENT FIGURES who brought you up in childhood.  List 
each family arrangement with different types of parent figures which lasted a 
year or longer.  Consider natural parents, step-parents (including parents’ live 
in partners), aunt, friends of the family, adoptive parents, foster parents, etc. 
 
If you have only lived in one arrangement, then fill in the first family 
arrangement and leave the other boxes blank.  For example, if this was with 
your natural parents, write in ‘Mother’ and ‘Father’ and age ‘0’. 
 
Family arrangement Mother figure Father figure Your age at start 
First (ALL)    
 
 
If you have lived in other arrangements such as with mother alone or mother 
and step-father, then list them below together with age you were when the 
arrangement began. 
 
Family arrangement Mother figure Father figure Your age at start 
Second (If applicable)    





Were you ever in a children’s home or institution prior to age 17? 
 
 0 No 
 1 Yes 
 
If NO, go to question 2. 
 
If yes: Type of institution 




   





2) PARENTAL LOSS AND SEPARATION [Please circle or write in answer] 
 
 Mother Father 
Did either parent die before you were aged 17? 
 
No Yes No Yes 
If YES, what age were you? 
 
Age ......... Age ......... 
Have you ever been separated from either parent 
for 6 months or more before age 17? 
No Yes No Yes 
 
If NO separation, then go to question 3. 
  
If YES separated:   
At what age were you first separated? 
 
Age ......... Age ......... 






What was the reason for separation? 
 
  
 Parental illness 
 
No Yes No Yes 
 Parental divorce, separation 
 
No Yes No Yes 
 Abandoned by parent or never knew parent 
 
No Yes No Yes 
 Other reason (please specify below) 
 
No Yes No Yes 
 







3) PHYSICAL PUNISHMENT BEFORE THE AGE OF 17 BY A PARENT 
FIGURE OR OTHER HOUSEHOLD MEMBER 
 
When you were a child or a teenager were you ever hit repeatedly with an  
implement such as a belt or stick) or punched, kicked or burnt by someone  
in the household? 
 
 0 No 
 1 Yes 
 




 Mother Figure Father Figure 
How old were you when it 
began? 
Age ......... Age ......... 
Did the hitting happen on more 
than one occasion? 
No Yes No Yes 
How were you hit? 0 Belt or stick 
1 Punched/kicked 
2 Hit with hand 
3 Other 
 
0 Belt or stick 
1 Punched/kicked 
2 Hit with hand 
3 Other 
Were you ever injured, e.g. 
bruises, black eyes, broken 
limbs? 
No Yes No Yes 
Was this person ever so angry 
they seemed out of control? 
No Yes No Yes 
 





Did you experience this from anyone else in the household? 
 
 0 No 
 1 Yes 
 









4) UNWANTED SEXUAL EXPERIENCES BEFORE AGE 17 [Please circle as 
appropriate] 
 
When you were a child or teenager did you ever have any unwanted sexual 
experiences? 
 
 0 No 
 1 Yes 
 2  Unsure 
 
Did anyone force you or persuade you to have sexual intercourse against your  
wishes before age 17? 
 
 0 No 
 1 Yes 
 2 Unsure 
 
Can you think of any upsetting sexual experiences before age 17 with a related  
adult or someone in authority, e.g. teacher? 
 
 0 No 
 1 Yes 
 2 Unsure 
 
If NONE, end interview. 
 
If YES or UNSURE to any of the above, then complete the following: 
 
 First Experience Second 
Experience 
How old were you when it began? Age ......... Age ......... 
Was the other person someone you 
knew? 
No Yes No Yes 
Was the other person a relative? No Yes No Yes 
Did this person do it on more than one 
occasion? 
No Yes No Yes 
Did it involve touching private parts of 
your body? 
No Yes No Yes 
Did it involve sexual intercourse? No Yes No Yes 
 











Brief Life Events Questionnaire 
 
The following questions are about events or problems which may have happened to 
you in the last 6 months which might have caused you distress and to seek help. 
   
_________________________________________________________________________ 
 
1. Did you suffer from a serious illness   Yes/No        Date: ________ 
      injury or an  assault?  
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
2. Did a serious illness, injury or assault  Yes/No        Date: ________ 
      happen to a close relative? 
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
3. Did a parent, spouse, partner, child,   Yes/No        Date: ________ 
      brother or sister of yours die? 
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
4. Did a close family friend or other   Yes/No        Date: ________ 
      relative die? 
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
5. Did you have a  separation due to   Yes/No        Date: ________ 
      marital difficulties or break off a 
      steady relationship? 
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
5b.  Did you end a long lasting friendship  Yes/No        Date: ________ 
      with a close friend or relative? 
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
6. Did you have serious problem with a   Yes/No        Date: ________ 
      close friend, neighbour or relative? 
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  






7. Were  you made redundant or sacked  Yes/No        Date: ________ 
      from your job? 
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
8. Were you seeking work without success  Yes/No        Date: ________ 
     for more  than 1 month? 
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
9. Did you have a major financial crisis  such  Yes/No        Date: ________ 
      as losing the equivalent of three  
      months income? 
       
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
10. Did you have problems with the police  Yes/No        Date: ________ 
      involving a court appearance? 
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
11. Was something you valued lost or stolen?  Yes/No        Date: ________ 
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
12. Did you/your wife or partner give   Yes/No        Date: ________ 
      birth to a child? 
 
If yes, at that time, how bad was that for you? Very      Moderately        Not Too  
        Bad  Bad  Bad 
 
13. Have you had any other significant negative events? 
…………………………………………………………………………………………….……
……………………………………………………………………………………………. 




Substance Use (Cannabis Experience Questionnaire, Section 2) 
 
Please indicate in the table below any drug(s) (cannabis, amphetamines, cocaine, 
ecstasy, acid, LSD, tranquilisers, crack, heroin) including alcohol and tobacco 
which you use/have used recreationally, the frequency with which you use/have used 
this drug, your age when you first tried the drug(s) and whether you are a past or 




Drug Frequency Age Use When 
 Everyday   
 
More than once a week 
 
A few times each month 
 
A few times each year 
 


















 Everyday   
 
More than once a week 
 
A few times each month 
 
A few times each year 
 


















 Everyday   
 
More than once a week 
 
A few times each month 
 
A few times each year 
 


















 Everyday   
 
More than once a week 
 
A few times each month 
 
A few times each year 
 




















Illness Perception Questionnaire 
Your views about your illness 
Listed below are a number of symptoms that you may or may not have experienced 
since your illness. Please indicate by circling yes or no, whether you have 
experienced any of these symptoms since your illness, and whether you believe that 
these symptoms are related to your illness. 
 
 
    I have experienced this  This symptom is related  
    symptom since my illness  to my illness 
 
 
Pain     Yes / No    Yes / No 
Sore Throat    Yes / No    Yes / No 
Nausea    Yes / No    Yes / No 
Breathlessness   Yes / No    Yes / No 
Weight Loss   Yes / No    Yes / No 
Fatigue    Yes / No    Yes / No 
Stiff Joints    Yes / No    Yes / No 
Sore Eyes    Yes / No    Yes / No 
Wheeziness   Yes / No    Yes / No 
Headaches   Yes / No    Yes / No 
Upset Stomach   Yes / No    Yes / No 
Sleep Difficulties   Yes / No    Yes / No 
Dizziness    Yes / No    Yes / No 











We are interested in your own personal views of how you see your current illness. 
 
Please indicate how much you agree or disagree with the following statements about 
your illness by ticking the appropriate box. 
 










My illness will last a 
short time 
     
IP2 My illness is likely to 
be permanent rather 
than temporary 
     
IP3 My illness will last for 
a long time 
     
IP4 
* 
This illness will pass 
quickly 
     
IP5 I except to have this 
illness for the rest of 
my life 
     
IP6 My illness is a serious 
condition 
     
IP7 My illness has major 
consequences on my 
life 
     
IP8 
* 
My illness does not 
have much effect on 
my life 
     
IP9 My illness strongly 
affects the way others 
see me 
     
IP10 My illness has serious 
financial 
consequences 
     
IP11 My illness causes 
difficulties for those 
who are close to me  
     
IP12 There is a lot which I 
can do to control my 
symptoms 
     
IP13 What I do can 
determine whether 
my illness gets better 
or worse 
     
IP14 The course of my 
illness depends on 
me 
     
IP15
* 
Nothing I do will affect 
my illness 
     
IP16 I have the power to 
influence my illness 
     
IP17
* 
My actions will have 
no affect on the 
outcome of my illness 
     
IP18
* 
My illness will 
improve in time 














There is very little that 
can be done to 
improve my illness 
     
IP20 The treatment will be 
effective in curing my 
illness 
     
IP21 The negative effects 
of my illness can be 
prevented by my 
treatment 
     
IP22 My treatment can 
control my illness 
     
IP23
* 
There is nothing 
which can help my 
condition 
     
IP24
* 
The symptoms of my 
condition are puzzling 
to me 
     
IP25
* 
My illness is a 
mystery to me  
     
IP26
* 
I don’t understand my 
illness 
     
IP27
* 
My illness doesn’t 
make any sense to 
me 
     
IP28 I have clear picture or 
understanding of my 
condition 
     
IP29 The symptoms of my 
illness change a great 
deal from day to day 
     
IP30 My symptoms come 
and go in cycles 
     
IP31 My illness is very 
unpredictable 
     
IP32 I go through cycles in 
which my illness gets 
better and worse 
     
IP33 I get depressed when 
I  think about my 
illness 
     
IP34 When I think about 
my illness I get upset 
     
IP35 My illness makes me 
feel angry 
     
IP36
* 
My illness does not 
worry me  
     
IP37 Having this illness 
makes me feel 
anxious 
     
IP38 My illness makes me 
feel afraid 




Causes of my illness 
We are interested in what you consider may have been the cause of your illness. As 
people are very different, there is no correct answer for this question. We are most 
interested in your own views about the factors that caused your illness rather than 
what others, including doctors of family, may have suggested to you. Below is a list 
of possible causes for your illness. Please indicate how much you agree or disagree 
that they were causes for you by ticking the appropriate box. 
 







C1 Stress or worry 
     
C2 Hereditary – runs in 
my family 
     
C3 A germ or virus 
     
C4 Diet or eating 
habits 
     
C5 Chance or bad luck 
     
C6 Poor medical care 
in my past 
     
C7 Pollution in the 
environment 
     
C8 My own behaviour 
     
C9 My mental attitude 
e.g. thinking about 
life negatively 
     
C10 Family problems or 
worries caused my 
illness 
     
C11 Overwork 
     
C12 My emotional state 
e.g. feeling down, 
lonely, empty, 
anxious  
     
C13 Ageing 
     
C14 Alcohol 
     
C15 Smoking 
     
C16 Accident or injury 
     
C17 My personality 
     
C18 Altered immunity 
     
 
In the table below, please list in rank order the three most important factors that you 
now believe caused your illness. You may use any of the items from the box above, 
or you may additional ideas of your own.  
 









Inventory of Depressive Symptomatology (IDS) 
 
Please read each group of statements carefully and then pick out the one statement 
in each group that best describes the way that you have been feeling during the past 
seven days, including today. Circle the number beside each statement that you 
have picked.  
 
 
1. Falling Asleep     5. Feeling Sad 
  0    I never take longer than 30 minutes to fall           0    I do not feel sad.  
        asleep.        1    I feel sad less than half the time. 
  1    I take at least 30 minutes to fall asleep, less    2    I feel sad more than half the time. 
        than half the time.           3    I feel sad nearly all of the time. 
  2    I take at least 30 minutes to fall asleep, more           
        than half the time.            6. Feeling Irritable 
  3    I take more than 60 minutes to fall asleep, more   0    I do not feel irritable. 
        than half of the time.       1    I feel irritable less than half the time. 
         2    I feel irritable more than half the time. 
2. Sleep During the Night      3    I feel extremely irritable nearly all of the time. 
  0    I do not wake up at night. 
  1    I have restless, light sleep with few brief  7. Feeling Anxious or Tense 
        awakenings each night.      0    I do not feel anxious or tense. 
  2    I wake up at least once a night, but I go back to   1    I feel anxious/tense less than half the time. 
        sleep easily.       2    I feel anxious/tense more than half the time. 
  3    I awaken more than once a night and stay    3    I feel extremely anxious/tense nearly all of the 
        awake for 20 minutes or more, more than half          time. 
        the time. 
       8. Response of Your Mood to Good Events 
3. Waking up too Early      0   My mood brightens to a normal level which  
  0    Most of the time, I awaken no more than 30          lasts for several hours. 
        minutes before I need to get up.     1    My mood brightens but I do not feel like my 
  1    More than half the time, I awaken more than 30         normal self when good events occur. 
        minutes before I have to get up.     2    My mood brightens only somewhat to a rather 
  2    I almost always awaken at least one hour or so          limited range of desired events. 
        before I need to, but I go back to sleep eventually.   3    My mood does not brighten at all, even when 
  3    I awaken at least one hour before I need to, and         very good or desired events occur in my life. 
        can’t go back to sleep. 
        9. Mood in Relation to Time of Day 
4. Sleeping Too Much       0    There is no regular relationship between my 
  0    I sleep no longer than 7-8 hours/night, without          mood and the time of day. 
        napping during the day.      1    My mood often relates to the time of day 
  1    I sleep no longer than 10 hours in a 24 hour period         because of environmental events (e.g. being 
        including naps.             alone, working). 
  2    I sleep no longer than 12 hours in a 24 hour period   2    In general, my mood is more related to the       
        including naps.               time of day than to environmental events 
  3    I sleep longer than 12 hours in a 24 hour period   3    My mood is clearly and predictably better or 




9A. Is your mood typically worse in the morning, 15. Concentration/Decision Making 
       afternoon or night (circle one).      0   There is no change in my usual capacity to 
                 concentrate or make decisions. 
9B. Is your mood variation attributed to the      1   I occasionally feel indecisive or find that my 
       environment? Yes / No (circle one).            attention wanders. 
2  Most of the time, I struggle to focus my         
attention or to make decisions. 
10. The Quality of your Mood       3   I cannot concentrate well enough to read or 
  0   The mood (internal feelings) that I experience is          cannot make even minor decisions, 
        very much a normal good mood.    
  1   My mood is sad, but this sadness is pretty much 
       like sad mood I would feel if someone close to  16. View of Myself 
      died or left.  0   I see myself as equally worthwhile and 
  2   My mood is sad, but this sadness has a rather     deserving as other people.  
       different quality to it than the sadness I’d feel 1   I am more self-blaming than usual.  
       if someone close to me died or left.  2   I largely believe that I cause problems for  
  3   My mood is sad, but this sadness is different from       others.  
       they type of sadness associated with grief or loss. 3  I think almost constantly about major and      
minor defects in myself. 
 
  Please complete either 11 or 12 (not both)  17. View of my future 
 11. Decreased Appetite         0   I have an optimistic view of my future.  
  0   There is no change in my usual appetite.     1   I am occasionally pessimistic about my future, 
  1   I eat somewhat less often or lesser amounts         but mostly I believe things will get better.  
  2   I eat much less than usual and only with personal   2   I’m pretty certain that my immediate future 
       effort.              does not hold much promise of good things for 
  3   I rarely eat within a 24hour period, and only with         me.  
       extreme personal effort or when other persuade me    3  I see no hope of anything good happening to me 
       to eat.             anytime in the future. 
           
12. Increased Appetite     18. Thought of Death or Suicide 
  0   There is no change in my usual appetite.    0   I do not think of suicide or death. 
  1   I feel a need to eat more frequently than usual,.     1  I feel that life is empty or wonder if it’s worth 
  2   I regularly eat more often and/or greater amounts       living.  
      of food than usual.       2  I think of suicide or death several times a week 
  3   I feel driven to overeat both at mealtimes and              for several minutes.  
       in between meals.       3   I think of suicide or death several times a day   
                        in some detail, or I have made specific plans for 
  Please complete either 13 or 14 (not both)        suicide or have actually tried to take my life. 
 13. Decreased Weight (within the last 2 weeks)     
  0    I have not had a change in my weight.  19. General Interest 
  1    I feel as if I’ve had a slight weight loss.    0  There is no change from usual in how interested 
  2    I have lost 2 pounds or more.          I am in other people or activities.  
  3    I have lost 5 pounds or more.     1   I notice that I am less interested in people or          
                       activities. 
14. Increased Weight (within the last 2 weeks)     2   I find I have interest in only one or more of my 
  0    I have not had a change in my weight.         formerly pursued activities.  
  1    I feel as if I’ve had a slight weight gain.     3    I have virtually no interest in formerly pursued 
  2    I have gained 2 pounds or more                  activities. 
  3    I have gained 5 pounds or more 
                  20. Energy Level 
0    There is no change in my usual level of energy. 
       1    I get tired more easily than usual. 
2    I have to make a big effort to start or finish my  
usual daily activities 
3    I really cannot carry out most of my usual daily 
activities because I don’t have the energy. 
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21. Capacity for Pleasure of enjoyment (excluding sex) 26. Other bodily symptoms 
  0    I enjoy pleasurable activities just as much as    0   I don’t have any of these symptoms: heart 
        usual.             pounding fast, blurred vision, sweating, hot  
  1    I do not feel my usual sense of enjoyment from         and cold flashes, chest pain, heart turning over  
        pleasurable activities.           in my chest, ringing in my ears, or shaking 
  2    I rarely get a feeling of pleasure from any    1  I have some of these symptoms but they are  
        activity.             mild and are present only sometimes 
  3    I am unable to get any pleasure or enjoyment     2  I have several of these symptoms and they  
       from anything.          bother me quite a bit. 
                             3    I have several of these symptoms and 
                     .         when they occur I have to stop doing whatever  
22. Interest in Sex (please rate interest, not activity)          I am doing  
   0    I’m just as interested in sex as usual. 
   1    My interest in sex is somewhat less than usual or I  27. Panic/Phobic Symptoms  
        do not get the same pleasure from sex as I used to.         0    I have no spells of panic or specific fears/phobia    
   2    I have little desire for or rarely derive pleasure 1    I have mild panic episodes or fears that do not  
        from sex.            usually change my behaviour or stop me from 
   3    I have absolutely no interest in or derive no         functioning.  
         pleasure from sex.     2    I have significant panic episodes or fears that 
                                                                                                                   force me to change my behaviour but do 
23. Feeling Slowed Down          not stop me from functioning.  
  0    I think, speak, and move at my usual rate of speed.  3    I have panic episodes at least once a week or  
  1    I find that my thinking is slowed down or my voice              severe fears that stop me from carrying on my                             
         sounds dull or flat.              daily activities.  
  2    It takes me several seconds to respond to most 
        questions and I’m sure my thinking is slowed.  28. Constipation/Diarrhoea 
  3    I am often unable to respond to questions  0   There is no change in my usual  bowel habits. 
        without extreme effort.    1    I have intermittent constipation or diarrhoea 
                      which is mild. 
24. Feeling restless     2    I have diarrhoea or constipation most of the    
  0    I do not feel restless           time but it does not interfere with my day to day 
  1    I’m often fidgety, wringing my hands or need       functioning.  
        to shift how I am sitting.    3    I have constipation or diarrhoea for which I take 
  2    I have impulses to move about and am quite       take medicine or which interferes with my day to  
        restless.                  day functioning. 
  3    At times, I am unable to stay seated and need  
        to pace around.     29. Interpersonal Sensitivity 
                 0   I have not felt easily rejected, slighted, criticised 
25. Aches and Pains           or hurt by others at all.  
  0    I don’t have any feeling of heaviness in my   1   I have occasionally felt rejected, slighted,  
        arms or legs and don’t have any aches or pains.       criticised or hurt by others. 
  1    Sometimes I get headaches or pains in my stomach,       2    I have often felt rejected, slighted, criticised or  
        back or joints but these pains are only sometimes         hurt by others, but these feelings have had only 
        present and they don’t stop me from doing what         slight effects on my relationships or work. 
        I need to.       3    I have often felt rejected, slighted, criticised or 
  2    I have these sorts of pains most of the time.         hurt by others and these feelings have impaired 
  3   These pains are so bad that they stop what I am         my relationships or work. 
        doing.        
30. Leaden Paralysis/Physical Energy    
          0    I have not experienced the physical sensation   
                      of feeling weighted down and without physical   
             energy.   
          1   I have occasionally experienced periods of  
                   feeling physically weighted down and without 
                physical energy, but without a negative effect on 
                   work, school, activity level. 
 2   I feel physically weighted down and without   
                     physical energy, more than half the time. 
           3    I feel physically weighted down and without   
                    physical energy, most of the time, several hours  





Hospital Anxiety & Depression Scale 
 
Instructions: Read each item and place a firm tick in the box opposite the reply 
which comes closest to how you have been feeling in the past week. Don’t take 
too long over your replies: your immediate reaction to each item will probably be 
more accurate. 
 
I feel tense or ‘wound up’:   A  I feel as if I am slowed down:  D   
Most of the time   3  Nearly all of the time  3   
A lot of the time   2  Very often  2   
Time to time, occasionally   1  Sometimes  1   
Not at all   0  Not at all  0   
I still enjoy the things I used to enjoy: D   I get a sort of frightened feeling like 
‘butterflies in the stomach’:  
 A  
Definitely as much  0   Not at all   0  
Not quite so much  1   Occasionally   1  
Only a little  2   Quite often   2  
Not at all  3   Very often   3  
I get a sort of frightened feeling like 
something awful is about to happen:  
 A  I have lost interest in my 
appearance:  
D   
Very definitely and quite badly   3  Definitely  3   
Yes, but not too badly   2  I don’t take as much care as I should  2   
A little, but it doesn’t worry me   1  I may not take quite as much care  1   
Not at all   0  I take just as much care as ever  0   
I can laugh and see the funny side of 
things:  
D   I feel restless as if I have to be on 
the move:  
 A  
As much as I always could  0   Very much indeed   3  
Not quite so much now  1   Quite a lot   2  
Definitely not so much now  2   Not very much   1  
Not al all  3   Not at all   0  
Worrying thoughts go through my 
mind:  
 A  I look forward with enjoyment to 
things:  
D   
A great deal of the time   3  A much as I ever did  0   
A lot of the time   2  Rather less than I used to  1   
From time to time but not too often   1  Definitely less than I used to  2  
Only occasionally   0  Hardly at all  3   
I feel cheerful:  D   I get sudden feelings of panic:   A  
Not at all  3   Very often indeed   3  
Not often  2   Quite often   2  
Sometimes  1   Not very often   1  
Most of the time  0   Not at all   0  
I can sit at ease and feel relaxed:   A  I can enjoy a good book or radio or 
TV programme:  
D   
Definitely   0  Often  0   
Usually   1  Sometimes  1   
Not often   2  Not often  2   
Not at all   3  Very seldom  3   




Chalder Fatigue Questionnaire 
 
We would like to know more about any problems you have had with feeling 
tired, weak or lacking in energy in the LAST MONTH. Please answer all the 
questions by ticking the answer which applies to you most closely. Please 
















Do you have problems with 
tiredness? 
    
Do you need to rest more? 
 
    
Do you feel sleepy or 
drowsy? 
    
Do you have problems 
starting things? 
    
Do you start things without 
difficulty but get weak as 
you go on? 
    
Do you lack energy? 
 
    
Do you have less strength in 
your muscles? 
    
Do you feel weak? 
 
    
Do you have difficulty    
concentrating?  
    
Do you have problems 
thinking clearly? 
    
Do you make slips of the 
tongue when speaking? 





Perceived Stress Scale- 10 Item 
 
The questions in this scale ask you about your feelings and thoughts during the 
last month. In each case, please indicate with a check how often you felt or 
thought a certain way. 
 
Please write here the time of the day at which  this questionnaire was 
completed: ____________ 
 
1. In the last month, how often have you been upset because of something that 
happened unexpectedly? 
0=never         1=almost never 2=sometimes 3=fairly often 4=very often 
 
2. In the last month, how often have you felt that you were unable to control the 
important things in your life? 
0=never 1=almost never 2=sometimes 3=fairly often 4=very often 
 
3. In the last month, how often have you felt nervous and "stressed"? 
0=never 1=almost never 2=sometimes 3=fairly often 4=very often 
 
4. In the last month, how often have you felt confident about your ability to handle 
your personal problems? 
0=never 1=almost never 2=sometimes 3=fairly often 4=very often 
 
5. In the last month, how often have you felt that things were going your way? 
0=never 1=almost never 2=sometimes 3=fairly often 4=very often 
 
6. In the last month, how often have you found that you could not cope with all the 
things that you had to do? 
0=never 1=almost never 2=sometimes 3=fairly often 4=very often 
 
7. In the last month, how often have you been able to control irritations in your 
life? 
0=never 1=almost never 2=sometimes 3=fairly often 4=very often 
 
8. In the last month, how often have you felt that you were on top of things? 
0=never 1=almost never 2=sometimes 3=fairly often 4=very often 
 
9. In the last month, how often have you been angered because of things that were 
outside of your control? 
0=never 1=almost never 2=sometimes 3=fairly often 4=very often 
 
10. In the last month, how often have you felt difficulties were piling up so high 
that you could not overcome them? 





Medical Outcomes Study Short-Form 36 (SF-36) 
 
1  In general how would you say your health is? 
 
 Excellent   
Very Good   
Good    
Fair    
 Poor    
 
2  Compared to one year ago, how would you rate your health in general 
now? 
 
 Much better now than one year ago?   
Somewhat better now than one year ago?   
About the same                
Somewhat worse now than one year ago?   
Much worse now than one year ago?   
 
3 The following questions are about activities you might do during a 
typical day. Does your health now limit you in these activities? If so how 
much? 
      Yes  Yes  No not 
      limited  limited  limited  
      a lot  a little  at all 
 
Vigorous activities such as running,   
lifting heavy objects, participating in        
strenuous sports 
Moderate activities such as moving  
a table, pushing a vacuum cleaner,        
bowling or playing golf 
Lifting or carrying groceries        
Climbing several flights of stairs       
Climbing one flight of stairs        
Bending, kneeling or stooping       
Walking more than a mile        
Walking half a mile         
Walking 100 yards         
Bathing or dressing yourself       
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4  During the past 4 weeks have you had any of the following problems 
with your work or other regular daily activities as result of you physical 
health? 
        Yes  No 
 
Cut down the amount of time you spent on work  
or other activities.          
Accomplished less than you would like      
Were limited in the kind of work or other activities     
Had difficulty performing the work or other activities     
(for example, it took extra effort) 
 
5  During the past 4 weeks have you had any of the following problems 
with your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)? 
 
        Yes  No 
 
Cut down the amount of time you spent on work or       
other activities. 
Accomplished less than you would like      
Didn’t do work or other activities as carefully      
as usual  
 
6  During the past 4 weeks to what extent have your physical health or 
emotional problems interfered with your social activities with family, 
friends, neighbours or groups? 
 
  Not at all  
  Slightly  
  Moderately  
  Quite a bit  
  Extremely  
 
7   How much bodily pain have you had during the past 4 weeks? 
 
  None   
  Very mild  
  Mild   
  Moderate     
  Severe   





8   During the past 4 weeks how much did pain interfere with your  
normal work (including both work outside the home and housework)? 
 
 
  Not at all   
  A little bit  
  Moderately  
  Quite a bit  
  Extremely  
 
9   How much of the time during the past 4 weeks… 
 
    All Most A Good  Some A little None   
    of the of the bit of the of the of the of the  
    time time time  time time time 
 
Did you feel full of life?        
Have you been a very  
nervous person?         
Have you felt so down in  
the dumps that nothing        
could cheer you up? 
Have you felt calm and 
peaceful?          
Did you feel worn out?        
Have you felt           
downhearted and low?     
Did you have a lot of          
energy?  
Have you been a happy 
person?          
Did you feel tired?         
Has your health limited  
your social activities (like 





10  Please choose the answer that best describes how true or false each 
of the following statements is for you. 
 
   Definitely Mostly  Not Mostly  Definitely   
true  true  sure false  false 
I seem to get ill  
more easily than          
other people 
 
I am as healthy as          
anybody I know 
 
I expect my health          
to get worse 
 







Salivary Cortisol Collection 
Wake up (before 10 a.m.). Immediately after waking up collect your saliva 
putting the Sorbette under the tongue and leaving it for 60 seconds, then put it 
back in the tube marked 0.  
Write here the EXACT TIME OF AWAKENING: ________________________ 
Try to sit down and relax in the next hour. YOU CANNOT BRUSH YOUR 
TEETH AND CANNOT HAVE ANYTHING TO EAT OR DRINK FOR THE 
NEXT HOUR. If you need, you can drink water, but only immediately AFTER 
you have taken the sample.  
15 minutes after waking up, collect your saliva using the tube marked 15. 
• What time is it now? ____________________________________________ 
• What were you doing before giving the 
sample?_______________________________________________________
______________________________________________________________ 
• Did you accidentally have anything to eat or drink before taking the sample? 
If yes, please describe it here: 
______________________________________________________________
______________________________________________________________ 
• Did you have any difficult or tense situation, unpleasant thoughts or any kind 





30 minutes after waking up, collect your saliva using the tube marked 30. 
• What time is it now? ____________________________________________ 
• What were you doing before giving the sample? 
______________________________________________________________
______________________________________________________________ 
• Did you accidentally have anything to eat or drink before taking the sample? 
If yes, please describe it here: 
______________________________________________________________
______________________________________________________________ 
• Did you have any difficult or tense situation, unpleasant thought or any kind 






60 minutes (1 hour) after waking up collect your saliva using the tube marked 
60. 
• What time is it now? ____________________________________________ 
• What were you doing before giving the sample? 
______________________________________________________________
______________________________________________________________ 
• Did you accidentally have anything to eat or drink before taking the sample? 
If yes, please describe it here: 
______________________________________________________________
______________________________________________________________ 
• Did you have any difficult or tense situation, unpleasant thought or any kind 






*****  You can now have breakfast and brush your teeth!  ***** 
 
 
At 12, noon - before lunch collect your saliva using the tube marked 12.  
You should not eat or drink anything, or do not brush your teeth in the 30 
minutes before noon. 
• What time is it now? ____________________________________________ 
• What were you doing before giving the sample? 
______________________________________________________________
______________________________________________________________ 
• Did you accidentally have anything to eat or drink before taking the sample? 
If yes, please describe it here: 
______________________________________________________________
______________________________________________________________ 
• Did you have any difficult or tense situation, unpleasant thought or any kind 






At 8 pm - before dinner collect your saliva using the tube marked 8.  
You should not eat or drink anything, or do not brush your teeth in the 30 
minutes before 8pm. 
• What time is it now? ____________________________________________ 
• What were you doing before giving the sample? 
______________________________________________________________
______________________________________________________________ 
• Did you accidentally have anything to eat or drink before taking the sample? 
If yes, please describe it here: 
______________________________________________________________
______________________________________________________________ 
• Did you have any difficult or tense situation, unpleasant thought or any kind 





Store the tubes away from the heat and direct sunlight and put them into the 
fridge as soon as possible.  




Do you have any medical problem? If so, please list them here: 
______________________________________________________________
______________________________________________________________ 
If you are female: Please indicate the age of your first menstrual cycle: 
______________________________________________________________ 




Qualitative Study Semi-Structured Interview Topic Guide 
Please note that these questions may vary depending on the context of the 
interview and may be modified as the study progresses to take into account 
emerging results. 
 
Exploration of role 
1. Please explain your role 
2. How long have you been doing this job? 
3. Could you please explain the process for treating Hepatitis C patients? 
Assessment of Hepatitis C patients 
4. At the assessment interview what aspects of the patients’ psychological 
history do you ask about? Prompt – previous psychiatric hospitalization, 
previous psychiatric diagnosis, suicidal ideation, family history of 
psychiatric illness, aggression, alcohol, drug use, previous aggression or 
violence. 
5. What other risk factors are important? Prompt – recent bereavement, 
current employment, current relationships and social support, financial 
status, other health problem, current activities 
6. At the assessment interview what psychological signs and symptoms do 
you assess? Prompt – current mood, depression, anxiety, aggression, 
agitation, suicidal ideation, withdrawal, crying spells, feelings of 
hopelessness, rumination, guilt, sleep problems, fatigue. 
7. At the follow up visits what psychological signs and symptoms do you 
assess? Prompt – current mood, depression, anxiety, aggression, 
agitation, suicidal ideation, withdrawal, crying spells, feelings of 
hopelessness, rumination, guilt, fatigue, sleep problems, fatigue. 
8. At the follow up visits what other risk factors do you assess? Prompt – 
alcohol and drug use, life events, employment, relationships, social 
support, financial status, other health problems, current activities. 
9. Do you use formal assessment instruments at either the initial 
assessment or the follow up visits? Prompt BDI, HAD, Zung 
10. If there is anything else that you think would help your clinical decision 
making, what would that be? (e.g. formal assessment tool, staff support 
group, education and training)  
11. (Hypothetically speaking, if a decision making support tool is developed) 
To what extent would you be willing to use such a tool, and how much do 
you think you would rely on it? (how much do they value other sources of 
judgements such as their own experience, personal relationship with 
patients and advice from peers and specialists) 
12. What would prompt you to refer a patient to the psychiatrist prior to 
commencing treatment? Prompt – signs, symptoms, history, life events 
13. What do you base your judgement of the urgency on when you decide 
whether you would refer a patient to the psychiatrist?  
14. What would prompt you to refer a patient to the psychiatrist during 
treatment – signs, symptoms, history, life events 
15. How confident are you that the risk of a patient developing psychiatric 
side effects can be predicted? Can you tell me more about how confident 





16. Can you remember a serious or unexpected incident occurring with a 
patient while they were taking the medication? Prompt – suicide, 
aggression, violence, unexpected response. (If they cannot think of any 
AIs – can you remember an episode where you were uncertain about 
your decision? Which aspect were you not certain about? How did you 
deal with it?) 
17. Can you tell me more about it? What were your first impressions of the 
patient? Were you surprised?  
18. Do you think there is a way to identify such patients before a problem 
occurs? 
 
19. What are the main challenges of your role? 
20. What are the rewarding aspects of your role? 
 
 
 
